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BCL6 INHIBITORS
INTRODUCTION
[0001] The present invention relates to certain compounds that function as inhibitors of
BCL6 (B-cell lymphoma 6) activity. The present invention also relates to processes for the
preparation of these compounds, to pharmaceutical compositions comprising them, and to
their use in the treatment of proliferative disorders, such as cancer, as well as other diseases
or conditions in which BCL6 activity is implicated.
BACKGROUND OF THE INVENTION
[0002] BCL6 is a zinc finger transcription repressor that plays a key role in the formation
and development of germinal centres, in which B cells undergo somatic hypermutation and
recombination of the immunoglobulin genes, in order to generate diversity in antibodies
against a variety of foreign antigens (Dent et al. , Science , 1997, 276 , 589-592). BCL6 allows
the proliferation of antibody producing B cells by repressing genes involved in DNA damage
response, cell cycle arrest and apoptosis. BCL6 mediates this repression by recruiting the
corepressor proteins SMRT, NCoR and BCoR to an extended groove motif that forms along
the dimer interface of the BCL6 BTB (BR-C, Ttk and Bab) domain (Ahmad et al., Mol Cell ,
2003, 12, 1551-1564; Ghetu et al. , Mol Cell , 2008, 29, 384-391). Genetic upregulation of the
BCL6 gene, as seen in many lymphomas, leads to malignant B cell proliferation (Hatzi &
Melnick, Trends Mol Med , 2014, 20, 343-352). Therefore, there exists a need to develop
agents that inhibit the tumourigenic effects of BCL6, either by selectively binding to the BTB
domain and preventing corepressor recruitment, or by binding to the BTB domain and
inducing protein degradation (Kerres et al. Cell Rep. , 2017, 20, 2860-2875).
SUMMARY OF THE INVENTION
[0003] According to a first aspect of the present invention, there is provided a compound, or
a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.
[0004] According to a further aspect of the present invention, there is provided a
pharmaceutical composition comprising a compound as defined herein, or a
pharmaceutically acceptable salt, hydrate or solvate thereof, in admixture with a
pharmaceutically acceptable diluent or carrier.
[0005] According to a further aspect of the present invention, there is provided a method of
inhibiting BCL6 activity, in vitro or in vivo, said method comprising contacting a cell with an
effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate
thereof as defined herein.
l
[0006] According to a further aspect of the present invention, there is provided a method of
inhibiting cell proliferation, in vitro or in vivo, said method comprising contacting a cell with an
effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate
thereof as defined herein, or a pharmaceutical composition as defined herein.
[0007] According to a further aspect of the present invention, there is provided a method of
treating a disease or disorder in which BCL6 activity is implicated in a patient in need of such
treatment, said method comprising administering to said patient a therapeutically effective
amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as
defined herein, or a pharmaceutical composition as defined herein.
[0008] According to a further aspect of the present invention, there is provided a method of
treating a proliferative disorder in a patient in need of such treatment, said method
comprising administering to said patient a therapeutically effective amount of a compound or
a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a
pharmaceutical composition as defined herein.
[0009] According to a further aspect of the present invention, there is provided a method of
treating cancer in a patient in need of such treatment, said method comprising administering
to said patient a therapeutically effective amount of a compound or a pharmaceutically
acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical
composition as defined herein.
[0010] According to a further aspect of the present invention, there is provided a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical
composition as defined herein for use in therapy.
[0011] According to a further aspect of the present invention, there is provided a compound
or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a
pharmaceutical composition as defined herein, for use in the treatment of a proliferative
condition.
[0012] According to a further aspect of the present invention, there is provided a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical
composition as defined herein for use in the treatment of cancer. In a particular
embodiment, the cancer is human cancer.
[0013] According to a further aspect of the present invention, there is provided a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in
the inhibition of BCL6 activity.
[0014] According to a further aspect of the present invention, there is provided a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in
the treatment of a disease or disorder in which BCL6 activity is implicated.
[0015] According to a further aspect of the present invention, there is provided the use of a
compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined
herein in the manufacture of a medicament for the treatment of a proliferative condition.
[0016] Suitably, the proliferative disorder is cancer, suitably a human cancer (for example
haematological cancers such as lymphomas (including diffuse large B-cell lymphoma
(DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL) and angioimmunoblastic T-cell
lymphoma (AITL)), leukaemias (including acute lymphoblastic leukaemia (ALL) and chronic
myeloid leukaemia (CML)) and multiple myeloma, and solid tumours (including glioma,
breast cancer, non-small cell lung cancer (NSCLC) and squamous cell carcinomas (SCC)
(including SCC of the head and neck, oesophagus, lung and ovary)).
[0017] According to a further aspect of the present invention, there is provided the use of a
compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined
herein in the manufacture of a medicament for the treatment of cancer.
[0018] According to a further aspect of the present invention, there is provided a use of a
compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined
herein in the manufacture of a medicament for the inhibition of BCL6 activity.
[0019] According to a further aspect of the present invention, there is provided a use of a
compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined
herein in the manufacture of a medicament for the treatment of a disease or disorder in
which BCL6 activity is implicated.
[0020] According to a further aspect of the present invention, there is provided a process for
preparing a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as
defined herein.
[0021] According to a further aspect of the present invention, there is provided a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, obtainable by, or obtained
by, or directly obtained by a process of preparing a compound as defined herein.
[0022] According to a further aspect of the present invention, there are provided novel
intermediates as defined herein which are suitable for use in any one of the synthetic
methods set out herein.
[0023] Features, including optional, suitable, and preferred features in relation to one aspect
of the invention may also be features, including optional, suitable and preferred features in
relation to any other aspect of the invention.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0024] Unless otherwise stated, the following terms used in the specification and claims
have the following meanings set out below.
[0025] It is to be appreciated that references to “treating” or “treatment” include prophylaxis
as well as the alleviation of established symptoms of a condition. “Treating” or “treatment” of
a state, disorder or condition therefore includes: (1) preventing or delaying the appearance
of clinical symptoms of the state, disorder or condition developing in a human that may be
afflicted with or predisposed to the state, disorder or condition but does not yet experience or
display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting the
state, disorder or condition, i.e., arresting, reducing or delaying the development of the
disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or
subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing
regression of the state, disorder or condition or at least one of its clinical or subclinical
symptoms.
[0026] A “therapeutically effective amount” means the amount of a compound that, when
administered to a mammal for treating a disease, is sufficient to effect such treatment for the
disease. The "therapeutically effective amount" will vary depending on the compound, the
disease and its severity and the age, weight, etc., of the mammal to be treated.
[0027] In this specification the term “alkyl” includes both straight and branched chain alkyl
groups. References to individual alkyl groups such as “propyl” are specific for the straight
chain version only and references to individual branched chain alkyl groups such as
“isopropyl” are specific for the branched chain version only. For example, “(1 -6C)alkyl”
includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl and f-butyl.
[0028] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group
having m to n carbon atoms.
[0029] An “alkylene” group is an alkyl group that is positioned between and serves to
connect two other chemical groups. Thus, “(1-6C)alkylene” means a linear saturated divalent
hydrocarbon radical of one to six carbon atoms or a branched saturated divalent
hydrocarbon radical of three to six carbon atoms, for example, methylene (-CH2-), ethylene
(-CH2CH2-), propylene (-CH2CH2CH2-), 2-methylpropylene (-CH2CH(CH3)CH2-), pentylene (-
CH2CH2CH2CH2CH2-), and the like.
[0030] The term “alkenyl” refers to straight and branched chain alkyl groups comprising 2 or
more carbon atoms, wherein at least one carbon-carbon double bond is present within the
group. Examples of alkenyl groups include ethenyl, propenyl and but-2,3-enyl and includes
all possible geometric (E/Z) isomers.
[0031] The term “alkynyl” refers to straight and branched chain alkyl groups comprising 2 or
more carbon atoms, wherein at least one carbon-carbon triple bond is present within the
group. Examples of alkynyl groups include acetylenyl and propynyl.
[0032] “(3-10C)cycloalkyl” means a hydrocarbon ring containing from 3 to 10 carbon atoms,
for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and
bicyclo[2.2.1]heptyl.
[0033] “(3-10C)cycloalkenyl” means a hydrocarbon ring containing from 3 to 10 carbon
atoms and at least one double bond, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl
or cycloheptenyl, such as 3-cyclohexen-1-yl, or cyclooctenyl.
[0034] The term “alkoxy” refers to O-linked straight and branched chain alkyl groups.
Examples of alkoxy groups include methoxy, ethoxy and f-butoxy.
[0035] The term “haloalkyl” or “haloalkoxy” is used herein to refer to an alkyl or alkoxy group
respectively in which one or more hydrogen atoms have been replaced by halogen (e.g.
fluorine) atoms. Examples of haloalkyl groups include -CH2F, -CH F2 and -CF 3 . Examples of
haloalkoxy groups include -OCH2F, and -OCF 3 .
[0036] The term “aminoalkyl” refers to an alkyl group in which one or more hydrogen atoms
have been replaced by an amino group (N H2). Examples of aminoalkyl groups include -
CH2N H2 and -C2H4N H2.
[0037] The term “halo” or “halogeno” refers to fluoro, chloro, bromo and iodo, suitably fluoro,
chloro and bromo, more suitably, fluoro and chloro.
[0038] The term “carbocyclyl”, “carbocyclic” or “carbocycle” means a non-aromatic saturated
or partially saturated monocyclic, fused, bridged, or spiro bicyclic carbon-containing ring
system(s). Monocyclic carbocyclic rings contain from about 3 to 12 (suitably from 3 to 7) ring
atoms. Bicyclic carbocycles contain from 6 to 17 member atoms, suitably 7 to 12 member
atoms, in the ring. Bicyclic carbocyclic(s) rings may be fused, spiro, or bridged ring systems.
Examples of carbocyclic groups include cyclopropyl, cyclobutyl, cyclohexenyl and
spiro[3.3]heptanyl.
[0039] The term “heterocyclyl”, “heterocyclic” or “heterocycle” means a non-aromatic
saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring
system(s). Monocyclic heterocyclic rings contain from about 3 to 12 (suitably from 3 to 7)
ring atoms, with from 1 to 5 (suitably 1 , 2 or 3) heteroatoms selected from nitrogen, oxygen
or sulfur in the ring. Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to
12 member atoms, in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged
ring systems. Examples of heterocyclic groups include cyclic ethers such as oxiranyl,
oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles containing
nitrogen include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl,
tetrahydrotriazinyl, tetrahydropyrazolyl, and the like. Typical sulfur containing heterocycles
include tetrahydrothienyl, dihydro-1 ,3-dithiol, tetrahydro-2/-/-thiopyran, and
hexahydrothiepine. Other heterocycles include dihydro-oxathiolyl, tetrahydro-oxazolyl,
tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl,
tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl,
octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For
heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or S0 2 groups
are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and
thiomorpholinyl such as tetrahydrothiene 1,1 -dioxide and thiomorpholinyl 1, 1-dioxide.
Heterocycles may comprise 1 or 2 oxo (=0) or thioxo (=S) substituents. A suitable value for
a heterocyclyl group which bears 1 or 2 oxo (=0) or thioxo (=S) substituents is, for example,
2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl,
2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl.
Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls
containing 1 , 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example
azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl,
tetrahydrothienyl 1,1 -dioxide, thiomorpholinyl, thiomorpholinyl 1, 1-dioxide, piperidinyl,
homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person would appreciate, any
heterocycle may be linked to another group via any suitable atom, such as via a carbon or
nitrogen atom. However, reference herein to piperidino or morpholino refers to a piperidin-1-
yl or morpholin-4-yl ring that is linked via the ring nitrogen.
[0040] By “bridged ring systems” is meant ring systems in which two rings share more than
two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley
Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include,
aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-
bicyclo[3.2.1]octane and quinuclidine.
[0041] By “spiro bi-cyclic ring systems” we mean that the two ring systems share one
common spiro carbon atom, i.e. the heterocyclic ring is linked to a further carbocyclic or
heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring
systems include 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-
azaspiro[3.3]heptanes, 2-oxa-6-azaspiro[3.3]heptanes, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-
2-azaspiro[3.4]octane, 2-oxa-7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.
[0042] The term “heteroaryl” or “heteroaromatic” means an aromatic mono-, bi-, or polycyclic
ring incorporating one or more (for example 1-4, particularly 1, 2 or 3) heteroatoms selected
from nitrogen, oxygen or sulfur. The term heteroaryl includes both monovalent species and
divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups
containing from five to twelve ring members, and more usually from five to ten ring members.
The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10-
membered bicyclic ring, for example a bicyclic structure formed from fused five and six
membered rings or two fused six membered rings. Each ring may contain up to about four
heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically the heteroaryl ring
will contain up to 3 heteroatoms, more usually up to 2 , for example a single heteroatom. In
one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen
atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or
essentially non-basic as in the case of an indole or pyrrole nitrogen. In general the number of
basic nitrogen atoms present in the heteroaryl group, including any amino group substituents
of the ring, will be less than five.
[0043] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl,
pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl,
pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl,
benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl,
purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl,
naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl,
thieno[2,3-b]furanyl, 2H-furo[3,2-b]-pyranyl, 5H-pyrido[2,3-d]-o-oxazinyl,
1H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5-d]thiazolyl, pyrazino[2,3-d]pyridazinyl,
imidazo[2,1-b]thiazolyl, imidazo[1,2-b][1 ,2,4]triazinyl. “Heteroaryl” also covers partially
aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one
or more of the other ring(s) is a non-aromatic, saturated or partially saturated ring, provided
at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or sulfur.
Examples of partially aromatic heteroaryl groups include for example,
tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1 ,2,3,4-tetrahydroquinolinyl,
dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1 ,3]dioxolyl,
2,2-dioxo-1 ,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl,
1.2.3.4-tetrahydro-1 ,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl and
3.4-dihydro-2/-/-pyrido[3,2-b][1,4]oxazinyl.
[0044] Examples of five membered heteroaryl groups include but are not limited to pyrrolyl,
furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl,
isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.
[0045] Examples of six membered heteroaryl groups include but are not limited to pyridyl,
pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.
[0046] A bicyclic heteroaryl group may be, for example, a group selected from:
a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;
a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;
a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1 , 2 or 3 ring
heteroatoms; and
a cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring
heteroatoms.
[0047] Particular examples of bicyclic heteroaryl groups containing a six membered ring
fused to a five membered ring include but are not limited to benzfuranyl, benzthiophenyl,
benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl,
isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl,
guaninyl), indazolyl, benzodioxolyl and pyrazolopyridinyl groups.
[0048] Particular examples of bicyclic heteroaryl groups containing two fused six membered
rings include but are not limited to quinolinyl, isoquinolinyl, chromanyl, thiochromanyl,
chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolizinyl,
benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl,
phthalazinyl, naphthyridinyl and pteridinyl groups.
[0049] The term “aryl” means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon
atoms. The term aryl includes both monovalent species and divalent species. Examples of
aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. In a
particular embodiment, an aryl is phenyl.
[0050] The term "optionally substituted" refers to either groups, structures, or molecules that
are substituted and those that are not substituted. The term “wherein a/any C H , CH2, C H3
group or heteroatom (i.e. NH) within a R1 group is optionally substituted” suitably means that
(any) one of the hydrogen radicals of the R1 group is substituted by a relevant stipulated
group.
[0051] Where optional substituents are chosen from “one or more” groups it is to be
understood that this definition includes all substituents being chosen from one of the
specified groups or the substituents being chosen from two or more of the specified groups.
[0052] The phrase “compound of the invention” means those compounds which are
disclosed herein, both generically and specifically.
Compounds of the invention
[0053] In one aspect, the present invention relates to compounds, or pharmaceutically




Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, (1-
2C)alkyl, halogen, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, cyano or
NR Rc, wherein R and Rc are each independently selected from hydrogen or
(1-2C)alkyl;
X 2 IS selected from N , C H , CF, CCI or C-CH 3;
R1 is selected from hydrogen or a group of the formula:
-L-Y-Z
wherein:
L is absent or (1-3C)alkylene;
Y is absent or O, C(O), C(0)0 or C(0)N(R e) , wherein Re is selected
from hydrogen or (1-4C)alkyl; and
Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5
or 6 membered heteroaryl or 4 to 7 membered heterocyclyl; wherein Z
is optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or (1-4C)alkyl;
R2 is selected from a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N , CH or CF;
X b is selected from N or CRx 1 , wherein Rx 1 is selected from
hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy,
cyano, acetylenyl, CH2F, CF2H or C F3 ;
R6 is selected from hydrogen, fluoro, chloro, bromo, (1-
2C)alkyl, (1-2C)alkoxy, cyano, acetylenyl, CH2F, CF2H or CFs;
R7 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy,
(1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl,
(2-4C)alkynyl or a group of the formula:
-Y3-Z3
wherein:
Y 3 is absent or O, S, SO, SO2, N(Rj)(CR jRk)qi (where q i
is 0 , 1 or 2), C(O), C(0)0, OC(O), C(0)N(R ) ,
N(R )C(0), N(Rj)C(0)N(R k) , N(R )C(0)0, 0C(0)N(Ri),
S(0) 2N(Rj) or N(Rj)S0 2, wherein Rj and Rk are each
independently selected from hydrogen or (1-4C)alkyl;
and
Z 3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2-
4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl,
heteroaryl or 4 to 12-membered heterocyclyl; wherein
Z 3 is optionally further substituted by one or more
substituent groups independently selected from (1-
4C)alkyl, (3-6C)cycloalkyl, halo, oxo, (1-4C)haloalkyl,
(1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano, CO2H,
SO2NH2, C(0)NR'R m, NR'Rm, OR' or SR' wherein R' and
Rm are each independently selected from hydrogen, (1-
4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further
substituted by a group of the formula:
-Lz-Wz
wherein:
l_z is a (1-5C)alkylene optionally substituted by
one or more substituents selected from (1-
2C)alkyl or oxo; and
W z is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy,
cyano, hydroxy, (1-4C)alkoxy, C(0)R x ,
COOR xa , C(0)NR xaRx or NRxaRx , wherein R 3
and R’* are each independently selected from
hydrogen or (1-4C)alkyl;
R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)haloalkyl or cyano,
wherein each (1-4C)alkyl and/or (3-6C)cycloalkyl substituent is optionally
further substituted by one or more substituents selected from (1-4C)alkyl, (3-
6C)cycloalkyl, hydroxy, (1-2C)alkoxy, NR RV, (1-2C)aminoalkyl or halo,
wherein R and Rv are independently selected from hydrogen or (1-2C)alkyl;




Y 5 is absent or selected from C(0)0 or C(0)N(R w) , wherein Rw
is selected from hydrogen or (1-2C)alkyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, 5 or 6
membered heteroaryl or 4 to 6-membered heterocyclyl;
wherein Z 5 is optionally substituted by one or more
substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano, nitro or hydroxy;
or
R30 and R3 1 are linked such that, together with the carbon atom to which they
are attached, they form a 4-6 membered carbocyclic ring or a heterocyclic
ring; and
Ring A is a 6- or 7-membered heterocyclic ring, which, in addition to the
substituent groups R30 and R3 1 , is optionally further substituted by one or
more substituent groups selected from oxo, (1-2C)alkyl, cyclopropyl, spiro-
cyclopropyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, NH2,
cyano or hydroxy.
[0054] In a particular group of compounds of the present invention, no more than one of X 1
and X 2 is nitrogen.
[0055] Particular compounds of the invention include, for example, compounds of the
Formula I , or pharmaceutically acceptable salts, hydrates and/or solvates thereof, wherein,
unless otherwise stated, each of X 1, X2, R1, R2, R7, R30, R3 1 , Ring A and any associated
substituent groups has any of the meanings defined hereinbefore or in any of paragraphs (1)
to (64) hereinafter: -
(1) Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, (1-2C)alkyl,
fluoro, chloro, (1-2C)alkoxy, CH2F, C H F2, C F3 , OCF 3 , cyano or NR Rc, wherein R
and Rc are independently selected from hydrogen or (1-2C)alkyl;
(2) Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, methyl, fluoro,
chloro, hydroxy, OCH 3 , CH2F, C H F2, C F3 , OCF 3 , acetylenyl, cyano or N H2;
(3) Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, methyl, fluoro,
chloro, hydroxy, OCH 3 , CH2F, C H F2, acetylenyl or cyano;
(4) Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, methyl, fluoro,
chloro, OCH 3 , acetylenyl or cyano;
(5) Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, (1-2C)alkyl or (1-
2C)alkoxy;
(6) Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, methyl, OCH 3 ,
fluoro or chloro;
(7) Xi is selected from N or CH;
(8) Xi is N ;
(9) Xi is CH;
(10) X2 is selected from CH, CF or C-CH3;
( 1 1) X2 is selected from CH or CF;
(12) X2 is CH;
(13) R1 is selected from hydrogen or a group of the formula:
-L-Y-Z
wherein:
L is absent or (1-3C)alkylene;
Y is absent or C(O), C(0)0 or C(0)N(R e) , wherein Re is selected from
hydrogen or methyl; and
Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5
or 6 membered heteroaryl or 4 to 7 membered heterocyclyl; wherein Z
is optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or (1-4C)alkyl;
(14) R1 is selected from hydrogen or a group of the formula:
-L-Z
wherein:
L is absent or (1-3C)alkylene; and
Z is (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6
membered heteroaryl or 4 to 7 membered heterocyclyl; wherein Z is
optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or (1-2C)alkyl;
(15) R1 is selected from hydrogen or a group of the formula:
-L-Z
wherein:
L is absent or (1-2C)alkylene; and
Z is (1-6C)alkyl, (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl;
wherein Z is optionally further substituted by one or more substituent
groups independently selected from oxo, (1-2C)alkyl, halo, (1-
2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or
OR9; wherein R9 and Rh are each independently selected from
hydrogen or (1-2C)alkyl;
(16) R1 is selected from hydrogen or a group of the formula:
-L-Z
wherein:
L is absent or (1-2C)alkylene; and
Z is (1-6C)alkyl, (3-6C)cycloalkyl, 4 to 7 membered heterocyclyl;
wherein Z is optionally further substituted by one or more substituent
groups independently selected from oxo, methyl, fluoro, NR Rh or OR9
wherein R9 and Rh are each independently selected from hydrogen or
(1-2C)alkyl;
(17) R1 is selected from hydrogen, (1-6C)alkyl or a group of the formula:
-L-Z
wherein:
L is (1-2C)alkylene; and
Z is (a 3-6C)cycloalkyl or a 4 to 7 membered heterocyclyl; wherein Z is
optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or methyl;
(18) R1 is selected from hydrogen or a group of the formula:
-L-Z
wherein:
L is absent or (1-2C)alkylene; and
Z is a (3-6C)cycloalkyl or a 4 to 6 membered heterocyclyl; wherein Z is
optionally further substituted by one or more substituent groups
independently selected from oxo, methyl, fluoro, NR Rh or OR9,
wherein R9 and Rh are each independently selected from hydrogen or
(1-2C)alkyl;
(19) R1 is selected from hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl, wherein the (1-6C)alkyl
or (3-6C)cycloalkyl groups are optionally further substituted by one or more
substituent groups independently selected from methyl, fluoro, NR Rh or OR9,
wherein R9 and Rh are each independently selected from hydrogen or (1-2C)alkyl;
(20) R1 is (1-6C)alkyl optionally further substituted by one or more substituent groups
independently selected from fluoro, NR Rh or OR9, wherein R9 and Rh are each
independently selected from hydrogen or (1-2C)alkyl;
(21) R1 is (1-3C)alkyl optionally further substituted by one or more substituent groups
independently selected from NR Rh or OH, wherein R9 and Rh are each
independently selected from hydrogen or (1-2C)alkyl;
(22) R1 is (1-6C)alkyl (e.g. methyl);
(23) R1 is a group of the formula:
-L-Z
wherein:
L is (1-2C)alkylene; and
Z is (3-6C)cycloalkyl; wherein Z is optionally further substituted by one
or more substituent groups independently selected from oxo, methyl,
fluoro, NR Rh or OR9, wherein R9 and Rh are each independently
selected from hydrogen or (1-2C)alkyl;
(24) R1 is a group of the formula:
-L-Z
wherein:
L is CH2; and
Z is (3-4C)cycloalkyl; wherein Z is optionally further substituted by one
or more substituent groups independently selected from methyl, fluoro
and OH;
(25) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N , CH or CF;
X b is selected from N or CRx 1
,
wherein Rx 1 is selected from
hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy,
cyano, acetylenyl, CH2F, CF2H or C F3 ;
R6 is selected from hydrogen, fluoro, chloro, bromo, (1-
2C)alkyl, (1-2C)alkoxy, cyano, acetylenyl, CH2F, CF2H or CFs;
R7 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy,
(1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, (2-4C)alkenyl, (2-
4C)alkynyl or a group of the formula:
-Y3-Z3
wherein:
Y 3 is absent or O, S, N(Rj)(CR jRk)qi (where qi is 0 , 1 or
2), C(O), C(0)0, OC(O), C(0)N(R j) or N(Ri)C(0),
wherein Rj and Rk are each independently selected
from hydrogen or (1-4C)alkyl; and
Z 3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-
6C)cycloalkenyl, 5- or 6-membered heteroaryl or 4 to
12-membered heterocyclyl; wherein Z 3 is optionally
further substituted by one or more substituent groups
independently selected from (1-4C)alkyl, cyclopropyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano,
C(0)NR'R m, NR'Rm or OR', wherein R' and Rm are each
independently selected from hydrogen, (1-4C)alkyl or
(3-6C)cycloalkyl; or Z3 is optionally further substituted
by a group of the formula:
-Lz-Wz
wherein:
l_z is a (1-5C)alkylene optionally substituted by
one or more substituents selected from (1-
2C)alkyl or oxo; and
W z is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy,
cyano, hydroxy, (1-4C)alkoxy, C(0)R xa ,
COOR xa , C(0)NR xaRx or NRxaRx , wherein R 3
and R’* are each independently selected from
hydrogen or (1-4C)alkyl;
(26) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N , CH or CF;
X b is selected from N or CRx 1
,
wherein Rx 1 is selected from hydrogen,
fluoro, chloro, bromo, (1-2C)alkyl, cyano, acetylenyl, CH2F, CF2H or
CF3;
R6 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-
2C)alkoxy, cyano, acetylenyl, CH2F, CF2H or CF3;
R7 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-
2C)haloalkyl, (1-2C)haloalkoxy, cyano or a group of the formula:
-Y3-Z3
wherein:
Y3 is absent or O, S, C(O), C(0)0, OC(O), C(0)N(R ) or
N(Rj)C(0), wherein Rj is selected from hydrogen or (1-4C)alkyl;
and
Z3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-
membered heteroaryl or 4 to 12-membered heterocyclyl;
wherein Z3 is optionally further substituted by one or more
substituent groups independently selected from (1-4C)alkyl,
cyclopropyl, halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-
4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or OR', wherein R'
and Rm are each independently selected from hydrogen, (1-
4C)alkyl or (3-6C)cycloalkyl;
(27) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N , CH or CF;
Xb is selected from N or CRx 1 , wherein Rx 1 is selected from hydrogen,
fluoro, chloro, bromo or methyl;
R6 is selected from fluoro, chloro, bromo, methyl, cyano or acetylenyl;
R7 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-
2C)haloalkyl, (1-2C)haloalkoxy, cyano or a group of the formula:
-Y3-Z3
wherein:
Y 3 is absent or O, C(O), C(0)0 or C(0)N(R j) , wherein Rj is
selected from hydrogen or (1-4C)alkyl; and
Z 3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-
membered heteroaryl or 4 to 11-membered heterocyclyl;
wherein Z 3 is optionally further substituted by one or more
substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-
4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or OR', wherein R'
and Rm are each independently selected from hydrogen, (1-
4C)alkyl or (3-6C)cycloalkyl;
(28) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N or CH;
Xb is selected from N or CRx 1 , wherein Rx 1 is selected from hydrogen,
fluoro, chloro, bromo or methyl;
R6 is selected from fluoro, chloro, bromo, methyl, cyano or acetylenyl;
R7 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-
2C)haloalkyl, (1-2C)haloalkoxy, cyano, (2-4C)alkenyl, (2-4C)alkynyl or
a group of the formula:
-Y3-Z3
wherein:
Y 3 is absent or O, C(O), C(0)0 or C(0)N(R j) , wherein Rj is
selected from hydrogen or (1-4C)alkyl; and
Z 3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-
membered heteroaryl or a 4 to 8-membered heterocyclyl;
wherein Z 3 is optionally further substituted by one or more
substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-
4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or OR', wherein R'
and Rm are each independently selected from hydrogen or (1-
4C)alkyl;
(29) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
X a is selected from N or CH;
X b is selected from C H , CCI, CF, CBr or CCH 3 ;
R6 is selected from chloro, fluoro or cyano;
R7 is selected from (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-membered
heteroaryl or a 4 to 8-membered heterocyclyl; wherein each (1-
6C)alkyl, (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or 4 to 8-
membered heterocyclyl is optionally further substituted by one or more
substituent groups independently selected from (1-4C)alkyl, halo, oxo,
(1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano,
C(0)NR'R m, NR'Rm or OR', wherein R' and Rm are each independently
selected from hydrogen or (1-4C)alkyl;
(30) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N or CH;
Xb is selected from C H , CCI, CF, CBr or CCH 3 ;
R6 is selected from chloro, fluoro or cyano;
R7 is selected from a 5- or 6-mem bered heteroaryl or a 4 to 8-
membered heterocyclyl; wherein said 5- or 6-membered heteroaryl or
4 to 8-membered heterocyclyl is optionally further substituted by one
or more substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano,
C(0)NR'R m, NR'Rm or OR', wherein R' and Rm are each independently
selected from hydrogen or (1-4C)alkyl;
(31) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N or CH;
Xb is selected from C H , CCI or CCH 3 ;
R6 is selected from chloro, fluoro or cyano;
R7 is selected from a 5- or 6-membered heteroaryl or a 4 to 8-
membered heterocyclyl; wherein said 5- or 6-membered heteroaryl or
4 to 8-membered heterocyclyl is optionally further substituted by one
or more substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano
or OH;
(32) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N or CH;
Xb is selected from C H, CCI or CCH 3;
R6 is selected from chloro, fluoro or cyano;
R7 is a 4 to 8-membered heterocyclyl (e.g. piperidinyl); wherein said 4
to 8-membered heterocyclyl is optionally further substituted by one or
more substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano
or OH;
(33) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N or CH;
Xb is selected from C H, CCI or CCH 3;
R6 is selected from chloro, fluoro or cyano;
R7 is piperidinyl or piperazinyl, each optionally substituted by one or
more substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano
or OH;
(34) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is CH;
Xb is selected from CH or CCI;
R6 is selected from chloro, fluoro or cyano;
R7 is selected from hydrogen or a group of the formula:
-Y3-Z3
wherein:
Y 3 is O, C(O), C(0)0 or C(0)N(R j) , wherein Rj is hydrogen or
(1-4C)alkyl; and
Z 3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, or 4 to 11-
membered heterocyclyl; wherein Z 3 is optionally further
substituted by one or more substituent groups independently
selected from (1-4C)alkyl, halo, oxo, (1-4C)haloalkyl, (1-
4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano or OH;
(35) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is CH;
Xb is selected from CH or CCI;
R6 is selected from chloro, fluoro or cyano;
R7 is selected from hydrogen or a group of the formula:
-Y3-Z3
wherein:
Y 3 is C(O) or C(0)N(R j) , wherein Rj is hydrogen or (1-4C)alkyl;
and
Z 3 is hydrogen, (1-6C)alkyl, or 4 to 11-membered heterocyclyl;
wherein Z 3 is optionally further substituted by one or more
substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-
4C)alkoxyalkyl, cyano or OH;
(36) R2 is a group of Formula A shown below:
Formula A
wherein:




R7 is selected from hydrogen or a group of the formula:
-Y3-Z3
wherein:
Y 3 is C(O); and
Z 3 is azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or
morpholinyl; wherein Z 3 is optionally further substituted by one
or more substituent groups independently selected from (1-
4C)alkyl, fluoro, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-
4C)alkoxyalkyl, cyano or OH;
(37) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is N ;
Xb is selected from CH or CCI;
R6 is selected from chloro, fluoro or cyano;
R7 is selected from (3-6C)cycloalkyl, 5- or 6-membered heteroaryl or a
4 to 10-membered heterocyclyl; wherein R7 is optionally further
substituted by one or more substituent groups independently selected
from (1-4C)alkyl, halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-
4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or OR', wherein R' and Rm
are each independently selected from hydrogen or (1-4C)alkyl; or R7 is
optionally further substituted by a group of the formula:
-Lz-Wz
wherein:
l_z is a (1-3C)alkylene; and
W z is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-
4C)alkoxy, C(0 )Rxa , C R3, C(0)NR xaRx or NR^R’*, wherein R 3
and R’* are each independently selected from hydrogen or (1-
4C)alkyl;
(38) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
X a is N ;
X b is selected from C H or CCI;
R6 is chloro or fluoro;
R7 is selected from 5- or 6-membered heteroaryl or 4 to 10-membered
heterocyclyl; each R7 is optionally further substituted by one or more
substituent groups independently selected from (1-4C)alkyl, halo, oxo,
(1-4C)haloalkyl, OH or C(0)NR'R m, wherein R' and Rm are each
independently selected from hydrogen or (1-4C)alkyl; or
R7 is optionally further substituted by a group of the formula:
-Lz-Wz
wherein:
Lz is a (1-2C)alkylene; and
W z is fluoro, (1-4C)haloalkyl, cyano, hydroxy or (1-2C)alkoxy;
(39) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is N ;
X is CH;
R6 is chloro or fluoro;
R7 is 4 to 10-membered heterocyclyl optionally substituted by one or
more substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, OH or C(0)NR'R m, wherein R' and Rm are
each independently selected from hydrogen or methyl; or
R7 is optionally further substituted by a group of the formula:
-Lz-Wz
wherein:
Lz is Η2; and
W z is cyano, hydroxy or methoxy;
(40) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is N ;
X is CH;
R6 is chloro or fluoro;







azabicyclo[3.2.1]octanyl, each being optionally substituted by one or
more substituent groups independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, OH, or C(0)NR'R m, wherein R' and Rm are
each independently selected from hydrogen or methyl; or
R7 is optionally further substituted by a group of the formula:
-Lz-Wz
wherein:
Lz is CH2; and
W z is cyano, hydroxy or methoxy;
(41) R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is N ;
X is CH;
R6 is chloro or fluoro;
R7 is selected from piperidinyl, piperazinyl, 3-oxa-8-azabicyclo[3.2.1]-
octanyl, 3-oxa-9-azabicyclo[3.3.1]nonanyl, 2-oxa-6-azaadamantanyl,
8-azabicyclo[3.2.1]octanyl, 3-azabicyclo[3.2.1]octanyl and 3,3-dioxido-
3-thia-8-azabicyclo[3.2.1]octanyl, each being optionally substituted by
one or more substituent groups independently selected from methyl,
fluoro, oxo, OH and CH2OH;
(42) R7 is hydrogen;
(43) R7 is a 4 to 10-membered nitrogen-containing heterocyclyl ring linked via a ring
nitrogen to the rest of the compound of formula (I) and optionally containing a second
heteroatom selected from nitrogen, oxygen and sulfur, wherein the heterocyclyl ring is
optionally substituted by one or more substituents independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or
OR', wherein R' and Rm are each independently selected from hydrogen, (1-4C)alkyl or (3-
6C)cycloalkyl; or Z3 is optionally further substituted by a group of the formula:
-Lz-Wz
wherein:
l_z is a (1-5C)alkylene optionally substituted by one or more substituents selected
from (1-2C)alkyl or oxo; and
W z is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy, (1-4C)alkoxy,
C(0 )Rxa , C R3, C(0)NR xaRx or NRxaRx , wherein R 3 and R’* are each
independently selected from hydrogen or (1-4C)alkyl;
(44) R7 is a 7 to 10-membered nitrogen-containing bicyclic heterocyclyl group linked via a
ring nitrogen to the rest of the compound of formula (I) and optionally containing a second
heteroatom selected from nitrogen, oxygen and sulfur, wherein the heterocyclyl group is
optionally substituted by one or more substituents independently selected from (1-4C)alkyl,
halo, oxo, (1-4C)haloalkyl, hydroxy, C(0)NR'R m, NR'Rm or OR', wherein R' and Rm are each
independently selected from hydrogen and (1-4C)alkyl;
(45) R7 is selected from one of the following heterocyclyl groups:
wherein the heterocyclyl ring is optionally substituted by one or more substituents
independently selected from (1-4C)alkyl, halo, oxo, (1-4C)haloalkyl, hydroxy, C(0)NR'R m,
NR'Rm or OR', wherein R' and Rm are each independently selected from hydrogen and (1-
4C)alkyl; and wherein the heterocyclyl ring is optionally further substituted by CH2CN,
CH2OH or CH2OMe;
(46) R7 is selected from one of the following heterocyclyl rings:
wherein the heterocyclyl ring is optionally substituted by one or more substituents
independently selected from methyl, fluoro, oxo, OH and CH2OH.
(47) R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)haloalkyl or cyano, wherein
each (1-4C)alkyl and/or (3-6C)cycloalkyl substituent is optionally further substituted by one
or more substituents selected from (1-4C)alkyl, cyclopropyl, hydroxy, (1-2C)alkoxy, NR RV or
halo, wherein R and Rv are independently selected from hydrogen or (1-2C)alkyl;
(48) R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)haloalkyl, or cyano,
wherein each (1-4C)alkyl and/or (3-6C)cycloalkyl substituent is optionally further substituted
by one or more substituents selected from (1-4C)alkyl, cyclopropyl, hydroxy, (1-2C)alkoxy or
halo;
(49) R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)haloalkyl or cyano, wherein
each (1-4C)alkyl and/or (3-6C)cycloalkyl substituent is optionally further substituted by one
or more substituents selected from (1-4C)alkyl, hydroxy, (1-2C)alkoxy or halo;
(50) R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl or (1-4C)fluoroalkyl, wherein each
(1-4C)alkyl and/or (3-6C)cycloalkyl substituent is optionally further substituted by one or
more substituents selected from hydroxy, (1-2C)alkoxy or fluoro;
(51) R30 is selected from (1-4C)alkyl or (3-4C)cycloalkyl, wherein each (1-4C)alkyl and/or
(3-4C)cycloalkyl substituent is optionally further substituted by one or more fluoro groups;
(52) R30 is (1-4C)alkyl (e.g. methyl or ethyl) or cyclopropyl;
(53) R30 is cyclopropyl;




Y 5 is absent or selected from C(0)0 or C(0)N(R w) , wherein Rw
is selected from hydrogen or (1-2C)alkyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl or a 5 or 6
membered heteroaryl; wherein Z 5 is optionally substituted by
one or more substituents selected from (1-2C)alkyl, halo, (1-
2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano, nitro
or hydroxy;




Y 5 is absent or C(0)N(R w) , wherein Rw is selected from
hydrogen or methyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl or a 5 or 6
membered heteroaryl; wherein Z 5 is optionally substituted by
one or more substituents selected from (1-2C)alkyl, halo, (1-
2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano, nitro
or hydroxy;




Y 5 is absent or C(0)N(R w) , wherein Rw is selected from
hydrogen or methyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is hydrogen, (1-6C)alkyl, cyclopropyl or a 5 or 6 membered
heteroaryl; wherein is Z 5 optionally substituted by one or more
substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano, nitro or hydroxy;
(57) R3 1 is selected from hydrogen (1-4C)alkyl, (1-4C)haloalkyl or a group of the formula:
Y5-L5-Z5
wherein:
Y 5 is absent or C(0)N(R w) , wherein Rw is selected from
hydrogen or methyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is (1-6C)alkyl or cyclopropyl; wherein Z 5 is optionally
substituted by one or more substituents selected from halo, (1-
2C)haloalkyl, (1-2C)alkoxy or cyano;
(58) R3 1 is selected from hydrogen, methyl, CF3, CH2OCH3 or C(0)NHCH 3;
(59) R3 1 is hydrogen;
(60) R30 and R3 1 are linked such that, together with the carbon atom to which they are
attached, they form a 4-6 membered carbocyclic ring;
(61) R30 and R3 1 are linked such that, together with the carbon atom to which they are
attached, they form a 4-6 membered heterocyclic ring;
(62) Ring A is a 7-membered heterocyclic ring, which, in addition to the substituent
groups R30 and R3 1 , is optionally further substituted by one or more substituent groups
selected from oxo, (1-2C)alkyl, cyclopropyl, spiro-cyclopropyl, halo, (1-2C)haloalkyl, (1-
2C)haloalkoxy, (1-2C)alkoxy, amino, cyano or hydroxy;
(63) Ring A is a 7-membered heterocyclic ring, which, in addition to the substituent
groups R30 and R3 1 , is optionally further substituted by one or more substituent groups
selected from oxo, (1-2C)alkyl, cyclopropyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-
2C)alkoxy, amino, cyano, nitro or hydroxy;
(64) Ring A is a 7-membered heterocyclic ring, which, in addition to the substituent
groups R30 and R3 1 , is optionally further substituted by one or more substituent groups
selected from oxo, (1-2C)alkyl, cyclopropyl, fluoro, (1-2C)fluorooalkyl, (1-2C)alkoxy or cyano.
[0056] Suitably, a heteroaryl is a 5- or 6-membered heteroaryl ring comprising one, two or
three heteroatoms selected from N , O or S.
[0057] Suitably an aryl group is phenyl.
[0058] Suitably, Xi is as described in any one of paragraphs (1) to (9) above. Most
suitably, Xi is as described in paragraph (9) above.
[0059] Suitably, X2 is as described in any one of paragraphs (10) to (12) above. Most
suitably, X2 is as described in paragraph (12) above.
[0060] Suitably, R1 is as described in any one of paragraphs (13) to (24) above. Most
suitably, R1 is as described in any one of paragraphs (20) to (24) above.
[0061] Suitably, R2 is as described in any one of paragraphs (25) to (41) above. More
suitably, R2 is as described in any one of paragraphs (29) to (41) above. Most suitably, R2 is
as described in any one of paragraphs (35) to (36) or paragraphs (40) to (41) above.
[0062] Suitably, R7 is as described in any one of paragraphs (42) to (46) above. Most
suitably, R30 is as described in paragraph (46) above.
[0063] Suitably, R30 is as described in any one of paragraphs (47) to (53), or (60) to (61)
above. Most suitably, R30 is as described in paragraph (53) above.
[0064] Suitably, R3 1 is as described in any one of paragraphs (54) to (61) above. Most
suitably, R3 1 is as described in paragraph (59) above.
[0065] Suitably, Ring A is as described in any one of paragraphs (62) to (64) above. Most
suitably, Ring A is as described in paragraph (64) above.
[0066] In a particular group of compounds of the invention, X2 is CH, i.e. the compounds
have the structural formula la (a sub-definition of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula la
wherein each of Xi, R1, R2, R30, R3 1 and Ring A are as defined hereinabove.
[0067] In an embodiment of the compounds of Formula la:
Xi is as defined in any one of paragraphs (1) to (9) above;
R1 is as defined in any one of paragraphs (13) to (24) above;
R2 is as defined in any one of paragraphs (25) to (41) above;
R30 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above; and
Ring A is as defined in any one of paragraphs (62) to (64) above.
[0068] In another embodiment of the compounds of Formula la:
Xi is as defined in paragraph (9) above;
R1 is as defined in paragraphs (20) to (24) above;
R2 is as defined in paragraphs (35) to (36) or paragraphs (40) to (41) above;
R30 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above; and
Ring A is as defined in paragraph (64) above.
[0069] In a particular group of compounds of the invention, Xi and X2 are CH, i.e. the
compounds have the structural formula lb (a sub-definition of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula lb
wherein each of R1, R2, R30 R3 1 and Ring A are as defined hereinabove.
[0070] In an embodiment of the compounds of Formula lb:
R1 is as defined in any one of paragraphs (13) to (24) above;
R2 is as defined in any one of paragraphs (25) to (41) above;
R30 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above; and
Ring A is as defined in any one of paragraphs (62) to (64) above.
[0071] In another embodiment of the compounds of Formula lb:
R1 is as defined in paragraphs (20) to (24) above;
R2 is as defined in paragraphs (35) to (36) or paragraphs (40) to (41) above;
R30 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above; and
Ring A is as defined in paragraph (64) above.
[0072] In a particular group of compounds of the invention, Xi, X2 and Xa are CH and R2 is
as shown below, i.e. the compounds have the structural formula lei (a sub-definition of
Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and/or solvate
thereof:
Formula lei
wherein each of R1, R6, R7, Xb, R30, R3 1 and Ring A are as defined hereinabove.
[0073] In an embodiment of the compounds of Formula lei :
R1 is as defined in any one of paragraphs (13) to (24) above;
R6 is as defined in any one of paragraphs (25) to (36) above;
R7 is as defined in any one of paragraphs (25) to (36) above;
Xb is as defined in any one of paragraphs (25) to (36) above;
R30 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above; and
Ring A is as defined in any one of paragraphs (62) to (64) above.
[0074] In another embodiment of the compounds of Formula lei :
R1 is as defined in paragraphs (20) to (24) above;
R6 is as defined in paragraph (36) above;
R7 is as defined in paragraph (36) above;
Xb is is as defined in paragraph (36) above;
R30 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above; and
Ring A is as defined in paragraph (64) above.
[0075] In a particular group of compounds of the invention, Xi and X2 , are CH, Xa is N and R2
is as shown below, i.e. the compounds have the structural formula lc2 (a sub-definition of
Formula (I)) shown below, or a pharmaceutically acceptable salt, hydrate and/or solvate
thereof:
Formula lc2
wherein each of R1, R6, R7, Xb, R30, R3 1 and Ring A are as defined hereinabove.
[0076] In an embodiment of the compounds of Formula lc2:
R1 is as defined in any one of paragraphs (13) to (24) above;
R6 is as defined in any one of paragraphs (25) to (33) and (37) to (41) above;
R7 is as defined in any one of paragraphs (25) to (33) and (37) to (46) above;
Xb is as defined in any one of paragraphs (25) to (33) and (37) to (41) above;
R30 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above; and
Ring A is as defined in any one of paragraphs (61) to (64) above.
[0077] In another embodiment of the compounds of Formula lc2:
R1 is as defined in paragraph (20) to (24) above;
R6 is as defined in paragraph (41) above;
R7 is as defined in paragraph (46) above;
Xb is is as defined in paragraph (41) above;
R30 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above; and
Ring A is as defined in paragraph (64) above.
[0078] In a particular group of compounds of the invention, the compounds have the
structural formula Id, le, If or Ig (sub-definitions of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula If Formula 1g
wherein each of X 1, X2, R1, R2, R30 and R3 1 are as defined hereinabove, X3 is CH2, O, S, SO2
or NH and R40, R4 1 , R50 and R5 1 are independently selected from hydrogen, (1-2C)alkyl, (3-
6C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-4C)alkoxyalkyl, (1-
2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 NR 2C(0)R 1 , wherein R 1
and R 2 are each independently selected from hydrogen or (1-2C)alkyl; or
R40 and R4 1 , and/or R50 and R5 1 , are linked such that, together with the carbon atom to which
they are attached, they form a 3-6 membered carbocyclic ring or heterocyclic ring.
[0079] In an embodiment of the compounds of Formula Id, Formula le, Formula If and/or
Formula Ig:
Xi is as defined in any one of paragraphs (1) to (9) above;
X2 is as defined in any one of paragraphs (10) to (12) above;
X3 is O or S ;
R1 is as defined in any one of paragraphs (13) to (24) above;
R2 is as defined in any one of paragraphs (25) to (41) above;
R3 0 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above; and
R40, R4 1 , R5 0 and R5 1 are independently selected from hydrogen, (1-2C)alkyl, (3-
6 C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 ,
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen
or (1-2C)alkyl; or
R4 0 and R4 1 , and/or R5 0 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a 3-6 membered carbocyclic ring.
[0080] In another embodiment of the compounds of Formula Id, Formula le, Formula If
and/or Formula Ig:
Xi is as defined in paragraph (9) above;
X2 is as defined in paragraph (12) above;
X 3 is O or S ;
R1 is as defined in paragraph (22) above;
R2 is as defined in paragraph (41) above;
R3 0 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above;
R40, R4 1 and R5 0 are independently selected from hydrogen, (1-2C)alkyl, (1-
2C)alkoxy, (1-2C)haloalkyl, (3-6C)cycloalkyl, halo or cyano; and
R5 1 is hydrogen; or
R4 0 and R4 1 , and/or R5 0 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a cyclopropyl ring.
[0081] In a particular group of compounds of the invention, the compounds have the
structural formula Ih, Ij, Ik or Im (sub-definitions of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula Ih Formula Ij
Formula Ik Formula Im
wherein each of R1, R2, R3 0 and R3 1 are as defined hereinabove, X 3 is selected from CH2, O,
S, SO2 or NH, and R40, R4 1 , R50 and R5 1 are independently selected from hydrogen, (1-
2C)alkyl, (3-6C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 ,
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen or (1-
2C)alkyl; or
R40 and R4 1 , and/or R50 and R5 1 , are linked such that, together with the carbon atom to which
they are attached, they form a 3-6 membered carbocyclic ring or heterocyclic ring.
[0082] In an embodiment of the compounds of Formula Ih, Ij, Ik and/or Im:
R1 is as defined in any one of paragraphs (13) to (24) above;
R2 is as defined in any one of paragraphs (25) to (41) above;
R30 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above;
X 3 is O or S ; and
R40, R4 1 , R50 and R5 1 are independently selected from hydrogen, (1-2C)alkyl, (3-
6C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 ,
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen
or (1-2C)alkyl; or
R40 and R4 1 , and/or R50 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a 3-6 membered carbocyclic ring.
[0083] In another embodiment of the compounds of Formula Ih, Ij, Ik and/or Im:
R1 is as defined in paragraph (22) above;
R2 is as defined in paragraph (41) above;
R3 0 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above;
X 3 is O or S ;
R40, R4 1 and R5 0 are independently selected from hydrogen, (1-2C)alkyl, (1-
2C)alkoxy, (1-2C)haloalkyl, (3-6C)cycloalkyl, halo or cyano; and
R5 1 is hydrogen; or
R4 0 and R4 1 , and/or R5 0 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a cyclopropyl ring.
[0084] In a particular group of compounds of the invention, the compounds have the
structural formula In, lo, Ip or Iq (sub-definitions of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula Ip Formula 1q
wherein each of R1, R6, R7, X b, R30 and R3 1 are as defined hereinabove, X 3 is selected from
CH2, O, S, SO2 or NH and R40, R4 1 , R50 and R5 1 are independently selected from hydrogen,
(1-2C)alkyl, (3-6C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 ,
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen or (1-
2C)alkyl; or
R4 0 and R4 1 , and/or R5 0 and R5 1 , are linked such that, together with the carbon atom to which
they are attached, they form a 3-6 membered carbocyclic ring or heterocyclic ring.
[0085] In an embodiment of the compounds of Formula In, lo, Ip and/or Iq:
R1 is as defined in any one of paragraphs (13) to (24) above;
R6 is as defined in any one of paragraphs (25) to (36) above;
R7 is as defined in any one of paragraphs (25) to (36) or (42) to (46) above;
X b is as defined in any one of paragraphs (25) to (36) above;
R3 0 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above;
X 3 is selected from O or S ; and
R40, R4 1 , R5 0 and R5 1 are independently selected from hydrogen, (1-2C)alkyl, (3-
6 C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 ,
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen
or (1-2C)alkyl; or
R4 0 and R4 1 , and/or R5 0 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a 3-6 membered carbocyclic ring.
[0086] In another embodiment of the compounds of Formula In, lo, Ip and/or Iq:
R1 is as defined in paragraph (22) above;
R6 is as defined in paragraph (36) above;
R7 is as defined in paragraph (36) above;
X b is as defined in paragraph (36) above;
R3 0 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above;
X 3 is O or S ;
R40, R4 1 and R5 0 are independently selected from hydrogen, (1-2C)alkyl, (1-
2C)alkoxy, (1-2C)haloalkyl, (3-6C)cycloalkyl, halo or cyano; and
R5 1 is hydrogen; or
R4 0 and R4 1 , and/or R5 0 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a cyclopropyl ring.
[0087] In a particular group of compounds of the invention, the compounds have the
structural formula Is or It (a sub-definition of Formula (I)) shown below, or a pharmaceutically
acceptable salt, hydrate and/or solvate thereof:
Formula Is Formula It
wherein each of R1, R6, R7, R3 0 and R3 1 are as defined hereinabove, X 3 is selected from CH2,
O, S, S0 2 or NH and R40, R4 1 and R5 0 are independently selected from hydrogen, (1-
2C)alkyl, (3-6C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)OR 1 , C(0)N(R 2)R 1
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen or (1-
2C)alkyl; or
R4 0 and R4 1 are linked such that, together with the carbon atom to which they are attached,
they form a 3-6 membered carbocyclic ring or heterocyclic ring.
[0088] In an embodiment of the compounds of Formula Is or It:
R1 is as defined in any one of paragraphs (13) to (24) above;
R6 is selected from chloro, fluoro or cyano;
R7 is as defined in any one of paragraphs (25) to (33) and (37) to (46) above;
R3 0 is as defined in any one of paragraphs (47) to (53) or (60) to (61) above;
R3 1 is as defined in any one of paragraphs (54) to (61) above;
X 3 is selected from O or S ; and
R40, R4 1 and R5 0 are independently selected from hydrogen, (1-2C)alkyl, (3-
6 C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1 ,
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen
or (1-2C)alkyl; or
R4 0 and R4 1 are linked such that, together with the carbon atom to which they are
attached, they form a 3-6 membered carbocyclic ring.
[0089] In another embodiment of the compounds of Formula Is or It:
R1 is as defined in paragraph (24) above ;
R6 is selected from chloro, fluoro or cyano;
R7 is as defined in paragraph (46) above;
R3 0 is as defined in paragraph (53) above;
R3 1 is as defined in paragraph (59) above;
X 3 is selected from O or S ; and
R40, R4 1 and R5 0 are independently selected from hydrogen, (1-2C)alkyl, (3-
6 C)cycloalkyl, halo or hydroxy; or
R4 0 and R4 1 are linked such that, together with the carbon atom to which they are
attached, they form a cyclopropyl ring.
[0090] In a particular group of compounds of the invention, the compounds have any of the
structural formulae Id to It shown above, or a pharmaceutically acceptable salt, hydrate
and/or solvate thereof, wherein R4 0 and R4 1 are independently selected from hydrogen and
fluoro.
[0091] In a further embodiment, the compounds have any of the structural formulae Id to It
shown above, or a pharmaceutically acceptable salt, hydrate and/or solvate thereof, wherein
R4 0 and R4 1 are both fluoro.
[0092] In a further embodiment, the compounds have any of the structural formulae Id to It
shown above, or a pharmaceutically acceptable salt, hydrate and/or solvate thereof, wherein
R4 0 and R4 1 are independently selected from hydrogen and fluoro and R3 0 is cyclopropyl.
[0093] In a further embodiment, the compounds have any of the structural formulae Id to It
shown above, or a pharmaceutically acceptable salt, hydrate and/or solvate thereof, wherein
R4 0 and R4 1 are independently selected from hydrogen and fluoro and R3 0 is cyclopropyl and
R3 1 is hydrogen.
[0094] In a further embodiment, the compounds have any of the structural formulae Id to It
shown above, or a pharmaceutically acceptable salt, hydrate and/or solvate thereof, wherein
R4 0 and R4 1 both fluoro and R3 0 is cyclopropyl.
[0095] In a further embodiment, the compounds have any of the structural formulae Id to It
shown above, or a pharmaceutically acceptable salt, hydrate and/or solvate thereof, wherein
R4 0 and R4 1 are both fluoro and R3 0 is cyclopropyl and R3 1 is hydrogen.
[0096] In a particular group of compounds of the invention, the compounds have the
structural formula lu or Iv (a sub-definition of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula lu Formula Iv
wherein each of X1, R1, R2 and R30 and R50 are as defined hereinabove.
[0097] In an embodiment of the compounds of Formula lu or Formula Iv:
X1 is as defined in any one of paragraphs (1) to (9) above;
R1 is as defined in any one of paragraphs (13) to (24) above;
R2 is as defined in any one of paragraphs (25) to (41) above;
R30 is as defined in any one of paragraphs (47) to (53) above; and
R50 is hydrogen, (1-2C)alkyl, (3-6C)cycloalkyl or halo.
[0098] In another embodiment of the compounds of Formula lu or Iv:
X1 is as defined in paragraph (7) above;
R1 is as defined paragraph (22) above;
R2 is as defined in paragraph (41) above;
R30 is as defined in paragraph (53) above; and
R50 is hydrogen.
[0099] In a particular group of compounds of the invention, the compounds have the
structural formula Iw or lx (a sub-definition of Formula (I)) shown below, or a
pharmaceutically acceptable salt, hydrate and/or solvate thereof:
Formula Iw Formula lx
wherein each of X1, R1, R6, R7 and R3 0 are as defined hereinabove and X 3 is selected from
CH2, O, S, S0 2 or NH.
[00100] In an embodiment of the compounds of Formula Iw or lx:
X 1 is as defined in any one of paragraphs (1) to (9) above;
R1 is as defined in any one of paragraphs (13) to (24) above;
R6 is selected from chloro, fluoro or cyano;
R7 is as defined in any one of paragraphs (25) to (33) and (37) to (46) above;
R3 0 is as defined in any one of paragraphs (47) to (53) above; and
X 3 is selected from O or S.
[00101] In another embodiment of the compounds of Formula Iw or lx:
X 1 is as defined in paragraph (7) above;
R1 is as defined in paragraph (22) above;
R6 is chloro;
R7 is as defined in paragraph (46) above;
R3 0 is as defined in paragraph (53) above; and
X3 is O.
[00102] Particular compounds of the present invention include any of the compounds
exemplified in the present application, or a pharmaceutically acceptable salt or solvate
thereof, and, in particular, any of the following:
(S)-2-chloro-4-((2,7-dimethyl-6-oxo-1 ,2,3,4,6,7-hexahydro-[1 ,4]oxazepino[2,3-c]quinolin-1 0-
yl)amino)nicotinonitrile;
(R)-2-chloro-4-((2,7-dimethyl-6-oxo-1 ,2,3,4,6,7-hexahydro-[1 ,4]oxazepino[2,3-c]quinolin-1 0-
yl)amino)nicotinonitrile;






2-chloro-4-((2,2,7-trimethyl-6-oxo-1 ,2,3,4,6,7-hexahydro-[1 ,4]oxazepino[2,3-c]quinolin-1 0-
yl)amino)nicotinonitrile;
2-chloro-4-((2-(methoxymethyl)-2,7-dimethyl-6-oxo-1,2,3,4,6,7-hexahydro-




























[ 1 .4]oxazepino[2,3-c]quinolin-1 0-yl)amino)picolinic acid;
(S)-6-(azetidine-1-carbonyl)-2-chloro-4-((2,7-dimethyl-6-oxo-1,2,3,4,6,7-hexahydro-






























































































trimethyl-2, 3-dihydro-[1,4]oxazepino[6,5-c]quinoline-5, 6(1 /-/,7/-/)-dione;
rac-(2S,3S)-10-((5-chloro-2-((3S,5f?)-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-2,3,7-
trimethyl-2, 3-dihydro-[1,4]oxazepino[6,5-c]quinoline-5, 6(1 /-/,7/-/)-dione;








































































cyclopropyl-3,3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((S)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-












cyclopropyl-3,3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((f?)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)amino)-2-







cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((3S,5f?)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-2-






















cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
or
(S)-10-((5-chloro-2-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)pyrimidin-4-yl)amino)-2-
cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one.
[00103] Further compounds of the present invention include any of the compounds
exemplified in the present application, or a pharmaceutically acceptable salt or solvate








[ 1 .4]thiazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitrile;
(S)-2-chloro-4-((2-cyclopropyl-3,3-difluoro-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-



































































cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((f?)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-
cyclopropyl-3,3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((S)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-












cyclopropyl-3,3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((f?)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)amino)-2-





















cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((3S,5f?)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-2-




cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(2S)-10-((5-chloro-2-(3-methyl-3,6-diazabicyclo[3.1.1]heptan-6-yl)pyrimidin-4-yl)amino)-2-
















[00104] Further compounds of the present invention include any of the compounds
exemplified in the present application, or a pharmaceutically acceptable salt or solvate
thereof, and, in particular, any of the following:
2-chloro-4-((2-cyclopropyl-3,3-difluoro-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-
[ 1 .4]oxazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitrile;
(F?)-2-chloro-4-((2-cyclopropyl-7-methyl-5,5-dioxido-6-oxo-1,2,3,4,6,7-hexahydro-
[ 1 .4]thiazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitrile;
(S)-2-chloro-4-((2-cyclopropyl-3,3-difluoro-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-
[ 1 .4]oxazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitriie;
(F?)-6-chloro-5-cyano-4-((2-cyclopropyl-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-




















cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((S)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-












cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((f?)-4,4-difluoro-2-(hydroxymethyl)pyrrolidin-1-yl)pyrimidin-4-yl)amino)-2-

















cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((3S,5f?)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-2-




cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(2S)-10-((5-chloro-2-(3-methyl-3,6-diazabicyclo[3.1.1]heptan-6-yl)pyrimidin-4-yl)amino)-2-




3,3-difluoro-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-c]quinolin-6(7/-/)-one; or
(f?)-10-((5-chloro-2-((1f?,5S,7S)-7-hydroxy-3-oxa-9-azabicyclo[3.3.1]nonan-9-yl)pyrimidin-4-
yl)amino)-2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1,4]thiazepino[2,3-c]quinolin-6(7/-/)-one.
[00105] Further compounds of the present invention include any of the compounds
exemplified in the present application, or a pharmaceutically acceptable salt or solvate
thereof, and, in particular, any of the following:
(S)-2-chloro-4-((2-cyclopropyl-3,3-difluoro-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-











cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((f?)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-
cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((S)-4,4-difluoro-3-(hydroxymethyl)piperidin-1-yl)pyrimidin-4-yl)amino)-2-




cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((3f?,5S)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-2-
cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one;
(S)-10-((5-chloro-2-((3S,5f?)-3-hydroxy-5-methylpiperidin-1-yl)pyrimidin-4-yl)amino)-2-




[00106] The various functional groups and substituents making up the compounds of the
Formula (I), or sub-formulae la to lx, are typically chosen such that the molecular weight of
the compound of the formula (I) does not exceed 1000. More usually, the molecular weight
of the compound will be less than 900, for example less than 800, or less than 750, or less
than 700, or less than 650. More preferably, the molecular weight is less than 600 and, for
example, is 550 or less.
[00107] A suitable pharmaceutically acceptable salt of a compound of the invention is, for
example, an acid-addition salt of a compound of the invention which is sufficiently basic, for
example, an acid-addition salt with, for example, an inorganic or organic acid, for example
hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane
sulfonate or maleic acid. In addition, a suitable pharmaceutically acceptable salt of a
compound of the invention which is sufficiently acidic is an alkali metal salt, for example a
sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium
salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically
acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine,
piperidine, morpholine or tris-(2-hydroxyethyl)amine.
[00108] Compounds that have the same molecular formula but differ in the nature or
sequence of bonding of their atoms or the arrangement of their atoms in space are termed
“isomers”. Isomers that differ in the arrangement of their atoms in space are termed
“stereoisomers”. Stereoisomers that are not mirror images of one another are termed
“diastereomers” and those that are non-superimposable mirror images of each other are
termed “enantiomers”. When a compound has an asymmetric center, for example, it is
bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be
characterized by the absolute configuration of its asymmetric center and is described by the
R- and S-sequencing rules of Cahn and Prelog, or by the manner in which the molecule
rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as
(+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer
or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a
“racemic mixture”.
[00109] The compounds of this invention may possess one or more asymmetric centers;
such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as
mixtures thereof. Unless indicated otherwise, the description or naming of a particular
compound in the specification and claims is intended to include both individual enantiomers
and mixtures, racemic or otherwise, thereof. The methods for the determination of
stereochemistry and the separation of stereoisomers are well-known in the art (see
discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J . March, John Wiley
and Sons, New York, 2001), for example by synthesis from optically active starting materials
or by resolution of a racemic form. Some of the compounds of the invention may have
geometric isomeric centres (E- and Z- isomers). It is to be understood that the present
invention encompasses all optical, diastereoisomers and geometric isomers and mixtures
thereof that possess antiproliferative activity.
[001 10] The present invention also encompasses compounds of the invention as defined
herein which comprise one or more isotopic substitutions. For example, H may be in any
isotopic form, including 1H , 2H(D), and 3H (T); C may be in any isotopic form, including 12C,
13C, and 14C; and O may be in any isotopic form, including 160 and180; and the like.
[001 11] It is also to be understood that certain compounds of the Formula (I), or sub
formulae la to lx, may exist in solvated as well as unsolvated forms such as, for example,
hydrated forms. It is to be understood that the invention encompasses all such solvated
forms that possess antiproliferative activity.
[001 12] It is also to be understood that certain compounds of the Formula I , or sub-formulae
la to lx, may exhibit polymorphism, and that the invention encompasses all such forms that
possess antiproliferative activity.
[001 13] Compounds of the Formula I , or sub-formulae la to lx, may exist in a number of
different tautomeric forms and references to compounds of the Formula I , or sub-formulae la
to lx, include all such forms. For the avoidance of doubt, where a compound can exist in
one of several tautomeric forms, and only one is specifically described or shown, all others
are nevertheless embraced by Formula I , or sub-formulae la to lx. Examples of tautomeric
forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric
pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidine,
nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
keto enol enolate
[001 14] Compounds of the Formula I , or sub-formulae la to lx, containing an amine function
may also form N-oxides. A reference herein to a compound of the Formula I , or sub
formulae la to lx, that contains an amine function also includes the N-oxide. Where a
compound contains several amine functions, one or more than one nitrogen atom may be
oxidised to form an N-oxide. Particular examples of N-oxides are the N-oxides of a tertiary
amine or a nitrogen atom of a nitrogen-containing heterocycle. N-Oxides can be formed by
treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or
a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by
Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, N-oxides can be
made by the procedure of L . W . Deady (Syn. Comm. 1977, 7 , 509-514) in which the amine
compound is reacted with m-chloroperoxybenzoic acid (mCPBA), for example, in an inert
solvent such as dichloromethane.
[001 15] The compounds of Formula (I), or sub-formulae la to lx, may be administered in the
form of a pro-drug which is broken down in the human or animal body to release a
compound of the invention. A pro-drug may be used to alter the physical properties and/or
the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed
when the compound of the invention contains a suitable group or substituent to which a
property-modifying group can be attached. Examples of pro-drugs include in vivo cleavable
ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound
of the Formula (I), or sub-formulae la to lx, and in-vivo cleavable amide derivatives that may
be formed at a carboxy group or an amino group in a compound of the Formula (I), or sub
formulae la to lx.
[001 16] Accordingly, the present invention includes those compounds of the Formula (I), or
sub-formulae la to lx, as defined hereinbefore, when made available by organic synthesis
and when made available within the human or animal body by way of cleavage of a pro-drug
thereof. Accordingly, the present invention includes those compounds of the Formula I , or
sub-formulae la to lx, that are produced by organic synthetic means and also such
compounds that are produced in the human or animal body by way of metabolism of a
precursor compound, that is a compound of the Formula (I), or sub-formulae la to lx, may be
a synthetically-produced compound or a metabolically-produced compound.
[001 17] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I),
or sub-formulae la to lx, is one that is based on reasonable medical judgement as being
suitable for administration to the human or animal body without undesirable pharmacological
activities and without undue toxicity.
[001 18] Various forms of pro-drug have been described, for example in the following
documents
a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K . Widder, et al. (Academic
Press, 1985);
b) Design of Pro-drugs, edited by H . Bundgaard, (Elsevier, 1985);
c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and
H . Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H . Bundgaard p. US-
191 (1991);
d) H . Bundgaard, Advanced Drug Delivery Reviews, 8 , 1-38 (1992);
e) H . Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988);
f) N . Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984);
g) T. Higuchi and V . Stella, “Pro-Drugs as Novel Delivery Systems”, A.C.S.
Symposium Series, Volume 14; and
h) E . Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.
[001 19] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I , or
sub-formulae la to lx, that possesses a carboxy group is, for example, an in vivo cleavable
ester thereof. An in vivo cleavable ester of a compound of the Formula I , or sub-formulae la
to lx, containing a carboxy group is, for example, a pharmaceutically acceptable ester which
is cleaved in the human or animal body to produce the parent acid. Suitable
pharmaceutically acceptable esters for carboxy include (1-6C)alkyl esters such as methyl,
ethyl and tert-butyl, (1-6C)alkoxymethyl esters such as methoxymethyl esters, (1-
6C)alkanoyloxymethyl esters such as pivaloyloxymethyl esters, 3-phthalidyl esters, (3-
8C)cycloalkylcarbonyloxy-(1-6C)alkyl esters such as cyclopentylcarbonyloxymethyl and 1-
cyclohexylcarbonyloxyethyl esters, 2-oxo-1 ,3-dioxolenylmethyl esters such as 5-methyl-2-
oxo-1,3-dioxolen-4-ylmethyl esters and (1-6C)alkoxycarbonyloxy-(1-6C)alkyl esters such as
methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl esters.
[00120] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I),
or sub-formulae la to lx, that possesses a hydroxy group is, for example, an in vivo cleavable
ester or ether thereof. An in vivo cleavable ester or ether of a compound of the Formula I , or
sub-formulae la to lx, containing a hydroxy group is, for example, a pharmaceutically
acceptable ester or ether which is cleaved in the human or animal body to produce the
parent hydroxy compound. Suitable pharmaceutically acceptable ester forming groups for a
hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic
cyclic esters). Further suitable pharmaceutically acceptable ester forming groups for a
hydroxy group include (1-10C)alkanoyl groups such as acetyl, benzoyl, phenylacetyl and
substituted benzoyl and phenylacetyl groups, (1-10C)alkoxycarbonyl groups such as
ethoxycarbonyl, N,N-(1-6C)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups.
Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl,
N-alkylaminomethyl, Ν,Ν-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and 4-
(1-4C)alkylpiperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether forming groups
for a hydroxy group include a-acyloxyalkyl groups such as acetoxymethyl and
pivaloyloxymethyl groups.
[00121] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I),
or sub-formulae la to lx, that possesses a carboxy group is, for example, an in vivo cleavable
amide thereof, for example an amide formed with an amine such as ammonia, a (1-
4C)alkylamine such as methylamine, a [(1-4C)alkyl] 2amine such as dimethylamine, N-
ethyl-N-methylamine or diethylamine, a (1-4C)alkoxy-(2-4C)alkylamine such as
2-methoxyethylamine, a phenyl-(1-4C)alkylamine such as benzylamine and amino acids
such as glycine or an ester thereof.
[00122] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula I , or
sub-formulae la to lx, that possesses an amino group is, for example, an in vivo cleavable
amide derivative thereof. Suitable pharmaceutically acceptable amides from an amino group
include, for example an amide formed with (1-10C)alkanoyl groups such as an acetyl,
benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring
substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-
alkylaminomethyl, Ν,Ν-dialkylaminomethyl, morpholinomethyl, piperazin-1-ylmethyl and
4-(1-4C)alkyl)piperazin-1-ylmethyl.
[00123] The in vivo effects of a compound of the Formula (I), or sub-formulae la to lx, may
be exerted in part by one or more metabolites that are formed within the human or animal
body after administration of a compound of the Formula (I), or sub-formulae la to lx. As
stated hereinbefore, the in vivo effects of a compound of the Formula (I), or sub-formulae la
to lx, may also be exerted by way of metabolism of a precursor compound (a pro-drug).
[00124] Though the present invention may relate to any compound or particular group of
compounds defined herein by way of optional, preferred or suitable features or otherwise in
terms of particular embodiments, the present invention may also relate to any compound or
particular group of compounds that specifically excludes said optional, preferred or suitable
features or particular embodiments.
[00125] Suitably, the present invention excludes any individual compounds not possessing
the biological activity defined herein. The following compounds were tested in the HTRF
assay described in the Examples section, but did not exhibit the desired activity, as they had
















[00126] In an embodiment, the compounds of the invention are compounds of formula I as
defined hereinbefore, with the proviso that the compound is not one of the compounds listed
in the preceding paragraph.
Synthesis
[00127] The compounds of the present invention can be prepared by any suitable technique
known in the art. Particular processes for the preparation of these compounds are described
further in the accompanying examples.
[00128] In the description of the synthetic methods described herein and in any referenced
synthetic methods that are used to prepare the starting materials, it is to be understood that
all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction
temperature, duration of the experiment and workup procedures, can be selected by a
person skilled in the art.
[00129] It is understood by one skilled in the art of organic synthesis that the functionality
present on various portions of the molecule must be compatible with the reagents and
reaction conditions utilised.
[00130] It will be appreciated that during the synthesis of the compounds of the invention in
the processes defined herein, or during the synthesis of certain starting materials, it may be
desirable to protect certain substituent groups to prevent their undesired reaction. The skilled
chemist will appreciate when such protection is required, and how such protecting groups
may be put in place, and later removed.
[00131] For examples of protecting groups see one of the many general texts on the
subject, for example, ‘Protective Groups in Organic Synthesis’ by Theodora Green
(publisher: John Wiley & Sons). Protecting groups may be removed by any convenient
method described in the literature or known to the skilled chemist as appropriate for the
removal of the protecting group in question, such methods being chosen so as to effect
removal of the protecting group with the minimum disturbance of groups elsewhere in the
molecule.
[00132] Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it
may be desirable to protect the group in some of the reactions mentioned herein.
[00133] By way of example, a suitable protecting group for an amino or alkylamino group is,
for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl
group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an
arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example
benzoyl. The deprotection conditions for the above protecting groups necessarily vary with
the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or
alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a
suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
Alternatively an acyl group such as a te/f-butoxycarbonyl group may be removed, for
example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or
trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group
may be removed, for example, by hydrogenation over a catalyst such as
palladium-on-carbon, or by treatment with a Lewis acid for example boron
tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for
example, a phthaloyl group which may be removed by treatment with an alkylamine, for
example dimethylaminopropylamine, or with hydrazine.
[00134] A suitable protecting group for a hydroxy group is, for example, an acyl group, for
example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an
arylmethyl group, for example benzyl. The deprotection conditions for the above protecting
groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl
group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis
with a suitable base such as an alkali metal hydroxide, for example lithium, sodium
hydroxide or ammonia. Alternatively an arylmethyl group such as a benzyl group may be
removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
[00135] A suitable protecting group for a carboxy group is, for example, an esterifying
group, for example a methyl or an ethyl group which may be removed, for example, by
hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may
be removed, for example, by treatment with an acid, for example an organic acid such as
trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by
hydrogenation over a catalyst such as palladium-on-carbon.
[00136] Resins may also be used as a protecting group.
[00137] The methodology employed to synthesise a compound of Formula (I), or sub
formulae la to lx, will vary depending on the nature of Xi, X2, R1, R2, R30, R3 1 , Ring A and any
substituent groups associated therewith. Suitable processes for their preparation are
described further in the accompanying Examples.
[00138] Once a compound of Formula (I), or sub-formulae la to lx, has been synthesised by
any one of the processes defined herein, the processes may then further comprise the
additional steps of:
(i) removing any protecting groups present;
(ii) converting the compound Formula (I) into another compound of Formula (I);
(iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and/or
(iv) forming a prodrug thereof.
[00139] A n example of (ii) above is when a compound of Formula (I) is synthesised and
then one or more of the groups Xi, X2, R1, R2, R30 , R3 1 , Ring A may be further reacted to
change the nature of the group and provide an alternative compound of Formula (I).
[00140] The resultant compounds of Formula (I), or sub-formulae la to Ixlx, can be isolated
and purified using techniques well known in the art.
[00141] The compounds of Formula (I) may be synthesised by the general synthetic routes
(Schemes 1 to 10b) below, specific examples of which are described in more detail in the
Examples.
Scheme 1
where Y is a halogen such as Cl, Br, I or a suitable alternative such as OTf, SOMe or
SC>2Me, R3 is H or formyl, and R1, R2, R30 , R3 1 , Xi, X2 and Ring A are suitable groups chosen
from those defined previously.
[00142] The reaction between aromatic amine (II) and aryl halide or equivalent R2-Y to form
compounds of formula (I) as shown in Scheme 1 may be carried out at elevated temperature
(e.g. 60-180 °C), using conventional or microwave heating, in a suitable solvent or solvent
mixture, such as NMP, DMA, DMF or acetonitrile. The reaction is carried out in the
presence of a base (such as triethylamine or DIPEA) or with no base. Alternative reaction
conditions include the use of a transition metal catalyst such as Pd2(dba)3 combined with a
suitable ligand such as Xantphos, in the presence of a base such as cesium carbonate at
elevated temperature, using a suitable solvent or solvent mixture, such as toluene or
mixtures of toluene and DMF or NMP. When Y is SOMe or S0 2Me, alternative reaction
conditions include the use of an acid such as TFA, at elevated temperature (e.g. 70 °C),
using a suitable solvent, such as trifluoroethanol. When R3 is formyl and Y is S0 2Me,
alternative reaction conditions include the use of a base such NaH, at elevated temperature
(e.g. 60 °C), using a suitable solvent, such as THF.
[00143] Compounds (II) may be prepared using methods such as those described in
Schemes 2 and 3 .
[00144] A compound of formula (I) may be converted to another compound of formula (I) by
methods generally known to those skilled in the art.
Scheme 2a
Where W is either NO2, or a halogen such as Cl, Br, I or a suitable alternative such as OTf
and R1, R30, R3 1 , X 1, X2, Ring A are suitable groups chosen from those defined previously.
[00145] The reduction of nitro compounds (III, W=NC>2) to amino compounds (II) may be
carried out by numerous methods which are well known in the art. Hydrogenation can be
carried out in the presence of a metal catalyst such as palladium, often in the form of
palladium on carbon, in an appropriate solvent or mixture of solvents such as ethanol,
methanol, ethyl acetate or ethanol/NMP at ambient or elevated temperature (such as 40-80
°C) using conventional or microwave heating. These reactions are carried out under a
hydrogen atmosphere, or alternatively by “transfer hydrogenation” using a reagent such as
ammonium formate or triethylsilane. An alternative method uses tin(ll) chloride in an
appropriate solvent or solvent mixture, such as ethanol and trifluoroethanol, at elevated
temperatures such as 120 °C using conventional or microwave heating. Other approaches
are known in the art such as iron or zinc metal mediated reductions.
[00146] The amination of halo compounds (e.g. W=CI) to aromatic amines (II) may be
carried out by methods which are well known in the art. For example, metal catalysed
amination may be employed, using a metal source and ligand. Conditions for this type of
reaction are known in the literature and include the use of palladium acetate and
benzophenone imine as described in Shen et al., Angew. Chem. Int. Ed. 2005, 44, 1371.
Reactions are typically carried out using a base such as sodium tert-butoxide in an
appropriate solvent or solvent mixture such as 1,2-dimethoxyethane at elevated
temperatures. Hydrolysis of the imine intermediate can be carried out in a one-pot procedure
at rt with the addition of an acid such as HCI. Aromatic amines (II) may also be formed from
aryl halides (e.g. W=Br) by reaction with ammonia (for example, from ammonium hydroxide
solution) in an appropriate solvent such as NMP, at elevated temperatures (such as 140 °C),
using conventional or microwave heating. These reactions are typically catalysed using a
metal catalyst such as copper (I) oxide.
[00147] Compounds (III) may be prepared by methods including those as shown in
Schemes 4a-c , 7a-7b, 8 and 9 .
Scheme 2b
Where R1, R30, R3 1 , X1, X2, Ring A are suitable groups chosen from those defined previously.
[00148] Methods for the preparation of formamide compounds (ll-d) are known in the art.
For example, this may be carried out in the presence of phenyl formate in an appropriate
solvent, such as dichloromethane at ambient temperature.
[00149] Compounds (II) may be prepared by methods including those as shown in Schemes
2a and 3 .
Scheme 3
Where R1, R30, R3 1 , Xi, X2 are suitable groups chosen from those defined previously. Z is an
appropriately substituted methylene group (-CR40R4 1-), for example (-CH2-) or (-CH(Me)-).
[00150] Aniline compounds (ll-c) can be prepared by the reduction of compounds (ll-b). This
reaction can be carried out at low temperatures (such as 0 °C) in a suitable solvent such as
THF with various reducing agents known in the art such as sodium borohydride. Various
additives such as Lewis acids (e.g. boron trifluoride diethyl etherate) may be used.
[00151] Compounds (ll-b) can be prepared as described in Scheme 2 .
Scheme 4a
where W is as previously defined, Y is a halogen such as Br or I , and R1, R30, R3 1 , X1, X2 and
Z is an appropriately substituted (1-2C)alkylene group, for example (-CH2-), (-CH2CH2-), (-
CF2CH2) or (-CH(Me)CH 2-).
[00152] Cyclised compounds (lll-a) can be prepared by the intramolecular cyclisation of
halogenated compounds (IV). This reaction can be carried out at elevated temperature
(such as 60 °C) in a suitable solvent such as DMSO, DMF, 1,2-dichloroethane (DCE), 1,2-
dimethoxyethane (DME) or THF (preferably in THF) in the presence of a base (e.g.
potassium tert-butoxide or lithium tert-butoxide (preferably lithium tert-butoxide)). Alternative
reaction conditions include the use of a transition metal catalyst (such as copper(l) iodide),
combined with a suitable ligand (such as 1,10-phenanthroline), in the presence of a base
(such as cesium carbonate) at elevated temperature, using a suitable solvent (such as
NMP).
[00153] Halogenated compounds (IV) may be prepared as shown in Scheme 5 .
Scheme 4b
where V is a halogen such as Cl, Br, I or a suitable alternative such as OTs, R2 is a suitable
protecting group such as acetate, Y is a halogen such as Br or I and R1, R30, R3 1 , Xi, X2 are
suitable groups chosen from those defined previously, and Z is an appropriately substituted
linker as defined previously.
[00154] The oxidation of sulfide compounds (lll-e) to sulfone compounds (lll-i) may be
carried out by numerous methods which are well known in the art. For example, oxidation
can be carried out using a suitable oxidising agent such as mCPBA, in an appropriate
solvent or mixture of solvents such as dichloromethane/acetonitrile, at low (such as 0 °C), or
ambient temperatures. Compound (lll-e) can be formed by thiol deprotection of IX-a followed
by in situ displacement of Y at the 3-position of the quinolinone (X). Suitable conditions for
this transformation include the use of an additive (such as sodium hydroxide) in an
appropriate solvent (such as methanol) at ambient temperature. Protected thiol (IX-a) can be
formed from the displacement of leaving group V . Suitable conditions for this transformation
include the use of elevated temperature (such as 50 °C) in an appropriate solvent (such as
DMF). Various additives (such as sodium iodide) may also be used. Alkylating agent (Vlll-a)
can be formed from the corresponding alcohol (IV). Various conditions are known in the art
for this activation of an alcohol; suitable methods include tosylation with tosyl chloride in
pyridine at ambient temperature. Compound (IV) can be prepared as described in Scheme
5 .
Scheme 4c
where W is as previously defined, Y is a halogen such as Cl, Br, I or a suitable alternative
such as OTs and R1, R30, R3 1 , Xi, X2 are suitable groups chosen from those defined
previously, R4 is (1-2C)alkyl, cyclopropyl, or (1-2C)haloalkyl, and Z is an appropriately
substituted linker as defined previously.
[00155] The reduction of nitro compounds (Vlll-b) to intermediate aromatic amines (XI) may
be carried out by numerous methods which are well known in the art. Hydrogenation can be
carried out in the presence of a metal catalyst such as palladium, often in the form of
palladium on carbon, in an appropriate solvent or mixture of solvents such as ethanol,
methanol, ethyl acetate or ethanol/NMP at ambient or elevated temperature (such as 60-75
°C) using conventional or microwave heating. These reactions are carried out under a
hydrogen atmosphere, or alternatively by “transfer hydrogenation” using a reagent such as
ammonium formate or triethylsilane. An alternative method uses tin(ll) chloride in an
appropriate solvent or solvent mixture, such as ethanol and trifluoroethanol, at elevated
temperatures such as 120 °C using conventional or microwave heating. Other approaches
are known in the art such as iron or zinc metal mediated reductions. In situ cyclisation to
compounds (lll-f) may occur spontaneously during the reduction step or with the addition of
an additive (such as DIPEA) at ambient temperature. Nitro compound (Vlll-b) can be formed
from the corresponding alcohol (V-b). Various conditions are known in the art for this
activation of an alcohol; suitable methods include tosylation with tosyl chloride in DCM at
ambient temperature with the use of an appropriate base (such as triethylamine). Various
additives (such as DMAP) may also be used. Further functionalisation of the C3-nitrogen
may be carried out by numerous methods which are well known in the art to prepare
compound (lll-g).
[00156] Compound (V-b) can be prepared as described in Scheme 6b.
Scheme 5
where W is as previously defined, Y is a halogen such as Br or I , and R1, R30, R3 1 , X1, X2,
suitable groups chosen from those defined previously and Z is an appropriately substituted
linker as defined previously.
[00157] Preparation of compound (IV) may be carried out by the halogenation of
compounds (V-a). This reaction can be carried out at a range of temperatures (such as 0 °C,
rt or 60 °C) in a suitable solvent or solvent mixture such as DCM, methanol/water with an
appropriate halogenation reagent such as /V-bromosuccinimide or iodine. Various additives
such as acids (e.g. TFA) may be used.
[00158] Compounds (V-a) may be prepared as shown in Scheme 6a.
Scheme 6a
where Y is a halogen such as Cl, Br, I or a suitable alternative such as OTf, R3 is a small
alkyl such as methyl or ethyl, and R1, R30, R3 1 , Xi, X2 are suitable groups chosen from those
defined previously and Z is an appropriately substituted linker as defined previously.
[00159] Nitro compounds (V) can be prepared by the reaction of amino-alcohols (VII) with
halo-aromatic or equivalent (Vl-a). This reaction can be carried out at elevated temperatures
(such as 80-200 °C) in a suitable solvent or solvent mixture such as NMP, NMP/THF or
using the amine as solvent. Various additives such as bases (e.g DIPEA, triethylamine) and
nucleophilic catalysts (e.g. DMAP) may be used. For less nucleophilic and more sterically
hindered amines, alternative conditions may be required. For example, metal catalysed
amination may be employed, using a metal source and ligand. Conditions for this type of
reaction are known in the literature and include the use of palladium acetate and BINAP as
described in Naik et al., J. Med. Chem. 2014, 57, 5419. Reactions are typically carried out
using a base such as cesium carbonate in an appropriate solvent or solvent mixture such as
toluene, again at elevated temperatures. Alternatively, use of an ester functionality (Vl-b) can
be used to aid the halogen displacement. Displacement of Y by (VII) is carried out at
elevated temperature (such as 90-160 °C) in a suitable solvent such as NMP, MeCN or
THF, typically using a base such as DIPEA. Removal of the ester group can be carried out
by known methods, such as the addition of lithium chloride or sodium hydroxide to the
reaction mixture and further heating (e.g. at 90-160 °C). Microwave or conventional heating
may be employed for the above reactions.
[00160] Amino-alcohols (VII) were obtained from commercial suppliers or prepared by
methods which are known in the art. Compounds (Vl-a) and (Vl-b) may be prepared as
shown in Scheme 10a-b.
Scheme 6b
(VII)
where W is as previously defined, Y is a halogen such as Cl, Br, I or a suitable alternative
such as OTf and R1, R30, R3 1 , Xi, X2 are suitable groups chosen from those defined
previously and Z is an appropriately substituted linker as defined previously.
[00161] Compounds (V-b) can be prepared by the reaction of amino-alcohols (VII) with halo-
aromatic or equivalent (Vl-c). This reaction can be carried out at elevated temperatures
(such as 140 °C) in a suitable solvent (such as NMP) with the use of an appropriate base
(such as DIPEA). Amino-alcohols (VII) were obtained from commercial suppliers or prepared
by methods which are known in the art. Compounds (Vl-c) may be prepared as shown in
Scheme 10b.
Scheme 7a
where Y is a halogen such as Cl, Br, I or a suitable alternative such as OTf, R3 is a small
alkyl such as methyl or ethyl, and R1, R30, R3 1 , Xi, X2 are suitable groups chosen from those
defined previously and Z is an appropriately substituted linker as defined previously.
[00162] Nitro compounds (lll-b) can be prepared by the reaction of amino-alcohols (VII) with
compound (Vl-b). Displacement of Y by (VII) is carried out at elevated temperature (such as
160 °C) in a suitable solvent such as NMP, typically using a base such as DIPEA.
Cyclisation to lactone (lll-b) can be carried out with the addition of an additive, such as
lithium chloride, to the reaction mixture and further heating (e.g. at 160 °C). Microwave or
conventional heating may be employed for the above reactions. This procedure may form
mixtures of compounds (lll-b) and (V-a) which can be separated by standard methods.
[00163] Amino-alcohols (VII) were obtained from commercial suppliers or prepared by
methods which are known in the art. Compounds (Vl-b) may be prepared as shown in
Scheme 10b.
Scheme 7b
where W is as previously defined, Y are a halogen such as Cl, Br, I or a suitable alternative
such as OTf, R2 is a suitable protecting group such as Boc, R3 is a small alkyl such as methyl
or ethyl, R4 is H , (1-2C)alkyl, cyclopropyl, or (2C)haloalkyl, and R1, R30, R3 1 , Xi, X2 are
suitable groups chosen from those defined previously and Z is an appropriately substituted
methylene linker as defined previously.
[00164] Cyclic lactam compounds (lll-h) can be prepared in a one-pot procedure from
compound (Vl-b). Compounds (V-d) can be prepared by the reaction of a suitably protected
diamine (XII) with a halo-aromatic (or equivalent) with an ester functionality (Vl-b).
Displacement of Y by diamine (XII) is carried out at elevated temperature (such as 100 °C) in
a suitable solvent such as acetonitrile, typically using a base such as DIPEA. In situ amine
deprotection can be achieved with the addition of an acid (such as HCI in dioxane) at
elevated temperatures (such as 75 °C). Cyclisation can then be achieved with the addition of
an excess of base (such as DIPEA) at elevated temperatures (such as 75 °C).
[0001] Suitably protected diamines (XII) were obtained from commercial suppliers or
prepared by methods which are known in the art. Compounds (Vl-b) may be prepared as
shown in Scheme 10b.
Scheme 7c
where W is as previously defined, Y is a halogen such as Cl, Br, I or a suitable alternative
such as OTf, R4 is a suitable protecting group such as Boc, R3 is a small alkyl such as methyl
or ethyl, and R1, R2, R30, R3 1 , Xi, X2 are suitable groups chosen from those defined
previously and Z is an appropriately substituted methylene linker as defined previously.
[00165] An alternative route to cyclic lactam compounds (l-h) is shown in Scheme 7c.
Compounds (lll-j) can be prepared by the reaction of suitably protected diamines (XII) with
use of halo-aromatic or equivalent (Vl-b). Displacement of Y by diamine (XII) can be carried
out at elevated temperature (such as 100 °C) in a suitable solvent, such as THF, typically
using a base such as DIPEA. The conversion of (lll-j) to (ll-j) can be carried out using
conditions described previously in Scheme 2a. The conversion of (ll-j) to (l-j) can be carried
out using conditions described previously in Scheme 1 . Formation of cyclic lactam
compounds (l-h) can be achieved in a one-pot procedure from compounds (l-j). Amine
deprotection can be achieved in a suitable solvent, such as THF) with the addition of an acid
(such as HCI in dioxane) at elevated temperatures (such as 70 °C). In situ cyclisation can
then be achieved with the addition of an excess of base (such as triethylamine) at elevated
temperatures (such as 70 °C).
[00166] Suitably protected diamines (XII) were obtained from commercial suppliers or
prepared by methods which are known in the art. Compounds (Vl-b) may be prepared as
shown in Scheme 10b.
Scheme 8
where Y is a halogen such as Cl, Br, I or a suitable alternative such as OTs, and R1, R30, R3 1 ,
Xi, X2 are suitable groups chosen from those defined previously, and Z is an appropriately
substituted ethylene linker as defined previously.
[00167] Compound (lll-d) can be formed by cyclisation at the 3-position of quinolinone,
displacing the leaving group Y . Suitable conditions for this transformation include the use of
elevated temperatures (such as 160 °C) in an appropriate solvent (such as NMP) with the
addition of a base (such as DIPEA). Alkylating agent (Vlll-d) can be formed from the
corresponding alcohol (V-a). Various conditions are known in the art for this activation of an
alcohol; suitable methods include tosylation with tosyl chloride in pyridine/DCM at ambient
temperature. Compound (V-a) can be prepared as described in Scheme 6a.
Scheme 9
where Y2 is a halogen such as Cl, Br, I or a suitable alternative such as OTf, W is as
previously defined, and R1, R30, R3 1 , X1, X2, Ring A are suitable groups chosen from those
defined previously.
[00168] Late-stage introduction of the R1 group onto compounds (XIII) may be carried out by
alkylation to form compounds (III). Alkylation conditions are well known in the art, and
include the use of an alkyl halide or equivalent (R1-Y2, such as bromomethyl cyclopropane
for R1 = C cPr) in an appropriate solvent such as DMF, in the presence of a base such as
sodium hydride, or cesium carbonate, at ambient or elevated temperature (e.g. 80 °C).
Alkylation may occur on oxygen or on nitrogen; choice of reaction conditions may modulate
selectivity, and these regioisomers can typically be separated using known methods.
Compound (XIII) can be prepared as described in Schemes 4a-c and 7a-b where R1 = H .
Further manipulation of compounds (III) by known methods can be used to modify R1.
Scheme 10a
where Y are halogens such as Cl and R1, Xi, X2 are suitable groups chosen from those
defined previously.
[00169] Introduction of R1 group onto compounds (A-lll) may be carried out by alkylation to
form compounds (Vl-a). Alkylation conditions are well known in the art, and include the use
of an alkyl halide or equivalent (R1-Y2, such as iodomethane for R1 = Me) in an appropriate
solvent such as DMF, in the presence of a base such as sodium hydride, or cesium
carbonate, at ambient or elevated temperature (e.g. 80 °C). Alkylation may occur on oxygen
or on nitrogen; choice of reaction conditions may modulate selectivity, and these
regioisomers can typically be separated using known methods. Compounds (A-lll) are
commercially available or can be prepared by known methods, such as the nitration of
compounds (A-ll) using conditions including those shown in van Oeveren et al., Bioorg. Med.
Chem. Lett. 2007, 17, 1527. Compounds (A-ll) are commercially available or can be
prepared by known methods, such as hydrolysis of dihalo derivatives (A-l) using conditions
including those shown in Naik et al., J. Med. Chem. 2014, 57, 5419.
Scheme 10b
where W is as previously defined, Y and Y3 are independently chosen from halogens such
as F, Cl, Br, I or a suitable alternative such as OTf or OTs, Y2 independently chosen from
halogens such as Cl, Br, I or a suitable alternative such as OTf or OTs, R2 and R3 are small
alkyl such as methyl or ethyl, and R1, Xi, X2 are suitable groups chosen from those defined
previously.
[00170] Introduction of R1 group onto compounds (B-l) may be carried out by alkylation to
form compounds (B-l I). Alkylation conditions are well known in the art, and include the use of
an alkyl halide or equivalent (R1-Y2, such as iodomethane for R1 = Me) in an appropriate
solvent such as DMF, in the presence of a base such as sodium hydride, or cesium
carbonate, at ambient or elevated temperature (e.g. 80 °C). Alkylation may occur on oxygen
or on nitrogen; choice of reaction conditions may modulate selectivity, and these
regioisomers can typically be separated using known methods. Compounds (Vl-b) and (Vl-c)
may be prepared by a multistep process starting from compound (B-ll), by analogy to a
process described in the literature (Coppola ei al., Synthesis 1981 , 391 ; Stadlbauer et al., J.
Het. Chem. 1998, 35, 627; Tomassoli et al., Eur. J. Med. Chem. 201 1 , 46, 1; Ohashi et al.,
Bioorg. Med. Chem. 2012, 20, 5496; Tomassoli et al., Monatsh. Chem. 2016, 147, 1069;
Gaeta et al., WO 02/094203).
[00171] Alternatively, introduction of an R1 group onto compounds (C-l) may be carried out
with the displacement of the Y3 group by a substituted amine. SNAr conditions are well
known in the art, and include the use of a substituted amine (R1-NH2, such as methylamine
for R1 = Me) in an appropriate solvent such as THF, at ambient or elevated temperature (e.g.
40 °C). Compounds (C-lll) can be formed by one-pot amide bond formation/cyclisation of
compounds (C-ll). Suitable conditions for this transformation include the use of elevated
temperatures (such as 60 °C) in an appropriate solvent (such as DCM) with the addition of a
base (such as triethylamine) and the suitable acylating reagent (e.g. ethyl 3-chloro-3-
oxopropanoate). Compounds (C-lll) can be converted to the corresponding halide (Vl-b)
using conditions that are well known in the art, and include the use of POC at elevated
temperature (e.g. 80 °C).
Biological Activity
[00172] The biological assays described in the Examples section herein may be used to
measure the pharmacological effects of the compounds of the present invention.
[00173] Although the pharmacological properties of the compounds of Formula I vary with
structural change, as expected, the compounds of the invention were found to be active in
the HTRF in vitro assay, the NanoBRET cell assay and in some cases also in the SUDHL4
degradation assay described in the Examples section.
[00174] In general, as illustrated by the Example compound data in Table 1, the compounds
of the invention demonstrate an IC50 of 2.5 µΜ or less, which corresponds to a pICso of 5.6 or
more, in the HTRF assay described in the Examples section. Preferred compounds of the
invention demonstrate an IC50 of 500 nM or less, which corresponds to a pICso of 6.3 or
more, or an IC50 of 250 nM or less, which corresponds to a p ICso of 6.6 or more. The more
preferred compounds of the invention demonstrate an IC50 of 100 nM or less, which
corresponds to a pICso of 7.0 or more. The most preferred compounds of the invention
demonstrate an IC5 0 of 10 nM or less, which corresponds to a pICso of 8.0 or more.
[00175] In the NanoBRET cell assay described herein in the Examples section, as
illustrated by the Example compound data in Table 2 , the compounds of Formula I typically
demonstrate a pICso of 5.0 or more (preferably 6.0 or more). The most preferred compounds
of the invention demonstrate a pICso of 7.0 or more.
[00176] In the SUDHL4 degradation assay described herein in the Examples section, as
illustrated by the Example compound data in Table 3 , the compounds of Formula I may also
demonstrate a pDCso of 6.0 or more (preferably 6.5 or more).






[00178] According to a further aspect of the invention there is provided a pharmaceutical
composition which comprises a compound of the invention as defined hereinbefore, or a
pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a
pharmaceutically acceptable diluent or carrier.
[00179] The compositions of the invention may be in a form suitable for oral use (for
example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions,
emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as
creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by
inhalation (for example as a finely divided powder or a liquid aerosol), for administration by
insufflation (for example as a finely divided powder) or for parenteral administration (for
example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular,
intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).
[00180] The compositions of the invention may be obtained by conventional procedures
using conventional pharmaceutical excipients, well known in the art. Thus, compositions
intended for oral use may contain, for example, one or more colouring, sweetening,
flavouring and/or preservative agents.
[00181] An effective amount of a compound of the present invention for use in therapy is an
amount sufficient to treat or prevent a proliferative condition referred to herein, slow its
progression and/or reduce the symptoms associated with the condition.
[00182] The amount of active ingredient that is combined with one or more excipients to
produce a single dosage form will necessarily vary depending upon the individual treated
and the particular route of administration. For example, a formulation intended for oral
administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active
agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an
appropriate and convenient amount of excipients which may vary from about 5 to about 98
percent by weight of the total composition.
[00183] The size of the dose for therapeutic or prophylactic purposes of a compound of the
formula I will naturally vary according to the nature and severity of the conditions, the age
and sex of the animal or patient and the route of administration, according to well-known
principles of medicine.
[00184] In using a compound of the invention for therapeutic or prophylactic purposes it will
generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75
mg/kg body weight is received, given if required in divided doses. In general lower doses
will be administered when a parenteral route is employed. Thus, for example, for
intravenous or intraperitoneal administration, a dose in the range, for example, 0.1 mg/kg to
30 mg/kg body weight will generally be used. Similarly, for administration by inhalation, a
dose in the range, for example, 0.05 mg/kg to 25 mg/kg body weight will be used. Oral
administration may also be suitable, particularly in tablet form. Typically, unit dosage forms
will contain about 0.5 mg to 0.5 g of a compound of this invention.
Therapeutic Uses and Applications
[00185] The present invention provides compounds that function as inhibitors of BCL6
activity.
[00186] The present invention therefore provides a method of inhibiting BCL6 activity in vitro
or in vivo, said method comprising contacting a cell with an effective amount of a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.
[00187] The present invention also provides a method of treating a disease or disorder in
which BCL6 activity is implicated in a patient in need of such treatment, said method
comprising administering to said patient a therapeutically effective amount of a compound,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical
composition as defined herein.
[00188] The present invention provides a method of inhibiting cell proliferation, in vitro or in
vivo, said method comprising contacting a cell with an effective amount of a compound, or a
pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.
[00189] The present invention provides a method of treating a proliferative disorder in a
patient in need of such treatment, said method comprising administering to said patient a
therapeutically effective amount of a compound, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, or a pharmaceutical composition as defined herein.
[00190] The present invention provides a method of treating cancer in a patient in need of
such treatment, said method comprising administering to said patient a therapeutically
effective amount of a compound, or a pharmaceutically acceptable salt, hydrate or solvate
thereof, or a pharmaceutical composition as defined herein.
[00191] The present invention provides a compound, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in
therapy.
[00192] The present invention provides a compound, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the
treatment of a proliferative condition.
[00193] The present invention provides a compound, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the
treatment of cancer. In a particular embodiment, the cancer is human cancer.
[00194] The present invention provides a compound, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, as defined herein for use in the inhibition of BCL6 activity (i.e. in
the inhibition of BCL6 transcriptional repression and/or co-repressor binding).
[00195] Certain compounds of the present invention have been found to bind to BCL6 and
initiated the degradation of BCL6. Thus, the present invention also provides a compound, or
a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in
the degradation of BCL6.
[00196] The present invention provides a compound, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, as defined herein for use in the treatment of a disease or disorder
in which BCL6 activity is implicated.
[00197] The present invention provides a use of a compound, or a pharmaceutically
acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a
medicament for the treatment of a proliferative condition.
[00198] The present invention provides a use of a compound, or a pharmaceutically
acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a
medicament for the treatment of cancer. Suitably, the medicament is for use in the
treatment of human cancers.
[00199] The present invention provides a use of a compound, or a pharmaceutically
acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a
medicament for the inhibition of BCL6 activity (i.e. in the inhibition of BCL6 transcriptional
repression and/or co-repressor binding).
[00200] The present invention provides a use of a compound, or a pharmaceutically
acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a
medicament for the degradation of BCL6.
[00201] The present invention provides a use of a compound, or a pharmaceutically
acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a
medicament for the treatment of a disease or disorder in which BCL6 activity is implicated.
[00202] The term "proliferative disorder" and “proliferative condition” are used
interchangeably herein and pertain to an unwanted or uncontrolled cellular proliferation of
excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth,
whether in vitro in vivo. Examples of proliferative conditions include, but are not limited to,
pre-malignant and malignant cellular proliferation, including but not limited to, malignant
neoplasms and tumours, cancers (including breast cancer, non-small cell lung cancer
(NSCLC) and squamous cell carcinomas (SCC) (including SCC of the head and neck,
oesophagus, lung and ovary), leukemias (including acute lymphoblastic leukaemia (ALL)
and chronic myeloid leukaemia (CML)), lymphomas (including acute lymphoblastic
leukaemia (ALL) and chronic myeloid leukaemia (CML)), psoriasis, bone diseases,
fibroproliferative disorders (e.g., of connective tissues), and atherosclerosis. Any type of cell
may be treated, including but not limited to, lymphatic, blood, lung, colon, breast, ovarian,
prostate, liver, pancreas, brain, and skin.
[00203] The anti-cancer effect may arise through one or more mechanisms, including but
not limited to, the regulation of cell proliferation, the inhibition of angiogenesis (the formation
of new blood vessels), the inhibition of metastasis (the spread of a tumour from its origin),
the inhibition of invasion (the spread of tumour cells into neighbouring normal structures), or
the promotion of apoptosis (programmed cell death).
[00204] The compound of Formula (I), or a pharmaceutically acceptable salt thereof, being
an inhibitor of BCL6, has potential therapeutic uses in a variety of BCL6-mediated disease
states. BCL6 expression has been linked to a variety of lymphomas (Wagner et al. , British J
Haematology , 2010, 152 , 3-12). BCL6 is involved in chromosomal translocations in diffuse
large B-cell lymphoma (DLBCL) and inhibitors of BCL6 have been reported to kill DLBCL
cells (Cerchietti et al., Cancer Cell , 2010, 17, 400-41 1), primary low grade follicular
lymphoma cells (Cardenas et al., Clin Cancer Res , 2017, 23(4) , 885-893) and Burkitt
lymphoma cells (Polo et al., Nat Med , 2004, 10, 1329-1335). BCL6 is required for the
formation of follicular helper T cells (Hatzi et al., J Exp Med , 2015, 212(4) , 539-553), which
raises the possibility that BCL6 inhibitors may be used to treat angioimmunoblastic T-cell
lymphoma (AITL), in which BCL6 is strongly expressed (Cortes & Palomero, Curr Opin
Hematol . 2016, 23, 434-443).
[00205] BCL6 has also been implicated in leukaemia cells which have acquired resistance
to tyrosine kinase inhibitors (TKIs). TKIs typically fail to eradicate leukaemia-initiating cells,
which may often cause recurrence of leukaemia after initial treatment. BCL6 has been
identified as an important component of the TKI drug-resistance pathway in both Ph+ acute
lymphoblastic leukaemia (ALL) (Duy et al. , Nature , 201 1 , 473 , 384-388) and Ph+ chronic
myeloid leukaemia (CML) (Hurtz et al., J Exp Med , 201 1, 208(1 1) , 2163-2174). Inhibitors of
BCL6 may therefore be used to treat ALL and CML in combination with a TKI.
[00206] Further non-haematological, solid tumours may be treated with an inhibitor of BCL6.
BCL6 is amplified in approximately 50% of breast tumours and is expressed in many breast
cancer cell lines, including triple negative breast cancer cell lines (Walker et al., Oncogene ,
2015, 34, 1073-1082). BCL6 is also important for the survival and proliferation of non-small
cell lung cancer (NSCLC) cells, primarily due to repression of genes involved in DNA
damage repair (Marullo et al., Proc 107th Annual Meeting AACR , 2016, Abstract nr 1271 and
Deb et al., Cancer Res., 2017, Apr. 4 doi: 10.1 158/0008-5472.CAN-1 5-3052). BCL6
amplification may also be prevalent in squamous cell carcinomas (SCC) (including SCC of
the head & neck, oesophagus, lung and ovary). Furthermore, inhibition of BCL6 has recently
been reported to be a suitable therapeutic target for glioma and glioblatoma (Xu et al., Proc.
Natl. Acad. Sci. U.S.A, 2017, 114(15) , 3981-3986).
[00207] According to a further aspect of the specification there is provided a compound of
Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in
the treatment of haematological cancers such as lymphomas (including diffuse large B-cell
lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL) and
angioimmunoblastic T-cell lymphoma (AITL)), leukaemias (including acute lymphoblastic
leukaemia (ALL) and chronic myeloid leukaemia (CML)) and multiple myeloma, and of solid
tumours (including glioma, breast cancer, non-small cell lung cancer (NSCLC) and
squamous cell carcinomas (SCC) (including SCC of the head and neck, oesophagus, lung
and ovary)).
[00208] According to a further feature of this aspect of the specification there is provided a
compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore for use in the treatment of lymphomas, including DLBCL, FL, BL and AITL.
[00209] According to a further feature of this aspect of the specification there is provided a
compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore for use in the treatment of DLBCL and FL.
[00210] According to a further feature of this aspect of the specification there is provided a
compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore for use in the treatment of leukaemias, including ALL and CML.
[00211] According to a further feature of this aspect of the specification there is provided a
compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore for use in the treatment of solid tumours, including glioma, breast cancer,
NSCLC and SCC.
[00212] According to a further feature of this aspect of the specification there is provided a
method for treating haematological cancers such as lymphomas (including DLBCL, FL, BL
and AITL), leukaemias (including ALL and CML) and multiple myeloma, and of solid tumours
(including glioma, breast cancer, NSCLC and SCC (including SCC of the head and neck,
oesophagus, lung and ovary)) in a warm-blooded animal such as man that is in need of such
treatment, which comprises administering an effective amount of a compound of Formula (I),
or a pharmaceutically acceptable salt thereof, as defined hereinbefore.
[00213] According to a further feature of this aspect of the specification there is provided a
method for treating lymphomas, including DLBCL, FL, BL and AITL, in a warm-blooded
animal such as man that is in need of such treatment, which comprises administering an
effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt
thereof, as defined hereinbefore.
[00214] According to a further feature of this aspect of the specification there is provided a
method for treating DLBCL and FL, in a warm-blooded animal such as man that is in need of
such treatment, which comprises administering an effective amount of a compound of
Formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore.
[00215] According to a further feature of this aspect of the specification there is provided a
method for treating leukaemias, including ALL and CML, in a warm-blooded animal such as
man that is in need of such treatment, which comprises administering an effective amount of
a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore.
[00216] According to a further feature of this aspect of the specification there is provided a
method for treating solid tumours (including glioma, breast cancer, NSCLC and SCC
(including SCC of the head and neck, oesophagus, lung and ovary)), in a warm-blooded
animal such as man that is in need of such treatment, which comprises administering an
effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt
thereof, as defined hereinbefore.
[00217] According to a further feature of this aspect of the specification there is provided the
use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore in the manufacture of a medicament for use in the treatment of haematological
cancers such as lymphomas (including DLBCL, FL, BL and AITL), leukaemias (including
ALL and CML) and multiple myeloma, and of solid tumours (including glioma, breast cancer,
NSCLC and SCC (including SCC of the head and neck, oesophagus, lung and ovary)).
[00218] According to a further feature of this aspect of the specification there is provided the
use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore in the manufacture of a medicament for use in the treatment of lymphomas,
including DLBCL, FL, BL and AITL.
[00219] According to a further feature of this aspect of the specification there is provided the
use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore in the manufacture of a medicament for use in the treatment of DLBCL and FL.
[00220] According to a further feature of this aspect of the specification there is provided the
use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore in the manufacture of a medicament for use in the treatment of leukaemias,
including ALL and CML.
[00221] According to a further feature of this aspect of the specification there is provided the
use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as defined
hereinbefore in the manufacture of a medicament for use in the treatment of solid tumours
(including glioma, breast cancer, NSCLC and SCC (including SCC of the head and neck,
oesophagus, lung and ovary)).
Routes of Administration
[00222] The compounds of the invention or pharmaceutical compositions comprising these
compounds may be administered to a subject by any convenient route of administration, whether
systemically, peripherally or topically (i.e. , at the site of desired action).
[00223] Routes of administration include, but are not limited to, oral (e.g, by ingestion);
buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal
(including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye
drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through
the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for
example, by injection, including subcutaneous, intraderrmal, intramuscular, intravenous, intra-arterial,
intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal,
intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or
reservoir, for example, subcutaneously or intramuscularly.
Combination Therapies
[00224] The antiproliferative treatment defined hereinbefore may be applied as a sole
therapy or may involve, in addition to the compound of the invention, conventional surgery or
radiotherapy or chemotherapy. Such chemotherapy may include one or more of the
following categories of anti-tumour agents:-
(i) other antiproliferative/antineoplastic drugs and combinations thereof, as used in
medical oncology, such as alkylating agents (for example cis-platin, oxaliplatin, carboplatin,
cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan, temozolamide
and nitrosoureas); antimetabolites (for example gemcitabine and antifolates such as
fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine
arabinoside, and hydroxyurea); antitumour antibiotics (for example anthracyclines like
adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C,
dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like
vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and taxotere and
polokinase inhibitors); and topoisomerase inhibitors (for example epipodophyllotoxins like
etoposide and teniposide, amsacrine, topotecan and camptothecin);
(ii) cytostatic agents such as antioestrogens (for example tamoxifen, fulvestrant,
toremifene, raloxifene, droloxifene and iodoxyfene), antiandrogens (for example
bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH
agonists (for example goserelin, leuprorelin and buserelin), steroid hormones, including
progestogens (for example megestrol acetate) and corticosteroids (for example
dexamethasone, prednisone and prednisolone), aromatase inhibitors (for example as
anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5a-reductase such as
finasteride;
(iii) anti-invasion agents [for example c-Src kinase family inhibitors like 4-(6-chloro-2,3-
methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-
yloxyquinazoline (AZD0530; International Patent Application WO 01/94341), A/-(2-chloro-6-
methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-
5-carboxamide (dasatinib, BMS-354825; J . Med. Chem. , 2004, 47, 6658-6661) and bosutinib
(SKI-606), and metalloproteinase inhibitors like marimastat, inhibitors of urokinase
plasminogen activator receptor function or antibodies to Heparanase];
(iv) inhibitors of growth factor function: for example such inhibitors include growth factor
antibodies and growth factor receptor antibodies (for example the anti-erbB2 antibody
trastuzumab [Herceptin™], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody
cetuximab [Erbitux, C225] and any growth factor or growth factor receptor antibodies
disclosed by Stern et ai (Critical reviews in oncology/haematology, 2005, Vol. 54, pp1 1-29);
such inhibitors also include tyrosine kinase inhibitors, for example inhibitors of the epidermal
growth factor family (for example EGFR family tyrosine kinase inhibitors such as A/-(3-chloro-
4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD1839),
A/-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-
acrylamido-/\/-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)-quinazolin-4-amine (Cl
1033), erbB2 tyrosine kinase inhibitors such as lapatinib); inhibitors of the hepatocyte growth
factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived
growth factor family such as imatinib and/or nilotinib (AMN107); inhibitors of serine/threonine
kinases (for example Ras/Raf signalling inhibitors such as farnesyl transferase inhibitors, for
example sorafenib (BAY 43-9006), tipifarnib (R1 15777) and lonafarnib (SCH66336)),
inhibitors of cell signalling through MEK and/or AKT kinases, c-kit inhibitors, abl kinase
inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor
(insulin-like growth factor) kinase inhibitors; aurora kinase inhibitors (for example AZD1 152,
PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528 AND AX39459) and cyclin
dependent kinase inhibitors such as CDK2 and/or CDK4 inhibitors;
(v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial
growth factor, [for example the anti-vascular endothelial cell growth factor antibody
bevacizumab (Avastin™) and for example, a VEGF receptor tyrosine kinase inhibitor such
as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU1 1248), axitinib (AG-013736),
pazopanib (GW 786034) and 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-
ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), compounds such as
those disclosed in International Patent Applications W097/22596, WO 97/30035, WO
97/32856 and WO 98/13354 and compounds that work by other mechanisms (for example
linomide, inhibitors of integrin ανβ3 function and angiostatin)];
(vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in
International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669,
WO 01/92224, WO 02/04434 and WO 02/08213;
(vii) an endothelin receptor antagonist, for example zibotentan (ZD4054) or atrasentan;
(viii) antisense therapies, for example those which are directed to the targets listed above,
such as ISIS 2503, an anti-ras antisense;
(ix) gene therapy approaches, including for example approaches to replace aberrant
genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme
pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or
a bacterial nitroreductase enzyme and approaches to increase patient tolerance to
chemotherapy or radiotherapy such as multi-drug resistance gene therapy; and
(x) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to
increase the immunogenicity of patient tumour cells, such as transfection with cytokines
such as interleukin 2 , interleukin 4 or granulocyte-macrophage colony stimulating factor,
approaches to decrease T-cell anergy, approaches using transfected immune cells such as
cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines
and approaches using anti-idiotypic antibodies.
[00225] In a particular embodiment, the antiproliferative treatment defined hereinbefore may
involve, in addition to the compound of the invention, conventional surgery or radiotherapy or
chemotherapy, wherein the chemotherapy may include one or more anti-tumour agents
selected from procarbazine, carmustine, lomustine, irinotecan, temozolomide, cisplatin,
carboplatin, methotrexate, etoposide, cyclophosphamide, ifosfamide, and vincristine.
[00226] In another particular embodiment, the antiproliferative treatment defined
hereinbefore may involve, in addition to the compound of the invention, conventional surgery
or radiotherapy or chemotherapy, wherein the chemotherapy may include one or more
chemotherapeutic agents selected from a BCL-2 family inhibitor (e.g. Venetoclax and/or
navitoclax), a BTK inhibitor (e.g. Ibrutinib, Acalabrutinib, Tirabrutinib (ONO/GS-4059), BGB-
3 111 or Spebrutinib (CC-292), a TNF inhibitor (e.g. Lenalidomide) or an EZH2 inhibitor (e.g.
Tazmetostat, CPI-1205, PF-06821497, GSK126, GSK343 or EPZ01 1989).
[00227] Such conjoint treatment may be achieved by way of the simultaneous, sequential or
separate dosing of the individual components of the treatment. Such combination products
employ the compounds of this invention within the dosage range described hereinbefore and
the other pharmaceutically-active agent within its approved dosage range.
[00228] According to this aspect of the invention there is provided a combination for use in
the treatment of a cancer (for example a cancer involving a solid tumour) comprising a
compound of the invention as defined hereinbefore, or a pharmaceutically acceptable salt,
hydrate or solvate thereof, and another anti-tumour agent.
[00229] According to this aspect of the invention there is provided a combination for use in
the treatment of a proliferative condition, such as cancer (for example a cancer involving a
solid tumour), comprising a compound of the invention as defined hereinbefore, or a
pharmaceutically acceptable salt, hydrate or solvate thereof, and any one of the anti-tumour
agents listed herein above.
[00230] According to this aspect of the invention there is provided a combination for use in
the treatment of a cancer comprising a compound of the invention as defined hereinbefore,
or a pharmaceutically acceptable salt, hydrate or solvate thereof, and a tyrosine kinase
inhibitor.
[00231] According to this aspect of the invention there is provided a combination for use in
the treatment of leukaemia (such as ALL or CML) comprising a compound of the invention
as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof,
and a tyrosine kinase inhibitor.
[00232] According to this aspect of the invention there is provided a combination for use in
the treatment of lymphomas comprising a compound of the invention as defined
hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and an EZH2
inhibitor.
[00233] In a further aspect of the invention there is provided a compound of the invention or
a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of
cancer in combination with another anti-tumour agent, optionally selected from one listed
herein above.
[00234] In a further aspect of the invention there is provided a compound of the invention or
a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of
cancer in combination with a tyrosine kinase inhibitor, optionally selected from one listed
herein above.
[00235] In a further aspect of the invention there is provided a compound of the invention or
a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of
leukaemia (such as ALL or CML) in combination with a tyrosine kinase inhibitor, optionally
selected from one listed herein above.
[00236] In a further aspect of the invention there is provided a compound of the invention or
a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of
cancer in combination with an EZH2 inhibitor, optionally selected from one listed herein
above.
[00237] In a further aspect of the invention there is provided a compound of the invention or
a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment of
lymphomas in combination with an EZH2 inhibitor, optionally selected from one listed herein
above.
[00238] Herein, where the term “combination” is used it is to be understood that this refers
to simultaneous, separate or sequential administration. In one aspect of the invention
“combination” refers to simultaneous administration. In another aspect of the invention
“combination” refers to separate administration. In a further aspect of the invention
“combination” refers to sequential administration. Where the administration is sequential or
separate, the delay in administering the second component should not be such as to lose
the beneficial effect of the combination.
[00239] According to a further aspect of the invention there is provided a pharmaceutical
composition which comprises a compound of the invention, or a pharmaceutically acceptable
salt, hydrate or solvate thereof, in combination with an anti-tumour agent (optionally selected
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[00240] LC/MS and HRMS analysis was performed on an Agilent 1200 series HPLC and
diode array detector coupled to a 6210 time of flight mass spectrometer with dual multimode
APCI/ESI source. Analytical separation was carried out at 40°C on a Merck Chromolith
Flash column (RP-18e, 25 x 2 mm) using a flow rate of 1.5 mL/min in a 2 minute gradient
elution with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A)
and water (solvent B), both containing formic acid at 0.1%. Gradient elution was as follows:
5:95 (A/B) to 100:0 (A/B) over 1.25 min, 100:0 (A/B) for 0.5 min, and then reversion back to
5:95 (A/B) over 0.05 min, finally 5:95 (A/B) for 0.2 min.
Method T4
[00241] As for method T2 except at 30°C, using a flow rate of 0.75 mL/min in a 4 minute
gradient elution as follows: 5:95 (A/B) to 100:0 (A/B) over 2.5 min, 100:0 (A/B) for 1 min, and
then reversion back to 5:95 (A/B) over 0.1 min, finally 5:95 (A/B) for 0.4 min.
Method X2
[00242] LC/MS and HRMS analysis was performed on a Waters Acquity UPLC and diode
array detector coupled to a Waters G2 QToF mass spectrometer fitted with a multimode
ESI/APCI source. Analytical separation was carried out at 30°C on a Phenomenex Kinetex
C 18 column (30 x 2 .1 mm, 2.6u, 100A) using a flow rate of 0.5 mL/min in a 2 minute gradient
elution with detection at 254 nm. The mobile phase was a mixture of methanol (solvent A)
and water (solvent B), both containing formic acid at 0.1%. Gradient elution was as follows:
10:90 (A/B) to 90:10 (A/B) over 1.25 min, 90:10 (A/B) for 0.5 min, and then reversion back to
10:90 (A/B) over 0.15 min, finally 10:90 (A/B) for 0.1 min.
Method X4
[00243] As for method X2, except using a flow rate of 0.3 mL/min in a 4 minute gradient
elution as follows: 10:90 (A/B) to 90:10 (A/B) over 3 min, 90:10 (A/B) for 0.5 min, and then
reversion back to 10:90 (A/B) over 0.3 min, finally 10:90 (A/B) for 0.2 min.
Analytical methods: NMR
[00244] NMR data was collected on a Bruker Avance 500 spectrometer equipped with a 5
mm BBO/QNP probe, or on a Bruker Avance Neo 600 spectrometer equipped with a 5 mm
TCI Cryo-Probe. The 1H and 1 C spectra were referenced to the internal deuterated solvent.
All NMR data were acquired at the temperature of 298 K . All data were acquired and
processed using Bruker Topspin 2.1 or Bruker Topspin 4 .
[00245] The 1H NMR spectra were acquired using a Bruker standard 1D zg30 pulse
sequence with 16 scans. The sweep width was 20.5 ppm, and the FID contained 64k time-
domain data points.
Purification methods
[00246] Unless otherwise described in the text, preparative HPLC purification was carried
out on an Agilent 6120 MS-Prep LC using an ACE 5 C18-PFP 250 x 2 1 .2 mm (or 30mm)
column using a 15 min gradient of water: methanol (both modified with 0.1% formic acid) -
for example 90:10 to 0:100 or 60:40 to 0:100 - at a flow rate of 20 mLmin 1 (or 40 mLmin 1
for the 30mm column).
[00247] Flash column chromatography was carried out using prepacked Biotage SNAP KP-
Sil columns. Reverse phase chromatography was carried out using a Biotage SNAP Ultra




[00248] A microwave vial (0. 5-2.0 ml_ volume) was charged with (S)-10-amino-2,7-
dimethyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate A1a, 9
mg, 0.034 mmol) and 2,4-dichloropyridine-3-carbonitrile (9 mg, 0.054 mmol). The reaction
vial was flushed with Ar, sealed with a cap and then further flushed with Ar. Anhydrous NMP
(0.6 ml_) was added followed by triethylamine (14 uL, 0.10 mmol). The reaction mixture was
heated at 160°C under microwave irradiation for 90 min. The reaction mixture was allowed
to cool to rt, diluted with DMSO (0.8 ml_) and directly purified using reverse-phase
chromatography (Biotage 12 g C-18; 10% to 100% MeOH in H2O (both containing 0.1%
formic acid) affording the title compound (7 mg, 53%) as an off-white solid. 1H NMR (600
MHz, Methanol-d ) δ 7.98 (d, J = 6.2 Hz, 1 H), 7.94 (d, J = 1.9 Hz, 1 H), 7.61 (d, J = 8.9 Hz,
1 H), 7.50 (dd, J = 8.9, 1.9 Hz, 1 H), 6.69 (d, J = 6.2 Hz, 1 H), 4.37^1.30 (m, 1 H), 4.28-4.22
(m, 1 H), 4.07-4.00 (m, 1 H), 3.73 (s, 3 H), 2.26-2.19 (m, 1 H), 1.92-1 .84 (m, 1 H), 1.38 (d, J
= 6.6 Hz, 3 H); LCMS (Method T4) RT 2.58 min; m/z calcd for C 20H 19CIN5CV [M+H]+:
396.1222, Found: 396.1215.
[00249] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 1a, starting from the intermediate(s) shown in the table.
For Example 1c, DIPEA was used instead of triethylamine and purification was conducted
by HPLC. For Example 1t, an additional purification step by preparative HPLC was
conducted. For Example 1u, DIPEA was used instead of trimethylamine and the reaction
was heated at 140 °C under microwave irradiation for 4 h .






Example 2a: (S)-6-chloro-5-cyano-4-((2,7-dimethyl-6-oxo-1 ,2,3,4,6,7-hexahydro-[1 ,4]ox-
azepino[2,3-c]quinolin-1 0-yl)amino)picolinic acid
[00250] A microwave vial (0. 5-2.0 ml_ volume) was charged with (S)-10-amino-2,7-
dimethyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate A1a, 13
mg, 0.049 mmol) and 4,6-dichloro-5-cyanopicolinic acid (15 mg, 0.071 mmol). The reaction
vial was flushed with Ar, sealed with a cap and then further flushed with Ar. Anhydrous NMP
(0.5 ml_) was added and the reaction mixture was heated at 100°C for 2 h . The reaction
mixture was cooled to rt, diluted with DMSO (0.8 ml_) and directly purified by reverse-phase
chromatography (Biotage reverse-phase 12 g C-18 column; 10-100% MeOH in H2O
(containing 0.1% formic acid)), affording the title compound (13 mg, 61%) as a yellow solid.
1H NMR (500 MHz, DMSO-cfe) δ 13.67 (br s , 1 H), 9.89 (s, 1 H), 8.04 (d, J = 2.1 Hz, 1 H),
7.51 (d, J = 9.0 Hz, 1 H), 7.46 (dd, J = 9.0, 2.1 Hz, 1 H), 7.18 (s, 1 H), 5.64 (d, J = 2.8 Hz, 1
H), 4.20—4.09 (m, 2 H), 3.92-3.86 (m, 1 H), 3.58 (s, 3 H), 2.13-2.06 (m, 1 H), 1.81-1 .73 (m,
1 H), 1.29 (d, J = 6.6 Hz, 3 H); LCMS (Method T4) RT 2.46 min; m/z calcd for C2 1H19CIN5CV
[M+H]+: 440.1 120, Found: 440.1 114.
[00251] The following tabulated example was prepared by a method analogous to that used
for the preparation of Example 2a, starting from the intermediate(s) shown in the table.
Example 3a: (S)-6-(azetidine-1 -carbonyl)-2-chloro-4-((2,7-dimethyl-6-oxo-1 ,2,3,4,6,7-
hexahydro-[1,4]oxazepino[2,3-c]quinolin-10-yl)amino)nicotinonitrile
[00252] DIPEA (14 uL, 0.079 mmol) followed by T3P (50 wt% in EtOAc, 25 mg, 0.040
mmol) and azetidine (2 uL, 0.0282 mmol) were added sequentially to a solution of (S)-6-
chloro-5-cyano-4-((2,7-dimethyl-6-oxo-1,2,3,4,6,7-hexahydro-[1,4]oxazepino[2,3-c]quinolin-
10-yl)amino)picolinic acid (Example 2a, 12 mg, 0.026 mmol) in DMF (0.5 ml_) at rt. The
reaction mixture was stirred at rt for 90 min. Water (8 drops) was added to quench the
reaction. The aqueous suspension was dissolved in DMSO (0.8 ml_) and directly purified by
reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 10-100% MeOH
in H2O (containing 0.1% formic acid)), affording the title compound (4 mg, 29%) as a yellow
solid. 1H NMR (600 MHz, CDCh) δ 7.44-7.31 (m, 4 H), 7.03 (s, 1 H), 4.74^1.66 (m, 2 H),
4.48—4.41 (m, 1 H), 4.41^1.33 (m, 1 H), 4.20-4.14 (m, 2 H), 4.08-4.00 (m, 1 H), 3.94-3.82
(m, 1 H), 3.73 (s, 3 H), 2.38-2.32 (m, 2 H), 2.29-2.21 (m, 1 H), 1.85-1.78 (m, 1 H), 1.39
(d, J = 6.1 Hz, 3 H); LCMS (Method T4) RT 2.77 min; m/z calcd for C24H24CIN6 [M+H]+:
479.1593, Found: 479.1578.
[00253] The following tabulated example was prepared by a method analogous to that used
for the preparation of Example 3a, starting from the intermediate(s) shown in the table and
appropriate amine.
Example 4a: (S)-1 0-((2,3-dichloropyridin-4-yl)amino)-2,7-dimethyl-1 ,2,3,4-tetrahydro-
[1,4]oxazepino[2,3-c]quinolin-6(7H)-one
[00254] A microwave vial (0. 5-2.0 ml_ volume) was charged with (S)-10-amino-2,7-
dimethyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate A1a, 7
mg, 0.027 mmol), 2,3-dichloro-4-iodopyridine (9 mg, 0.032 mmol), cesium carbonate (71 mg,
0.22 mmol), Pd2(dba)3 (2.5 mg, 0.003 mmol) and Xantphos (9 mg, 0.016 mmol). The
reaction vial was flushed with Ar and sealed with a cap. Anhydrous DMF (0.2 ml_) and
toluene (0.6 ml_) were added and Ar was bubbled through the reaction mixture for 5 mins.
The reaction mixture was heated at 80°C under microwave irradiation for 1 h . The reaction
mixture was cooled to rt. Water (10 ml_) was added and the aqueous mixture was extracted
with EtOAc (3 x 10 ml_). The organic extracts were combined, washed with brine (10 ml_),
dried (Na2S0 4) and concentrated in vacuo. The crude product was dissolved in DMSO ( 1 .2
ml_) and directly purified by reverse-phase chromatography (Biotage reverse-phase 12 g
Ultra C-18 column; 10-100% MeOH in H2O (containing 0.1% formic acid)), affording the title
compound (5 mg, 48%) as an off-white solid. 1H NMR (600 MHz, Methanol-d ) δ 7.91 (d, J =
1.8 Hz, 1 H), 7.82 (d, J = 5.8 Hz, 1 H), 7.60 (d, J = 8.9 Hz, 1 H), 7.50 (dd, J = 8.9, 1.8 Hz, 1
H), 6.71 (d, J = 5.8 Hz, 1 H), 4.37-4.31 (m, 1 H), 4.28-4.23 (m, 1 H), 4.07-4.00 (m, 1 H),
3.73 (s, 3 H), 2.25-2.19 (m, 1 H), 1.92-1 .85 (m, 1 H), 1.38 (d, J = 6.6 Hz, 3 H); LCMS
(Method T4) RT 2.72 min; m/z calcd for C19H19C I2N4CV [M+H]+: 405.0880, Found: 405.0879.
[00255] The following tabulated example was prepared by a method analogous to that used
for the preparation of Example 4a, starting from the intermediate(s) shown in the table.
Example 4b was purified by preparative HPLC. For Example 4d, the reaction mixture was
heated at 80 °C under microwave irradiation for 4 h .
Example 5a: (/?)-10-((5-chloro-2-(3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrimidin-4-
yl)amino)-2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-
6(7H)-one
Step 1: (R)-2-cyclopropyl-10-((2, 5-dichloropyrimidin-4-yl)amino)-7-methyl-1 ,2,3,4-tetrahvdro-
[ 1,4loxazepino[2,3-clauinolin-6(7H)-one
[00256] An oven-dried microwave vial (0. 5-2.0 ml_ volume) was charged with (F?)-10-amino-
2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one
(Intermediate Aid, 19 mg, 0.065 mmol) and 2,4,5-trichloropyrimidine (20 mg, 0.1 10 mmol).
The reaction vial was flushed with Ar, sealed with a cap and then further flushed with Ar.
Anhydrous NMP (0.65 ml_) was added followed by DIPEA (45 uL, 0.26 mmol). The reaction
mixture was heated at 140°C under microwave irradiation for 1 h . The reaction mixture was
cooled to rt, diluted with DMSO (0.8 ml_) and directly purified by reverse-phase
chromatography (Biotage reverse-phase 12 g C-18 column; 10-80% MeOH in H2O
(containing 0.1% formic acid)), affording (F?)-2-cyclopropyl-10-((2,5-dichloropyrimidin-4-
yl)amino)-7-methyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (24 mg, 84%)
as a red/brown solid. LCMS (Method X2) RT 1.42 min; m/z 432.1000 [M+H]+.
Step 2: (R)-10-((5-chloro-2-(3-(trifluoromethyl)- 1H-pyrazol- 1-yl)pyrimidin-4-yl)amino)-2-
cvclopropyl-7-methyl-1 ,2,3,4Jetrahvdro-[1,4loxazepino[2,3-clquinolin-6(7H)-one
[00257] A microwave vial (0. 5-2.0 ml_ volume) was charged with (R)-2-cyclopropyl-10-((2,5-
dichloropyrimidin-4-yl)amino)-7-methyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-
6(7/-/)-one (from step 1 ; 9 mg, 0.021 mmol), 3-(trifluoromethyl)-1 H-pyrazole (28 mg, 0.207
mmol) and cesium carbonate (67 mg, 0.204 mmol). The reaction vial was flushed with Ar,
sealed with a cap and then further flushed with Ar. Anhydrous NMP (0.8 ml_) was added.
The reaction mixture was heated at 180°C under microwave irradiation for 1 h . The reaction
mixture was cooled to rt, diluted with DMSO (0.8 ml_) and directly purified by reverse-phase
chromatography (Biotage reverse-phase 12 g C-18 column; 10-50-100% MeOH in H2O
(containing 0.1% formic acid)), affording the title compound (7 mg, 62%) as a beige solid. 1H
NMR (600 MHz, CDCI3) δ 8.48 (br d , J = 2.4 Hz, 1 H), 8.44 (s, 1 H), 8.03 (d, J = 1.9 Hz, 1 H),
7.64 (dd, J = 8.9, 1.9 Hz, 1 H), 7.48 (s, 1 H), 7.39 (d, J = 8.9 Hz, 1 H), 6.70 (d, J = 2.4 Hz, 1
H), 4.54—4.47 (m, 1 H), 4.37 (br s , 1 H), 4.35^1.29 (m, 1 H), 3.75 (s, 3 H), 2.96 (dt, J = 9.7,
3.3 Hz, 1 H), 2.41-2.32 (m, 1 H), 2.1 1-2.03 (m, 1 H), 1.13-1.05 (m, 1 H), 0.66-0.59 (m, 1
H), 0.50-0.43 (m, 1 H), 0.35-0.28 (m, 1 H), 0.27-0.21 (m, 1 H); LCMS (Method X4) RT 3.25
min; m/z calcd for C CIF N [M+H]+: 532.1475, Found: 532.1500.
[00258] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 5a, starting from the intermediate(s) shown in the table
and the appropriate amine. No purification was conducted during step 1 in Examples 5b-
5h, 5k and 5p-5t. In Examples 5d-5i and 5k-5t DIPEA was used instead of cesium









[00259] A microwave vial (0. 5-2.0 ml_ volume) was charged with (F?)-10-amino-2-
cyclopropyl-7-((3,3-difluorocyclobutyl)methyl)-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-
c]quinolin-6(7/-/)-one (Intermediate A5b; 6.5 mg, 0.017 mmol) and DIPEA (12 uL, 0.069
mmol). A solution of (1F?,5S,7s)-9-(5-chloro-4-(methylsulfinyl)pyrimidin-2-yl)-3-oxa-9-
azabicyclo[3.3.1]nonan-7-ol (Intermediate J 1 ; 7.0 mg, 0.022 mmol) in isopropanol (0.7 ml_)
was then added and the vial was flushed with Ar and sealed with a cap. The reaction mixture
was heated at 140°C in a heating block for 18 h . After this time, the reaction mixture was
cooled to rt and additional DIPEA (20 uL, 0.1 1 mmol) was added. The vial was re-sealed
with a cap and heated at 140 C in a heating block for a further 6 h . The reaction mixture was
cooled to rt and concentrated in vacuo. The reaction mixture was dissolved in DMSO ( 1 ml_)
and directly purified by reverse-phase chromatography (Biotage reverse-phase 12 g C-18
column; 60-90% MeOH in H2O (containing 0.1% formic acid)), affording the desired product
which co-ran with an impurity. The crude product was further purified by flash
chromatography (10 g KP-sil; 50% to 100% EtOAc in cyclohexane followed by 0% to 20%
MeOH in EtOAc) affording an off-white solid. The solid was dissolved in MeOH and passed
through an SCX-2 ( 1 g) column, eluting with MeOH (15 ml_) followed by 2 N methanolic
ammonia (20 ml_). The basic fraction was concentrated in vacuo affording the title compound
( 1 .8 mg, 17%) as an off-white solid. 1H NMR (600 MHz, methanol-d ) δ 8.01 (s, 1 H), 7.94 (d,
J = 2.3 Hz, 1 H), 7.86 (dd, = 9.1, 2.3 Hz, 1 H), 7.54 (d, J = 9.1 Hz, 1 H), 4.56 (dd, J = 14.4,
7.2 Hz, 2 H), 4.54 (dd, J = 14.4, 6.9 Hz, 2 H), 4.41^1.36 (m, 1 H), 4.24^1.19 (m, 1 H), 3.94-
3.86 (m, 3 H), 3.80-3.74 (m, 2 H), 2.96 (dt, J = 9.5, 3.6 Hz, 1 H), 2.70-2.50 (m, 5 H), 2.38-
2.30 (m, 1 H), 2.25-2.16 (m, 2 H), 2.13-2.06 (m, 1 H), 1.82-1 .74 (m, 2 H), 1.25-1 .19 (m, 1
H), 0.68-0.61 (m, 2 H), 0.44-0.37 (m, 1 H), 0.37-0.30 (m, 1 H); LCMS (Method T4) RT 3.02
min; m/z calcd for C i H eCIF Ne [M+H]+: 629.2449, Found: 629.2436.
Example 6a: (S)-2-chloro-4-((2,7-dimethyl-5,6-dioxo-1 ,2,3,5,6,7-hexahydro-[1 ,4]oxaze-
pino[6,5-c]quinolin-10-yl)amino)nicotinonitrile
[00260] A suspension of DIPEA (10 uL, 0.077 mmol), 2,4-dichloropyridine-3-carbonitrile (6
mg, 0.036 mmol) and (S)-10-amino-2,7-dimethyl-2,3-dihydro-[1,4]oxazepino[6,5-c]quinoline-
5,6(1 /-/,7/-/)-dione (Intermediate B1a, 7 mg, 0.026 mmol) in NMP (1.5 ml_) was stirred under
microwave irradiation at 160°C for 1 h . The crude reaction mixture was directly purified by
preparative HPLC (15 min gradient of 60:40 to 0:100 H20:MeOH (both modified with 0.1 %
formic acid); flow rate 20 mLmin 1) affording the title compound ( 1 mg, 10%) as a light brown
solid which was subsequently washed with Et20 and dried. 1H NMR (500 MHz, DM F-c ) δ
8.43 (d, J = 2.2 Hz, 1 H), 8.27 (d, J = 6.2 Hz, 1 H), 7.87 (dd, J = 9.0, 2.2 Hz, 1 H), 7.80 (s, 1
H), 7.78 (d, J = 9.0 Hz, 1 H), 7.03 (d, J = 6.2 Hz, 1 H), 4.81 (dd, J = 13.0, 1.5 Hz, 1 H), 4.63
(dd, J = 13.0, 5.5 Hz, 1 H), 4.24-4.30 (m, 1 H), 3.80 (s, 3 H), 1.52 (d, J = 6.6 Hz, 3 H); LCMS
(Method T4) RT 2.35 min; m/z calcd for C 20H17CIN5CV [M+H]+: 410.1014, Found: 410.1007.
[00261] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 6a, starting from the intermediate(s) shown in the table.
Example 7a: (S)-10-((5-chloro-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridin-4-yl)amino)-2,7-
dimethyl-2, 3-dihydro-[1,4]oxazepino[6,5-c]quinoline-5, 6(1 H,7H)-d\one
[00262] A mixture of cesium carbonate (95 mg, 0.293 mmol), Xantphos (13 mg, 0.022
mmol), (S)-1 0-amino-2,7-dimethyl-2,3-dihydro-[1 ,4]oxazepino[6,5-c]quinoline-5,6(1 HJH)-
dione (Intermediate B1a, 10 mg, 0.037 mmol), 5-chloro-4-iodo-2-((tetrahydro-2/-/-pyran-4-
yl)oxy)pyridine (Intermediate H 1 , 12 mg, 0.037 mmol) and Pd2(dba)3 (3 mg, 0.004 mmol)
was suspended in a mixture of toluene (3 ml_) and DMF (0.5 ml_). The resulting suspension
was stirred under microwave irradiation at 140°C for 1 h . The reaction mixture was allowed
to cool to rt. The suspension was filtered, and the filtrated was diluted with water and
extracted with EtOAc. The organic extracts were combined, dried (Na2S0 4) and
concentrated in vacuo. Purification by preparative HPLC (15 min gradient of 60:40 to 0:100
H20:MeOH (both modified with 0.1 % formic acid); flow rate 20 mLmin 1) afforded the title
compound (4 mg, 23%) as a light yellow solid. 1H NMR (600 MHz, DMF-d ) δ 8.50 (s, 1 H),
8.38 (d, J = 2.2 Hz, 1 H), 8.19 (s, 1 H), 7.85 (dd, J = 8.9, 2.2 Hz, 1 H), 7.77 (d, J = 8.9 Hz, 1
H), 7.75 (br s , 1 H), 6.20 (s, 1 H), 5.28 (tt, J = 8.6, 4.1 Hz, 1 H), 4.81 (dd, J = 12.9, 1.6 Hz, 1
H), 4.65 (dd, J = 12.9, 5.6 Hz, 1 H), 4.32^1.23 (m, 1 H), 4.02 (dt, J = 11.5, 4.4 Hz, 2 H), 3.81
(s, 3 H), 3.67 (ddd, J = 11.5, 9.4, 2.8 Hz, 2 H), 2.21-2.07 (m, 2 H), 1.83-1.70 (m, 2 H), 1.54
(d, J = 6.6 Hz, 3 H); LCMS (Method X4) RT 2.49 min; m/z calcd for C24H26CIN40 5+ [M+H]+:
485.1586, Found: 485.1542.
Example 8a: (S)-1 0-((5-chloro-2-((2S,6/?)-2,6-dimethylmorpholino)pyrimidin-4-
yl)amino)-2,7-dimethyl-2,3-dihydro-[1,4]oxazepino[6,5-c]quinoline-5,6(1H,7H)-dione
Step 1: (S)-10-((2,5-dichloropyrimidin-4-yl)amino)-2, 7-dimethyl-2,3-dihydro-[ 1Aloxazepi no
te 5-clouinoline-5, 6(1H, 7H)-dione
[00263] A suspension of 2,4,5-trichloropyrimidine (12 mg, 0.066 mmol), (S)-10-amino-2,7-
dimethyl-2,3-dihydro-[1,4]oxazepino[6,5-c]quinoline-5,6(1/-/,7/-/)-dione (Intermediate B1a, 20
mg, 0.073 mmol) and DIPEA (20 uL, 0.1 10 mmol) in NMP ( 1 .5 ml_) was stirred under
microwave irradiation at 140°C for 1h. The reaction mixture containing (S)-10-((2,5-
dichloropyrimidin-4-yl)amino)-2,7-dimethyl-2,3-dihydro-[1,4]oxazepino[6,5-c]quinoline-
5,6(1 /-/,7/-/)-dione was divided into aliquots to be used in the next step without further
purification. LCMS (Method T2) RT 1.27 min; m/z 420.1 [M+H]+.
Step 2: (S)-10-((5-chloro-2-((2S,6R)-2,6-dimethylmorpholino)pyrimidin-4-yl)amino)-2, 1-
dimethyl-2,3-dihydro-i 1,4loxazepino[6,5-clauinoline-5, 6(1H, 7H)-dione
[00264] A mixture of crude (S)-10-((2,5-dichloropyrimidin-4-yl)amino)-2,7-dimethyl-2,3-
dihydro-[1,4]oxazepino[6,5-c]quinoline-5,6(1/-/,7/-/)-dione (from step 1 ; 5 mg, 0.012 mmol),
(2R,6S)-2,6-dimethylmorpholine (7 mg, 0.060 mmol) and DIPEA (6 uL, 0.036 mmol) in NMP
( 1 .5 mL) was stirred under microwave irradiation at 140 °C for 1h. The crude reaction
mixture was directly purified by preparative HPLC (3 runs; 15 min gradient of 60:40 to 0:100
H20:MeOH (both modified with 0.1 % formic acid); flow rate 20 mLmin - 1) affording the title
compound (2 g, 34% over 2 steps) as a brown oil. 1H NMR (600 MHz, Methanol-d ) δ 8.20
(d, J = 2.4 Hz, 1 H), 7.98 (s, 1 H), 7.88 (dd, J = 9.0, 2.4 Hz, 1 H), 7.54 (d, J = 9.0 Hz, 1 H),
4.66 (d, J = 12.8 Hz, 1 H), 4.44 (dd, J = 12.8, 5.0 Hz, 1 H), 4.34 (d, J = 13.1 Hz, 2 H), 4.14-
3.98 (m, 1 H), 3.67 (s, 3 H), 3.61-3.51 (m, 2 H), 2.49 (dt, J = 13.7, 10.2 Hz, 2 H), 1.41 (d, J =
6.7 Hz, 3 H), 1.15 (m, 6 H); LCMS (Method T4) RT 2.55 min; m/z calcd for C H CINe
[M+H]+: 499.1855, Found: 499.1827.
[00265] The following tabulated examples were prepared by a method analogous to that





[00266] The following tabulated examples were prepared by an analogous method to that
used for the preparation of Example 8a. Example 8p and Example 8q represent a pair of
diastereoisomers where one is cis- and one is trans- across the oxazepinone ring. The
compounds were separated by preparative HPLC (15 min gradient of 60:40 to 0:100
O eOH (both modified with 0.1 % formic acid); flow rate 20 mLmin 1) with Example 8p
eluting first followed by Example 8q. It has not been unambiguously determined which is the
cis- and which is the trans- structure. Both compounds are racemic.
Example 9a: (S)-2-chloro-4-((2,7-dimethyl-6-oxo-1,2,3,5,6,7-hexahydro-[1,4]oxaze-
pino[6,5-c]quinolin-10-yl)amino)nicotinonitrile
[00267] A suspension of DIPEA (7 uL, 0.041 mmol), 2,4-dichloropyridine-3-carbonitrile (3
mg, 0.019 mmol) and (S)-10-amino-2,7-dimethyl-2,3,5,7-tetrahydro-[1,4]oxazepino[6,5-
c]quinolin-6(1/-/)-one (Intermediate B2a, 4 mg, 0.014 mmol) in NMP (1.5 ml_) was stirred
under microwave irradiation at 160 °C for 1 h . The crude reaction mixture was directly
purified by preparative HPLC (15 min gradient of 60:40 to 0:100 H20:MeOH (both modified
with 0.1 % formic acid); flow rate 20 mLmin 1) affording the title compound ( 1 mg, 19%) as a
yellow solid. 1H NMR (600 MHz, Methanol-d ) δ 8.06 (d, J = 2.2 Hz, 1 H), 8.00 (d, J = 6.2 Hz,
1 H), 7.65 (d, J = 8.9 Hz, 1 H), 7.58 (dd, J = 8.9, 2.2 Hz, 1 H), 6.71 (d, J = 6.2 Hz, 1 H), 4.94
(d, J = 14.4 Hz, 1 H), 4.84 (d, J = 14.4 Hz, 1 H), 3.96 (ddd, J = 9.2, 6.5, 3.0 Hz, 1 H), 3.93
(dd, J = 11.1, 3.0 Hz, 1 H), 3.72 (s, 3 H), 3.64 (dd, J = 11. 1 , 8.9 Hz, 1 H), 1.27 (d, J = 6.6 Hz,
3 H). LCMS (Method T4) RT 2.53 min; m/z calcd for C2oH 19CIN50 2+ [M+H]+: 396.1222,
Found: 396.1214.
[00268] The following tabulated examples were prepared by a method analogous to that




[00269] To a microwave vial (0.5 - 2.0 ml_ volume) containing 9-amino-2, 6-dimethyl-2, 3,4,6-
tetrahydrobenzo[/7][1 ,6]naphthyridin-5(1/-/)-one (Intermediate C 1; 12 mg, 0.05 mmol) was
added 2,4-dichloropyridine-3-carbonitrile ( 1 1 mg, 0.06 mmol), NMP (0.51 ml_) and
triethylamine (14 uL, 0.10 mmol). The vial was sealed and purged with argon for 5 min. The
vial was then heated at 160 °C under microwave irradiation for 1 h . The reaction mixture was
allowed to cool to rt. The reaction mixture was diluted with MeCN and directly purified by
preparative HPLC (15 min gradient of 60:40 to 0:100 H20:MeOH (both modified with 0.1 %
formic acid); flow rate 20 mLmin 1) affording the title compound (10 mg, 51%) as an off-white
solid. 1H NMR (500 MHz, CDCh) δ 8.04 (d, J = 6.1 Hz, 1 H), 7.44-7.37 (m, 3 H), 6.92 (s, 1
H), 6.59 (d, J = 6.1 Hz, 1 H), 4.51 (s, 1 H), 3.70 (s, 3 H), 3.58-3.47 (m, 1 H), 2.86 (ddd, J =
17.6, 5.3, 3.9 Hz, 1 H), 2.60 (ddd, J = 17.6, 10.5, 5.9 Hz, 1 H), 2.09-2.00 (m, 1 H), 1.69-1.52
(m, 1 H), 1.34 (d, J = 6.4 Hz, 3H); LCMS (Method X4) RT 2.60 min; m/z calcd for




[00270] A microwave vial (0. 5-2.0 ml_ volume) was charged with 10-amino-2-cyclopropyl-
3,3-difluoro-7-methyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one
(Intermediate A1I; 15 mg, 0.047 mmol) and (1R,5S,7s)-9-(5-chloro-4-(methylsulfonyl)-
pyrimidin-2-yl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-ol (Intermediate J2; 17 mg, 0.050 mmol).
2,2,2-Trifluoroethanol ( 1 .0 ml_) was added followed by trifluoroacetic acid (4.00 uL, 0.052
mmol). The reaction vial was flushed with Ar and sealed with a cap. The reaction mixture
was heated at 70°C in a heating block for 18 h . The reaction mixture was cooled to rt and
concentrated in vacuo. The residue was re-dissolved in DMSO ( 1 ml_) and directly purified
by reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 10-100%
MeOH in H20 (containing 0.1% formic acid)), affording the title compound (7 mg, 27%) as an
off-white solid. 1H NMR (600 MHz, methanol-d ) δ 8.02-7.99 (m, 2 H), 7.88 (dd, J = 9.1, 1.7
Hz, 1 H), 7.54 (d, J = 9.1 Hz, 1 H), 4.62^1.37 (m, 4 H), 3.94-3.84 (m, 3 H), 3.79-3.73 (m, 2
H), 3.71 (s, 3 H), 3.30-3.26 (m, 1 H), 2.24-2.14 (m, 2 H), 1.83-1 .73 (m, 2 H), 1.43-1 .36 (m,
1 H), 0.82-0.76 (m, 1 H), 0.69-0.63 (m, 1 H), 0.63-0.57 (m, 1 H), 0.37-0.31 (m, 1 H); LCMS
(Method X4) RT 2.95 min; m/z calcd for C27H3oCIF2N60 4+ [M+H]+: 575.1985, Found:
575.1973.
[00271] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 11a, starting from the intermediate(s) shown in the




[00272] An microwave vial (2-5 ml_ volume) was charged with (S)-10-amino-2-cyclopropyl-
3,3-difluoro-7-methyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one
(Intermediate Aim; 29 mg, 0.09 mmol) and (1F?,5S,7s)-9-(5-chloro-4-(methylsulfonyl)-
pyrimidin-2-yl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-ol (Intermediate J2; 36 mg, 0.1 1 mmol).
Trifluoroethanol ( 1 .0 ml_) was added followed by trifluoroacetic acid (7.7 uL, 0.10 mmol). The
reaction vial was flushed with Ar and sealed with a cap. The reaction mixture was heated
at 70°C in a heating block for 20 h . The reaction mixture was cooled to rt and
concentrated in vacuo. The residue was re-dissolved in DMSO ( 1 ml_) and directly purified
by reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 10-100%
MeOH in H2O (containing 0.1% formic acid)). The product-containing fractions were passed
through an SCX-2 (2 g) column, eluting with MeOH (15 ml_) followed by 2 N methanolic
ammonia (30 ml_). The basic fraction was concentrated in vacuo affording the title compound
(16 mg, 31%) as an off-white solid. 1H NMR (600 MHz, methanol-d ) δ 8.02-7.99 (m, 2 H),
7.88 (dd, = 9.1 , 1.7 Hz, 1 H), 7.54 (d, J = 9.1 Hz, 1 H), 4.62^1.37 ( , 4 H), 3.94-3.84 ( , 3
H), 3.79-3.73 (m, 2 H), 3.71 (s, 3 H), 3.30-3.26 (m, 1 H), 2.24-2.14 (m, 2 H), 1.83-1 .73 (m,
2 H), 1.43-1 .36 (m, 1 H), 0.82-0.76 (m, 1 H), 0.69-0.63 (m, 1 H), 0.63-0.57 (m, 1 H), 0.37-
0.31 (m, 1 H); LCMS (Method X4) RT 2.98 min; m/z calcd for C27H30CIF2N6CV [M+H] +:
575.1985, Found: 575.1987.
Example 12a: (S)-1 0-((5-chloro-2-(4-methyl-3-oxopiperazin-1 -yl)pyrimidin-4-yl)amino)-
2-cyclopropyl-3,3-difluoro-7-methyl-1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-
6(7H)-one
[00273] An oven-dried microwave vial (0. 5-2.0 ml_ volume) was charged with (S)-2-
cyclopropyl-10-((2,5-dichloropyrimidin-4-yl)amino)-3,3-difluoro-7-methyl-1 ,2,3,4-tetrahydro-
[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate A10a; 7 mg, 0.015 mmol), 1-
methylpiperazin-2-one (4 mg, 0.037 mmol) and DIPEA (13 uL, 0.075 mmol). The reaction
vial was flushed with A r and sealed with a cap. NMP (0.65 ml_) was added and the reaction
mixture was heated at 140°C under microwave irradiation for 1 h . The reaction mixture was
dissolved in DMSO (0.8 ml_) and directly purified by reverse-phase chromatography (Biotage
reverse-phase 12 g Ultra C-18 column; 10-60-80-100% MeOH in H2O (containing 0.1%
formic acid)). The product-containing fractions were combined, passed through an SCX-2 ( 1
g), additional MeOH (10 ml_) was passed through and the product was eluted with 2 N
methanolic ammonia (25 ml_). The solvent was removed in vacuo affording the title
compound (5 mg, 57%) as an off-white solid. 1H NMR (600 MHz, methanol-d ) δ 8.04 (d, J =
2.2 Hz, 1 H), 8.01 (s, 1 H), 7.92 (dd, J = 9.1, 2.2 Hz, 1 H), 7.57 (d, J = 9.1 Hz, 1 H), 4.53-
4.38 (m, 2 H), 4.24 (d, J = 18.2 Hz, 1 H), 4.18 (d, J = 18.2 Hz, 1 H), 3.98-3.92 (m, 1 H),
3.92-3.87 (m, 1 H), 3.73 (s, 3 H), 3.47-3.39 (m, 2 H), 3.35-3.28 (m, 1 H), 2.98 (s, 3 H),
1.42-1 .37 (m, 1 H), 0.82-0.75 (m, 1 H) 0.68-0.57 (m, 2 H), 0.37-0.31 (m, 1 H); LCMS
(Method X4) RT 2.85 min; m/z calcd for C2 5H27CIF2N 7 0 3+ [M+H] +: 546.1832, Found:
546.18342.
[00274] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 12a, starting from the intermediate(s) shown in the
table and appropriate amine. For Example 12c, Example 12d, Example 12e and Example
12u, reactions were heated at 140 °C in a heating block for 2-3 h . For Example 12f,
Example 12i, Example 12p, Example 12s, Example 12t and Example 12x, reactions were
heated at 140 °C under microwave irradiation for 90 min-3 h . For Example 12n and
Example 12o, reactions were heated at 140 °C under microwave irradiation for 1 h followed
by 140 °C in a heating block for 4 h . For Example 12v, the reaction was heated at 140 °C in
a heating block for 6 h . For Example 12h the reaction was heated at 160 °C in a heating
block overnight. For Example 12j and Example 12w, reactions were heated at 160 °C
under microwave irradiation for 10-12 h . For Example 12c and Example 12d, the SCX-2
purification step was not conducted. An additional purification step by normal-phase









[00275] The following tabulated examples were prepared by an analogous method to that
used for the preparation of Example 12a starting from Intermediate A10b: (R)-2 -
cyclopropyl-1 0-((2,5-dichloropyrimidin-4-yl)amino)-7-methyl-1, 2 ,3 ,4-tetrahydro-[1,4]ox-
azepino[2,3-c]quinolin-6(7/-/)-one and rac-4,4-difluoropiperidin-3-ol hydrochloride. Example
12y and Example 12z represent a pair of enantiomers where one is the (R)- and the other is
the (S)-piperidinol. It has not been determined which is the (R)- and which is the (S)-
enantiomer. The compounds were separated by preparative chiral SFC using the following
method. The racemic mixture was dissolved to 9 mg/ml_ in EtOH C C (5:4) and was then
purified by SFC (Lux A 1 (21 .2 mm x 250 mm, 5 m), 40:60 EtOH:CC>2 (0.2%v/v N H 3) ; flow
rate 50 mLmin 1) . The earlier eluting enantiomer was identified as Example 12y and the later
eluting enantiomer was identified as Example 12z. Combined fractions of each were then
concentrated in vacuo before being stored in a vacuum oven at 35°C and 5mbar affording
Example 12y (19 mg) and Example 12z (17 mg) as white solids. Chiral purity analysis was
determied by SFC (Amy-C (4.6mm x 250mm, 5 m), 40:60 EtOH:CC>2 (0.2%v/v N H 3) ; flow
rate 4 mLmin 1) .
[00276] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 12a, starting from the intermediate(s) shown in the
table and appropriate amine. For Example 13a, the reaction was heated at 140 °C under
microwave irradiation for 8 h . For Example 13b and Example 13c, the reactions were
heated at 160 °C under microwave irradiationfor 8 h and 12 h respectively. For Example
13f, the reaction was heated at 120 °C under microwave irradiation for 1 h . For Example
13g and Example 13h, acetonitrile was used instead of NMP and the reactions were heated
at 80 °C in a heating block for 1 h and 12 h respectively. For Example 13i, the reaction was
heated at 140 °C under microwave irradiation for 10 h . For Example 13j, the reaction was
heated at 140 °C in a heating block for 46 h . For Example 13a-Example 13c, purification
was conducted using preparative HPLC. Example 13b was isolated as a mixture of
diastereoisomers. Example 13c was isolated as a mixture of endo- and exo-isomers. For






6(7H)-one or (R)-10-((5-chloro-2-((/?)-4,4-difluoro-3-methylpiperidin-1 -yl)pyrimidin-4-
yl)amino)-2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-
6(7H)-one
[00277] A vial containing (S)-4,5-dichloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidine or
(F?)-4,5-dichloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidine (Intermediate L2a; 10 mg,
0.035 mmol), DIPEA (20 uL, 0.089 mmol), and (F?)-10-amino-2-cyclopropyl-7-methyl-1,2,3,4-
tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate Aid; 10 mg, 0.035 mmol)
in NMP (0.56 ml_) was heated at 140°C under microwave irradiation for 3 h . The reaction
mixture was directly purified by reverse-phase chromatography (Biotage reverse-phase 12 g
Ultra C-18 column; 45-100% MeOH in H O (containing 0.1% formic acid)). To the resulting
mixture was added (R)-10-amino-2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1,4]oxaze-
pino[2,3-c]quinolin-6(7/-/)-one (Intermediate Aid; 10 mg, 0.035 mmol), NMP (0.56 ml_) and
3 M aq HCI (0.1 ml_) and the reaction was heated in a heating block at 80 °C for 22 h . The
reaction mixture was directly purified by reverse-phase chromatography (Biotage reverse-
phase 12 g Ultra C-18 column; 45-100% MeOH in H O (containing 0.1% formic acid))
affording the title compound (4 mg, 21%) as a grey solid. 1H NMR (600 MHz, methanol-d ) δ
8.34 (s, 1 H), 8.18 (s, 1 H), 7.91 (dd, J = 9.2, 2.0 Hz, 1 H), 7.84 (dd, J = 9.2, 2.0 Hz, 1 H),
4.52—4.44 (m, 1 H), 4.41-4.34 (m, 1 H), 4.20 (d, J = 13.9 Hz, 1 H), 4.10 (d, J = 13.0 Hz, 1 H),
3.89 (d, J = 1.5 Hz, 3 H), 3.47-3.39 (m, 1 H), 3.20-3.13 (m, 2 H), 2.48-2.40 (m, 1 H), 2.29-
2.14 (m, 3 H), 2.13-2.01 (m, 1 H), 1.37-1.29 (m, 1 H), 1.04 (d, J = 6.7 Hz, 3 H), 0.73-0.64
(m, 2 H), 0.51-0.45 (m, 1 H), 0.40-0.34 (m, 1 H); LCMS (Method X4) RT 3.47 min; m/z calcd
for C26H3OCIF 2N60 2+ [M+H]+: 531 .2087, Found: 531.2091 .
[00278] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 14a, starting from the intermediate(s) shown in the
table.
Example 15a: (/?)-10-((5-chloro-2-((1 /?,5S,7S)-7-hydroxy-3-oxa-9-azabicyclo[3.3.1]-
nonan-9-yl)pyrimidin-4-yl)amino)-2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-
[1,4]thiazepino[2,3-c]quinolin-6(7H)-one
[00279] To a solution of (R)-/\/-(2-cyclopropyl-7-methyl-6-oxo-1 ,2,3,4,6,7-hexahydro-
[1,4]thiazepino[2,3-c]quinolin-10-yl)formamide (Intermediate A8c; 5 mg, 0.015 mmol) in
THF (0.30 ml_) was added sodium hydride (60% dispersion in mineral oil; 10 mg, 0.25
mmol). The mixture was stirred for 15 min then cooled to 0 °C and (1R,5S,7s)-9-(5-chloro-4-
(methylsulfonyl)pyrimidin-2-yl)-3-oxa-9-azabicyclo[3.3.1]-nonan-7-ol (Intermediate J2; 15
mg, 0.045 mmol) was added. The mixture was stirred at 0 °C for 1 h . Further THF (0.3 ml_)
and sodium hydride (60% dispersion in mineral oil; 10 mg, 0.25 mmol) was added and the
mixture was warmed to rt and stirred overnight. The mixture was then heated in a sealed vial
to 60 °C for 3 h . The reaction mixture was cooled to rt, water was added with care to the
mixture which was then concentrated to remove the THF. The residue was diluted with
DMSO ( 1 .2 ml_) and directly purified by reverse-phase chromatography (Biotage reverse-
phase 12 g Ultra C-18 column; 10-100% MeOH in H20 (containing 0.1% formic acid)). The
product-containing fractions were combined, passed through an SCX-2 (2 g), and the
product was eluted with 2 N methanolic ammonia. The solvent was removed in vacuo
affording the title compound (3 mg, 36%) as a pale yellow solid. 1H NMR (600 MHz, CDCI3)
δ 8.03 (s, 1 H), 7.74-7.61 (m, 1 H), 7.56 (s, 1 H), 7.30 (d, J = 9.0 Hz, 1 H), 7.06 (s, 1 H),
5.67-5.53 (m, 1 H), 4.74^1.65 (m, 1 H), 4.54^1.46 (m, 1 H), 4.33-4.29 (m, 1 H), 3.98-3.89
(m, 4 H), 3.83-3.78 (m, 2 H), 3.75-3.69 (m, 1 H), 3.69 (s, 3 H), 2.95 (dd, J = 14.6, 6.2 Hz, 1
H), 2.27-2.15 (m, 3 H), 2.06-1.98 (m, 1 H), 1.92-1.83 (m, 2 H), 1.03-0.94 (m, 1 H), 0.75-
0.66 (m, 1 H), 0.62-0.54 (m, 1 H), 0.44-0.37 (m, 1 H), 0.31-0.22 (m, 1 H). LCMS (Method
T4) RT 2.93 min; m/z calcd for C H C IN O S [M+H] +: 555.1940, Found: 555.1931 .
[00280] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Example 15a, starting from the intermediate(s) shown in the
table and appropriate substituted pyrimidine. For Example 15b and Example 15c, the
reactions were stirred at 60 °C immediately after the addition of the sulfone. Additionaly, due
to hydrolysis of the sulfone starting material under the reaction conditions, additional






[00281] Sodium borohydride ( 1 .4 mg, 0.037 mmol) was added to a stirred solution of 2-((R)-
10-((5-chloro-2-((3S,5ft)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-2-
cyclopropyl-6-oxo-1 ,3,4,6-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-7(2/-/)-yl)acetaldehyde
(Intermediate A12a; 5.4 mg, 0.009 mmol) in anhydrous methanol (0.5 ml_) at 0°C under Ar.
The reaction mixture was stirred at 0 °C for 2 h . The reaction mixture was quenched with
saturated aq. NaHCC>3 (0.1 ml_) and stirred for 15 min. DMSO (0.5 ml_) was added and the
reaction mixture was concentrated in vacuo to remove the MeOH. The crude reaction
mixture in DMSO (additional 0.6 ml_ of DMSO used to wash out vial) was directly purified by
reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 10-30-100%
MeOH in H2O (containing 0.1% formic acid)), affording the title compound (4 mg, 76%) as an
off-white solid. 1H NMR (600 MHz, methanol-d ) δ 8.01 (d, J = 2.2 Hz, 1 H), 7.98 (s, 1 H),
7.82 (dd, = 9.1, 2.2 Hz, 1 H), 7.64 (d, J = 9.1 Hz, 1 H), 4.58-4.49 (m, 2 H), 4.46 (t, J = 6.3
Hz, 2 H), 4.42-4.37 (m, 1 H), 4.24-4.18 (m, 1 H), 3.85 (t, J = 6.3 Hz, 2 H), 2.95 (dt, J = 9.5,
3.5 Hz, 1 H), 2.74-2.65 (m, 2 H), 2.37-2.30 (m, 1 H), 2.14-2.06 (m, 1 H), 2.01-1.88 (m, 2
H), 1.25-1 .19 (m, 1 H), 1.00 (d, J = 6.7 Hz, 6 H), 0.68-0.60 (m, 2 H), 0.43-0.37 (m, 1 H),





[00282] Methylamine (2 M in THF; 0.20 ml_, 0.400 mmol) was added to a stirred solution of
2-((R)-10-((5-chloro-2-((3S,5R)-4,4-difluoro-3,5-dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-
2-cyclopropyl-6-oxo-1,3,4,6-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-7(2/-/)-yl)acetaldehyde
(Intermediate A12a; 6.5 mg, 0.01 1 mmol) in THF (0.2 ml_) under Ar. The reaction mixture
was stirred at rt for 5 min. Sodium triacetoxyborohydride (6.0 mg, 0.028 mmol) was added
and the reaction mixture was stirred at 25°C for 3 d . After this time, DCE (0.5 ml_) was
added as well as additional methyamine (2 M in THF; 1.5 ml_) and sodium
triacetoxyborohydride (22 mg, 0.1 mmol). The reaction mixture was stirred at 25°C for an
additional 18 h . After this time additional methylamine (2 M in THF; 0.5 ml_) added followed
by sodium acetate (12 mg ) and sodium triacetoxyborohydride (19 mg). The reaction mixture
was stirred at 45 °C for 24 h . After this time, a few drops of water were added and the
reaction mixture was concentrated in vacuo. The crude reaction mixture was re-dissolved in
DMSO (0.8 ml_) and directly purified by reverse-phase chromatography (Biotage reverse-
phase 12 g C-18 column; 10-30-100% MeOH in H20 (containing 0.1% formic acid)),
affording a mixture of products. The product-containing fractions were combined,
concentrated in vacuo and re-purified by flash chromatography (pipette column, 0%-5%-
10%-25% MeOH in CH2CI2) affording the title compound ( 1 mg, 13%) as an off white solid.
1H NMR (600 MHz, methanol-d ) δ 8.1 1 (d, J = 2.1 Hz, 1 H), 8.00 (s, 1 H), 7.86 (dd, J = 9.2,
2.1 Hz, 1 H), 7.53 (d, J = 9.2 Hz, 1 H), 4.63^1.59 (m, 2 H), 4.56-4.51 (m, 2 H), 4.44^1.38
(m, 1 H), 4.27—4.22 (m, 1 H), 3.29-3.25 (m, 2 H), 2.99 (dt, J = 9.4, 3.5 Hz, 1 H), 2.73-2.66
(m, 5 H), 2.39-2.32 (m, 1 H), 2.16-2.09 (m, 1 H), 2.00-1.91 (m, 2 H), 1.27-1 .22 (m, 1 H),
1.01 (d, J = 6.7 Hz, 6 H), 0.69-0.61 (m, 2 H), 0.42-0.37 (m, 1 H), 0.36-0.31 (m, 1 H); LCMS




[00283] To a solution of ethyl 4-((1-((te/f-butoxycarbonyl)amino)propan-2-yl)amino)-6-((2-
chloro-3-cyanopyridin-4-yl)amino)-1-methyl-2-oxo-1 ,2-dihydroquinoline-3-carboxylate
(Intermediate B3a; 62 mg, 0.1 1 mmol) in THF (2 ml_) was added 4 M HCI in dioxane (279
uL, 1.12 mmol) and the reaction mixture was heated to 70 °C for 15 min. Further 4 M HCI in
dioxane (279 uL, 1.12 mmol) was added and heating was continued for 90 min. The acidic
reaction mixture was quenched with triethylamine (389 uL, 2.79 mmol) and heated at 70 °C
overnight. The reaction mixture was cooled to rt and diluted with water. The organic solvents
were removed in vacuo and the reaction mixture was purified by reverse-phase
chromatography (Biotage reverse-phase 12 g C-18 column; 5-50% MeOH in H2O
(containing 0.1% formic acid)) affording the title compound (9 mg, 18%) as an off-white solid.
1H NMR (500 MHz, methanol-d ) δ 8.03-8.01 (m, 1 H), 8.00 (d, J = 6.2 Hz, 1 H), 7.62-7.61
(m, 2 H), 6.71 (d, J = 6.2 Hz, 1 H), 3.97-3.93 (m, 1 H), 3.67 (s, 3 H), 3.58 (dd, J = 13.4, 1.7
Hz, 1 H), 3.39-3.27 (m, 1 H), 1.32 (d, J = 6.5 Hz, 3 H); LCMS (Method X4) RT 2.01 min; m/z
calcd for C2oH 18CIN60 2 + [M+H]+: 409.1 180, Found: 409.1088.
Intermediate compounds
Intermediate A 1a : (S)-1 0-amino-2,7-dimethyl-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-
c]quinolin-6(7H)-one
Step 1: (S)-4-((4-hydroxybutan-2-yl)amino)- 1-methyl-6-nitroquinolin-2( 1H)-one
[00284] An oven-dried microwave vial (10-20 ml_ volume) was charged with 4-chloro-1-
methyl-6-nitroquinolin-2(1/-/)-one (Intermediate F 1 ; 800 mg, 3.4 mmol) and (S)-3-
aminobutan-1-ol (446 mg, 5.0 mmol). The reaction vial was flushed with Ar, sealed with a
cap and then further flushed with Ar. Anhydrous NMP (10 ml_) was added followed by DIPEA
( 1 .2 ml_, 6.9 mmol). The reaction mixture was heated at 160°C in a heating block for 20 h .
The reaction mixture was allowed to cool to rt. The reaction mixture was diluted with water
(100 ml_), and the aqueous mixture was extracted with EtOAc (100 ml_). The organic extract
was washed with water (2 x 25 ml_). The aqueous washings were combined and further
extracted with EtOAc (3 x 50 ml_). The organic extracts were combined, dried (Na2S0 4) and
concentrated in vacuo. The crude reaction mixture was dry-loaded onto silica and purified by
flash chromatography (50 g KP-sil; 0% to 10% MeOH in CH2CI2) affording (S)-4-((4-
hydroxybutan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (547 mg, 56%) as a yellow
solid. 1H NMR (500 MHz, DMSO-cfe) 9.1 1 (d, J = 2.5 Hz, 1 H), 8.37 (dd, J = 9.4, 2.5 Hz, 1
H), 7.60 (d, J = 9.4 Hz, 1 H), 7.1 1 (d, J = 7.9 Hz, 1 H), 5.59 (s, 1 H), 4.57 (t, J = 5.0 Hz, 1 H),
3.80-3.71 (m, 1 H), 3.55 (s, 3 H), 3.53-3.48 (m, 2 H), 1.94-1.87 (m, 1 H), 1.67-1 .60 (m, 1
H), 1.23 (d, J = 6.4 Hz, 3 H).
Step 2: (S)-3-bromo-4-((4-hvdroxybutan-2-yl)amino)-1-methyl-6-nitrociuinolin-2( 1H)-one
[00285] Trifluoroacetic acid (0.72 ml_, 9.4 mmol) was added to a stirred mixture of N-
bromosuccinimide (509 mg, 2.9 mmol) and (S)-4-((4-hydroxybutan-2-yl)amino)-1-methyl-6-
nitroquinolin-2(1/-/)-one (from step 1; 547 mg, 1.9 mmol) in anhydrous CH2CI2 (10 ml_) at 0°C
under Ar. The reaction mixture was stirred at 0°C for 10 min then at rt for 30 min. The
reaction mixture was diluted with EtOAc (100 ml_) and washed with water (30 ml_) followed
by saturated aq. NaHCCh (3 x 30 ml_). The aqueous washings were combined and further
extracted with EtOAc (30 ml_). The organic extracts were combined, dried (Na2S0 4) and
concentrated in vacuo. The crude reaction mixture was dry-loaded onto silica and purified by
flash chromatography (25 g KP-sil; 0% to 10% MeOH in CH2CI2) affording (S)-3-bromo-4-((4-
hydroxybutan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (532 mg, 77%) as a yellow
solid. 1H NMR (500 MHz, DMSO-cfe) δ 8.89 (d, J = 2.6 Hz, 1 H), 8.42 (dd, J = 9.4, 2.6 Hz, 1
H), 7.72 (d, J = 9.4 Hz, 1 H), 5.82 (d, J = 9.8 Hz, 1 H), 4.51 (t, J = 4.7 Hz, 1 H), 4.28-4.19
(m, 1 H), 3.69 (s, 3 H), 3.51-3.46 (m, 2 H), 1.90-1 .82 (m, 1 H), 1.79-1.71 (m, 1 H), 1.29 (d,
J = 6.5 Hz, 3 H).
Step 3: (S)-2, 7-dimethyi-10-nitro-1 ,2,3,4-tetrahydro-f 1,4loxazepino[2,3-clauinolin-6(7H)-one
[00286] An oven-dried microwave vial (2. 0-5.0 ml_ volume) was charged with (S)-3-bromo-
4-((4-hydroxybutan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (from step 2 ; 111 mg,
0.30 mmol). The reaction vial was flushed with Ar, sealed with a cap and then further flushed
with Ar. Anhydrous DMSO (4 ml_) was added followed by potassium tert-butoxide ( 1 M in
THF; 0.54 ml_, 0.54 mmol). The reaction mixture was heated at 60°C under microwave
irradiation for 50 min. The reaction mixture was allowed to cool to rt. Water (10 ml_) was
added followed by EtOAc (10 mL). The layers were separated and the aqueous layer was
further extracted with EtOAc (10 mL). The organic extracts were combined and concentrated
in vacuo. The crude product was dissolved in DMSO ( 1 .2 mL) and directly purified by
reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 45-75% MeOH in
H2O (containing 0.1% formic acid)), affording (S)-2,7-dimethyl-10-nitro-1 ,2,3,4-tetrahydro-
[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (36 mg, 41%) as a dark yellow solid. 1H NMR (600
MHz, CDCb) δ 8.93 (d, J = 2.1 Hz, 1 H), 8.33 (dd, J = 9.2, 2.1 Hz, 1 H), 7.40 (d, J = 9.2 Hz, 1
H), 4.49—4.38 (m, 2 H), 4.14-4.08 (m, 1 H), 4.01 (br s , 1 H), 3.76 (s, 3 H), 2.23-2.26 (m, 1
H), 1.91-1 .84 (m, 1 H), 1.47 (d, J = 6.3 Hz, 3 H).
Step 4: (S)-10-amino-2, 7-dimethyl-1,2,3,4-tetrahydro-f 1,4loxazepino[2,3-clauinolin-6(7H)-
one
[00287] A microwave vial (0. 5-2.0 mL volume) was charged with (S)-2,7-dimethyl-10-nitro-
1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (from step 3 ; 356 mg, 0.12
mmol), Pd/C (10 wt%, 6.3 mg) and ammonium formate (53 mg, 0.85 mmol). The reaction
vial was flushed with Ar, sealed with a cap and then further flushed with Ar. Anhydrous
methanol ( 1 .2 mL) was added. The reaction mixture was stirred at 80°C for 20 min. The
reaction mixture was cooled to rt, the cap removed and additional ammonium formate (33
mg, 0.52 mmol) and Pd/C (10 wt%, 2.6 mg) were added. The reaction vial was re-sealed
and heated at 80°C for a further 10 min. The reaction mixture was allowed to cool to rt,
filtered through Celite™, and the solids washed with MeOH (40 mL). The filtrate was
concentrated in vacuo, re-dissolved in MeOH and passed through an SCX-2 (2 g) column,
eluting with MeOH (40 mL) followed by 2 N methanolic ammonia (40 mL). The methanolic
ammonia fraction was concentrated in vacuo affording the title compound (22 mg, 67%) as a
dark yellow solid which was used without further purification. LCMS (Method T2) RT 0.41
min; m/z 260.1382 [M+H]+.
[00288] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate A1a, starting from the amino-alcohols shown in the
table. An alternative procedure for Step 1 was conducted for the preparation of Intermediate
A1I. Details of this procedure are described below for the preparation of Intermediate Aid.






[00289] An oven-dried microwave vial (10-20 ml_ volume) was charged with (S)-3-amino-3-
cyclopropyl-2,2-difluoropropan-1-ol hydrochloride ( 1 .02 g , 5.43 mmol) and ethyl 4-chloro-1-
methyl-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate (Intermediate F2; 1.41 g , 4.52
mmol). The reaction vial was flushed with Ar and sealed with a cap. Anhydrous acetonitrile
(15 ml_) was added followed by DIPEA (2 ml_, 11.48 mmol). The reaction mixture was
heated at 160°C under microwave irradation for 12 h . The reaction mixture was transferred
to a flask and 2 M sodium hydroxide (13.5 ml_, 27 mmol) was added. A reflux condenser was
attached and the reaction mixture was heated at 85 °C for 2 h . The reaction mixture was
cooled to rt. Water (40 ml_) was added and the reaction mixture was acidified to pH 5 with 3
M HCI. The resulting precipitate was filtered, washed with H2O (150 ml_) and dried
affording (S)-4-((1 -cyclopropyl-2, 2-difluoro-3-hydroxypropyl)amino)-1-methyl-6-nitroquinolin-
2(1/-/)-one ( 1 .41 g , 88%) as an off-white solid which was used without further purification. 1H
NMR (500 MHz, DMSO-cfe) δ 9.31 (d, J = 2.5 Hz, 1 H), 8.40 (dd, J = 9.4, 2.5 Hz, 1 H), 7.62
(d, J = 9.4 Hz, 1 H), 7.48 (d, J = 8.7 Hz, 1 H), 5.72 (s, 1 H), 5.60 (t, J = 6.1 Hz, 1 H), 3.90-
3.71 (m, 2 H), 3.57-3.45 (m, 4 H), 1.38-1 .29 (m, 1 H), 0.71-0.64 (m, 1 H), 0.63-0.56 (m, 1
H), 0.53-0.46 (m, 1 H), 0.27-0.20 (m, 1 H); LCMS (Method X2) RT 1.15 min; m/z 354.1270
[M+H]+.
Step 2: (S)-3-bromo-4-((1-cvclopropyl-2,2-difluoro-3-hvdroxypropyl)amino)-1 -methyl-6-
nitroquinolin-2( 1H)-one
[00290] Trifluoroacetic acid (1.2 mL, 15.67 mmol) was added to a stirred mixture of (S)-4-
((1 -cyclopropyl-2, 2-difluoro-3-hydroxypropyl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (from
step 1 ; 1.14 g , 3.21 mmol) and freshly recrystallised /V-bromosuccinimide (572 mg, 3.21
mmol) in anhydrous CH2CI2 (21 mL) at 0 °C under Ar. The reaction mixture was stirred at 0
°C for 15 min. The reaction mixture was diluted with CH2CI2 (60 mL) and washed with
saturated aq. NaHCC>3 (3 x 30 mL). The aqueous washings were further extracted with
CH2CI2 (60 mL). The organic extracts were combined, washed with brine (30 mL), dried
(Na2S0 4) and concentrated in vacuo affording (S)-3-bromo-4-((1-cyclopropyl-2,2-difluoro-3-
hydroxypropyl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (1.39 g , 100%) as a yellow solid
which was used without further purification. 1H NMR (500 MHz, DMSO-cfe) δ 8.95 (d, J = 2.5
Hz, 1 H), 8.43 (dd, J = 9.4, 2.5 Hz, 1 H), 7.75 (d, J = 9.4 Hz, 1 H), 5.86 (d, J = 11. 1 Hz, 1 H),
5.63 (t, J = 5.9 Hz, 1 H), 4.05-3.95 (m, 1 H), 3.89-3.74 (m, 2 H), 3.71 (s, 3 H), 1.29-1.21 (m,
1 H), 0.68-0.62 (m, 1 H), 0.62-0.51 (m, 2 H), 0.50-0.44 (m, 1 H); LCMS (Method X2) RT
1.31 min; m/z 432.0369 [M+H] +.
Step 3: (S)-2-cyc/opropy/-3, 3-difluoro- 7-methyl- 10-nitro- 1,2,3, 4-tetrah ydro-f 1,41oxazepino-
[2, 3-clquinolin-6(7H)-one
[00291] Lithium tert-butoxide ( 1 M in THF; 5.14 mL, 5.14 mmol) was added to a suspension
of (S)-3-bromo-4-((1 -cyclopropyl-2, 2-difluoro-3-hydroxypropyl)amino)-1-methyl-6-nitro-
quinolin-2(1/-/)-one (from step 2 ; 1.39 g , 3.21 mmol) in THF (32 mL) under Ar. A reflux
condenser and Ar balloon were fitted and the reaction mixture was heated at 60 °C for 15
min. The reaction mixture was cooled to rt. Water (40 mL) was added and the aqueous
mixture was extracted with CH2CI2 (3 x 40 mL). The organic extracts were combined,
washed with brine (2 x 40 mL), dried (Na2S0 4) and concentrated in vacuo affording (S)-2-
cyclopropyl-3,3-difluoro-7-methyl-10-nitro-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-
6(7/-/)-one ( 1 .08 g , 96%) as a yellow solid which was used without further purification. 1H
NMR (500 MHz, DMSO-cfe) δ 9.12 (d, J = 2.5 Hz, 1 H), 8.35 (dd, J = 9.4, 2.5 Hz, 1 H), 7.66
(d, J = 9.4 Hz, 1 H), 7.01 (d, J = 4.4 Hz, 1 H), 4.54-4.37 (m, 2 H), 3.62 (s, 3 H , NCH 3) , 3.29-
3.22 (m, 1 H), 1.39-1.31 (m, 1 H), 0.76-0.69 (m, 1 H), 0.58-0.49 (m, 2 H), 0.37-0.30 (m, 1
H); LCMS (Method X2) RT 1.29 min; m/z 352. 1105 [M+H] +.
Step 4: (S)-10-amino-2-cvclopropyl-3,3-difluoro-7-methyl-1,2,3,4-tetrahydro-
[ 1,4loxazepino[2, 3-clquinolin-6(7H)-one
[00292] A 100 mL flask was charged with (S)-2-cyclopropyl-3,3-difluoro-7-methyl-10-nitro-
1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (from step 3 ; 1.08 g , 3.09 mmol)
and 10 wt% Pd/C (108 mg). The reaction vial was flushed with Ar, and ethanol (15 ml_) was
added. The reaction mixture was stirred at 60°C under an atmosphere of H2 for 1 h . The
reaction mixture was allowed to cool to rt. The reaction mixture was filtered through celite,
the solids washed with EtOH (60 ml_). The filtrate was concentrated in vacuo affording the
title compound ( 1 .03 g , 100%) as an orange solid which was used without further
purification. LCMS (Method X2) RT 0.89 min; m/z 322.1370 [M+H]+.
[00293] This alternative synthesis has also been used for the larger scale synthesis of
Intermediate A1a and Intermediate Aid.
Intermediate A2a: 10-amino-2,2,7-trimethyl-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-
c]quinolin-6(7H)-one
Step 1: 4-((4-hydroxy-2-methylbutan-2-yl)amino)- 1-methyl-6-nitrociuinolin-2( 1H)-one
[00294] An oven-dried microwave vial (2. 0-5.0 ml_ volume) was charged with ethyl 4-chloro-
1-methyl-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate (Intermediate F2; 310 mg, 1.0
mmol) and 3-amino-3-methylbutan-1-ol (178 mg, 1.7 mmol). The reaction vial was flushed
with Ar, sealed with a cap and then further flushed with Ar. Anhydrous NMP (3.5 ml_) was
added followed by DIPEA (0.52 ml_, 2.9855 mmol). The reaction mixture was heated at
160°C under microwave irradiation for 1 h . The reaction was allowed to cool to rt. The cap
was removed and lithium chloride (239 mg, 5.6 mmol) was added. The reaction vial was re
sealed with a cap and heated at 160°C in a heating block for 3 h . The reaction mixture was
allowed to cool to rt. The reaction mixture was then added dropwise to water (25 ml_). The
aqueous mixture was extracted with EtOAc (3 x 30 ml_). The organic extracts were
combined, dried (Na2S0 4) and concentrated in vacuo. The crude product was dissolved in
DMSO ( 1 .5 ml_) and directly purified by reverse-phase chromatography (2 runs; Biotage
reverse-phase 12 g C-18 column; 10-100% MeOH in H2O (containing 0.1% formic acid)).
The fractions containing the impure product were combined and concentrated in vacuo and
dissolved in DMF ( 1 .5 ml_). The DMF mixture was added dropwise to stirred water (10 ml_).
The aqueous mixture was stirred for 30 min. The resulting suspension was filtered and the
solid was washed with water (50 ml_) and dried affording 4-((4-hydroxy-2-methylbutan-2-
yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (29 mg, 10%) as a cream solid. 1H NMR (500
MHz, DMSO-cfe) δ 8.83 (d, J = 2.5 Hz, 1 H), 8.37 (dd, J = 9.3, 2.5 Hz, 1 H), 7.61 (d, J = 9.3
Hz, 1 H), 7.07 (s, 1 H), 5.74 (s, 1 H), 5.12 (t, J = 4.5 Hz, 1 H), 3.66-3.62 (m, 2 H), 3.55 (s, 3
H), 1.93 (t, J = 6.3 Hz, 2 H), 1.44 (s, 6 H).
Step 2: 3-bromo-4-((4-hvdroxy-2-methylbutan-2-yl)amino )- 1-methyl-6-nitroguinolin-2( 1H)-
one
[00295] Trifluoroacetic acid (15 uL, 0.20 mmol) was added to a stirred mixture of N-
bromosuccinimide (22 mg, 0.13 mmol) and 4-((4-hydroxy-2-methylbutan-2-yl)amino)-1-
methyl-6-nitroquinolin-2(1/-/)-one (from step 1; 29 mg, 0.10 mmol) in anhydrous CH2CI2 (0.5
ml_) at 0°C under Ar. The reaction mixture was stirred at 0°C for 20 min. The reaction
mixture was diluted with EtOAc (20 ml_) and washed with saturated aq. NaHCC>3 (2 x 20
ml_). The aqueous washings were combined and extracted with EtOAc (20 ml_). The organic
extracts were combined, dried (Na2S0 4) and concentrated in vacuo. The crude reaction
mixture was dry-loaded onto silica and purified by flash chromatography (10 g KP-sil; 0% to
10% MeOH in CH2CI2) affording 3-bromo-4-((4-hydroxy-2-methylbutan-2-yl)amino)-1-methyl-
6-nitroquinolin-2(1/-/)-one (20 mg, 53%) as a yellow solid. 1H NMR (500 MHz, DMSO-cfe) δ
8.86 (d, J = 2.7 Hz, 1 H), 8.42 (dd, J = 9.4, 2.7 Hz, 1 H), 7.75 (d, J = 9.4 Hz, 1 H), 5.05 (br s ,
1 H), 3.75-3.73 (m, 2 H), 3.72 (s, 3 H), 1.90 (t, J = 6.7 Hz, 2 H), 1.22 (s, 6 H).
Step 3: 2,2, 7-trimethyl-10-nitro-1,2,3,4-tetrahydro-f 1,4loxazepino[2,3-clauinolin-6(7H)-one
[00296] A microwave vial (0. 5-2.0 ml_ volume) was charged with 3-bromo-4-((4-hydroxy-2-
methylbutan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (from step 2 ; 20 mg, 0.05
mmol). The reaction vial was flushed with Ar, sealed with a cap and then further flushed with
Ar. Anhydrous DMSO (0.68 ml_) was added followed by potassium tert-butoxide ( 1 M in
THF; 92 uL, 0.09 mmol). The reaction mixture was heated at 60°C under microwave
irradiation for 50 min. The reaction mixture was allowed to cool to rt. Water (10 ml_) was
added followed by EtOAc (10 ml_). The layers were separated and the aqueous layer was
further extracted with EtOAc (2 x 10 ml_). The organic extracts were combined and
concentrated in vacuo. The crude product was dissolved in DMSO ( 1 ml_) and directly
purified by reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 45-
65% MeOH in H2O (containing 0.1% formic acid)), affording 2,2,7-trimethyl-1 0-nitro-1 ,2,3,4-
tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7H)-one (5 mg, 29%) as a yellow solid. 1H NMR (500
MHz, DMSO-d ) δ 8.99 (d, J = 2.5 Hz, 1 H), 8.31 (dd, J = 9.3, 2.5 Hz, 1 H), 7.61 (d, J = 9.3 Hz, 1 H),
6.01 (s, 1 H), 4.13 (t, = 6.1 Hz, 2 H), 3.62 (s, 3 H), 1.92 (t, = 6.1 Hz, 2 H), 1.41 (s, 6 H).
Step 4: 10-amino-2.2. 7-trimethyl-1,2,3,4-tetrahydro-[ 1,4loxazepinoi2,3-clciuinolin-6(7H)-one
[00297] A microwave vial (0. 5-2.0 ml_ volume) was charged with 2,2, 7-trimethyl-10-nitro-
1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (from step 3 ; 5 mg, 0.015
mmol), Pd/C (10 wt%, 0.5 mg) and ammonium formate (8 mg, 0.13 mmol). The reaction vial
was flushed with Ar, sealed with a cap and then further flushed with Ar. Anhydrous methanol
(0.5 ml_) was added. The reaction mixture was stirred at 80°C for 10 min. The reaction
mixture was cooled to rt, the cap removed and additional ammonium formate (5 mg, 0.08
mmol) and Pd/C (10 wt%, 0.5 mg) were added. The reaction vial was re-sealed with a cap,
and heated at 80°C for a further 10 min. The reaction mixture was allowed to cool to rt,
filtered through Celite™ and the solids washed with MeOH (30 ml_). The filtrate was
concentrated in vacuo, re-dissolved in MeOH and passed through an SCX-2 ( 1 g) column,
eluting with MeOH (20 ml_) followed by 2 N methanolic ammonia (30 ml_). The methanolic
ammonia fraction was concentrated in vacuo affording the title compound (4 mg, 99%) as a
yellow solid which was used without further purification. LCMS (Method T2) RT 0.72 min;
m/z 274.1538 [M+H]+.
[00298] The following tabulated example was prepared by a method analogous to that used
for the preparation of Intermediate A2a, starting from the amino-alcohol shown in the table.
Intermediate A3: 9-amino-2,6-dimethyl-2,3-dihydro-1 H-[1,4]oxazino[2,3-c]quinolin-
5(6H)-one
Step 1: 4-((1-hvdroxypropan-2-yl)amino)- 1-methyl-6-nitrociuinolin-2( 1H)-one
[00299] A suspension of 4-chloro-1-methyl-6-nitroquinolin-2(1/-/)-one (Intermediate F 1 ; 250
mg, 1.05 mmol), 2-aminopropan-1-ol (236 mg, 3.14 mmol) and DIPEA (0.36 ml_, 2.10
mmol) in NMP ( 4.19 ml_) was heated to 160°C in a heating block for 24 h . The reaction
mixture was allowed to cool to rt. Water (3 ml_) was added to the reaction mixture and after 5
min a yellow precipitate formed. The aqueous mixture was added to water (20 ml_). After 15
min, the precipitate was filtered, washed with water (100 ml_) and dried affording 4-((1-
hydroxypropan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one as a yellow solid. 1H NMR
(500 MHz, DMSO-cfe) δ 9.12 (d, J = 2.5 Hz, 1H), 8.37 (dd, J = 9.4, 2.5 Hz, 1H), 7.60 (d, J =
9.4 Hz, 1H), 7.02 (d, J = 7.4 Hz, 1H), 5.62 (s, 1H), 4.82 (t, J = 5.8 Hz, 1H), 3.66-3.52 (m,
5H), 3.43-3.36 (m, 1H), 1.22 (d, J = 6.4 Hz, 3H).
Step 2: 4-((1-hvdroxypropan-2-yl)amino)-3-iodo- 1-methyl-6-nitroguinolin-2( 1H)-one
[00300] A microwave vial (0. 5-2.0 ml_ volume) was charged with 4-((1-hydroxypropan-2-
yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (from step 1 ; 52 mg, 0.19 mmol) and iodine
(145 mg, 0.57 mmol). The reaction vial was flushed with Ar, sealed with a cap and then
further flushed with Ar. Anhydrous methanol (1.2 ml_) was added and the reaction mixture
was heated at 60°C under microwave irradiation for 30 min. Water (0.6 ml_) was added the
reaction mixture was heated at 60°C under microwave irradiation for a further 90 min. The
reaction mixture was allowed to cool to rt, diluted with MeOH and directly dry-loaded onto
silica. Purification by flash chromatography (10 g KP-sil; 0% to 15% MeOH in CH2CI2)
afforded 4-((1-hydroxypropan-2-yl)amino)-3-iodo-1-methyl-6-nitroquinolin-2(1/-/)-one (29 mg,
38%) as a yellow solid. 1H NMR (500 MHz, CDCh) δ 8.92 (d, J = 2.6 Hz, 1 H), 8.40 (dd, J =
9.3, 2.6 Hz, 1 H), 7.46 (d, J = 9.3 Hz, 1 H), 4.62 (d, J = 10.6 Hz, 1 H), 3.99-3.90 (m, 1 H),
3.86-3.76 ( , 5 H), 3.71 (dd, = 11.2, 5.9 Hz, 1 H), 1.37 (d, J = 6.6 Hz, 3 H).
Step 3: 2,6-dimethyl-9-nitro-2, 3-dihydro- 1Η- 1,41oxazino[2,3-clguinolin-5( 6H)-one
[00301] A microwave vial (2. 0-5.0 ml_ volume) was charged with 4-((1-hydroxypropan-2-
yl)amino)-3-iodo-1-methyl-6-nitroquinolin-2(1/-/)-one (from step 2 ; 29 mg, 0.07 mmol), 1,10-
phenanthroline (6 mg, 0.03 mmol), copper(l) iodide (3 mg, 0.02 mmol) and cesium carbonate
(46 mg, 0.14 mmol). The reaction vial was evacuated under reduced pressure for 30 min.
The reaction vial was flushed with Ar, sealed with a cap and then further flushed with Ar.
Anhydrous NMP (2.4 ml_) was added. The reaction mixture was heated at 120°C under
microwave irradiation for 1 h . The reaction mixture was cooled to rt. Water (5 ml_) was added
and the aqueous mixture was extracted with CH2CI2 (3 x 15 ml_). The organic extracts were
combined, dried (Na2S0 4) and concentrated in vacuo. The crude product was purified by
flash chromatography (10 g KP-sil; 0% to 15% MeOH in CH2CI2). The product-containing
fractions was combined, concentrated in vacuo and passed through an SCX-2 column (5 g),
eluting with MeOH (50 ml_) followed by 2 N methanolic ammonia (50 ml_). The MeOH
fraction was collected and concentrated in vacuo. The impure product was diluted with
DMSO (0.8 ml_) and purified by reverse-phase chromatography (Biotage reverse-phase 12 g
C-18 column; 10-100% MeOH in H2O (containing 0.1% formic acid) affording 2,6-dimethyl-
9-nitro-2,3-dihydro-1/-/-[1,4]oxazino[2,3-c]quinolin-5(6/-/)-one (8 mg, 41%) as a yellow solid.
1H NMR (500 MHz, CDCh) δ 8.45 (d, J = 2.2 Hz, 1 H), 8.32 (dd, J = 9.3, 2.2 Hz, 1 H), 7.43
(d, J = 9.3 Hz, 1 H), 4.43 (br s , 1 H), 4.39 (dd, J = 10.5, 2.7 Hz, 1 H), 3.82 (dd, J = 10.5, 7.3
Hz, 1 H), 3.79 (s, 3 H), 3.76-3.72 (m, 1 H), 1.39 (d, J = 6.4 Hz, 3 H).
Step 4: 9-amino-2, 6-dimethyl-2, 3-dihydro- 1H-[1,4loxazino[2,3-clauinolin-5(6H)-one
[00302] A microwave vial (0. 5-2.0 ml_ volume) was charged with 2,6-dimethyl-9-nitro-2,3-
dihydro-1/-/-[1,4]oxazino[2,3-c]quinolin-5(6/-/)-one (from step 3 ; 11 mg, 0.0392 mmol), Pd/C
(10 wt%, 2 mg) and ammonium formate (13 mg, 0.20 mmol). The reaction vial was flushed
with Ar, sealed with a cap and then further flushed with Ar. Anhydrous methanol (0.4
ml_) was added and the reaction mixture was stirred at 80°C for 90 min. The reaction
mixture was allowed to cool to rt, filtered through Celite™, and the solids washed with MeOH
(20 ml_). The filtrate was concentrated in vacuo , re-dissolved in MeOH and passed through
an SCX-2 (2 g) column, eluting with MeOH (30 ml_) followed by 2 N methanolic ammonia (30
ml_). The methanolic ammonia fraction was concentrated in vacuo affording the title
compound (8 mg, 81%) as an off-white solid which was used without further purification.
LCMS (Method T2) RT 0.21 min; m/z 246.1253 [M+H] +.
Intermediate A4: (/?)-2-cyclopropyl-1 0-nitro-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-
c]quinolin-6(7H)-one
Step 1: (R)-4-((1-cvclopropyl-3-hvdroxypropyl)amino)-6-nitrociuinoHn-2( 1H)-one
[00303] A mixture of ethyl 4-chloro-6-nitro-2-oxo-1 ,2-dihydroquinoline-3-carboxylate
(Intermediate F3; 2.0 g , 6.74 mmol), (R)-3-amino-3-cyclopropylpropan-1-ol (Intermediate
D1a; 1.09 g , 9.44 mmol), and DIPEA (2.94 ml_, 16.9 mmol) in acetonitrile (13.5 ml_) was
heated at 80°C overnight. The reaction mixture was cooled to rt, and 2 M sodium hydroxide
(16.9 ml_, 33.7 mmol) was added and the reaction mixture was stirred at 80°C for 13 h .
Additional 2 M sodium hydroxide (16.9 ml_, 33.7 mmol) was added and stirring at 80°C was
continued for a further 16 h . The organic solvent was removed in vacuo and the aqueous
mixture was acidified to pH 4 using 2 M aq. HCI. The aqueous suspension was then washed
with EtOAc (10 x 200 ml_). The organic solvent was removed under vacuum and the crude
product purified by flash chromatography (25 g KP-sil; 0%-20% MeOH in EtOAc) to afford
crude product as a yellow solid ( 1 .7 g). The crude product was suspended in water and
filtered, washed further with 100 ml_ of water and dried overnight in air affording (R)-4-((1-
cyclopropyl-3-hydroxypropyl)amino)-6-nitroquinolin-2(1/-/)-one ( 1 .14 g , 56%) as a yellow
solid. LCMS (Method T2) RT 1.19 min; m/z 304.13 [M+H] +.
Step 2: (R)-3-bromo-4-((1-cvclopropyl-3-hvdroxypropyl)amino)-6-nitrociuinolin-2( 1H)-one
[00304] Trifluoroacetic acid (1.44 mL, 18.74 mmol) was added to a stirred mixture of N-
bromosuccinimide (1.01 g , 5.67 mmol) and (R)-4-((1-cyclopropyl-3-hydroxypropyl)amino)-6-
nitroquinolin-2(1/-/)-one (from step 1; 1.14 g , 3.76 mmol) in anhydrous CH2CI2 (38
mL) at 0°C. The reaction mixture was stirred at 0°C for 10 min. The reaction mixture was
partitioned between EtOAc (50 mL) and water (75 mL). The aqueous layer was extracted
twice with EtOAc (50 mL) and the organics were combined, washed with saturated aq.
NaHCOs, dried (MgS0 4) and concentrated in vacuo affording (R)-3-bromo-4-((1-cyclopropyl-
3-hydroxypropyl)amino)-6-nitroquinolin-2(1/-/)-one ( 1 .69 g) as a dark green solid containing
0.5 equiv. of succinimide by NMR which was used without further purification. LCMS
(Method T2) RT 1.33 min; m/z 384.04 [M+H] +.
Step 3: (R)-2-cycloprop yl- 10-nitro- 1,2,3, 4-tetrah ydro-f 1,4loxazepino[2, 3-c]guinolin-6(7H) -one
[00305] A microwave vial (0. 5-2.0 ml_ volume) was charged with (R)-3-bromo-4-((1-
cyclopropyl-3-hydroxypropyl)amino)-6-nitroquinolin-2(1/-/)-one (100 mg, 0.26
mmol) and DMSO ( 1 .0 ml_), evacuated, and backfilled with argon. Potassium tert-butoxide
(1M in THF; 0.47 ml_, 0.47 mmol) was then added and the reaction mixture was heated
to 65°C under microwave irradiation for 1 h .
[00306] 4 batches repeated as above. One batch conducted using 67 mg of (R)-3-bromo-4-
((1-cyclopropyl-3-hydroxypropyl)amino)-6-nitroquinolin-2(1/-/)-one and 0.32 ml_ of potassium
tert-butoxide (1M in THF) and 1.00 ml_ of DMSO. All batches combined for purification.
Purification by reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column;
30-70% MeOH in H2O (containing 0.1% formic acid) afforded the title compound as a brown
solid ( 1 10 mg, 38% over 2 steps). LCMS (Method T2) RT 1.28 min; m/z 302.12 [M+H]+.
Intermediate A5a: (R)-10-amino-2-cyclopropyl-7-(cyclopropylmethyl)-1 ,2,3,4-tetra-
hydro[1,4]oxazepino[2,3-c]quinolin-6(7H)-one
Step 1: (R)-2-cvclopropyl-7-(cvclopropylmethyl)-1 0-nitro-1 ,2,3,4-tetrahydro-[1 Aloxazepino-
[2, 3-clguinolin-6(7H)-one
[00307] A suspension of (R)-2-cyclopropyl-10-nitro-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-
c]quinolin-6(7/-/)-one (Intermediate A4) (46 mg, 0.15 mmol) and cesium carbonate (74 mg,
0.23 mmol) in DMF ( 1 .4 ml_) was stirred at rt for 15 min under argon. To this was added
bromomethyl cyclopropane (29 uL, 0.30 mmol) and the reaction mixture was stirred at rt
overnight. Water was added and the aqueous mixture was extracted with EtOAc (4 x 10 ml_).
The combined organic layers were dried (Na2S0 4) and concentrated in vacuo. Purification
flash chromatography ( 1Og, KP-Sil, 30%-80% EtOAc in cyclohexane) afforded (R)-4-((1-
cyclopropyl-3-hydroxypropyl)amino)-6-nitroquinolin-2(1/-/)-one (30 mg, 56%) as a yellow oil.
1H NNMR (500 MHz, CDC ) δ 8.50 (d, J = 2.4 Hz, 1 H), 8.33 (dd, J = 9.3, 2.4 Hz, 1 H), 7.55
(d, J = 9.4 Hz, 1 H), 4.49 (ddd, J = 12.0, 8.8, 5.3 Hz, 1 H), 4.38^1.32 (m, 1 H), 4.27 (dd, J =
6.9, 4.5 Hz, 2 H), 3.09-2.99 (m, 1 H), 2.40 (ddt, J = 19.6, 6.8, 3.8 Hz, 1 H), 1.43 (s, 5H),
1.23-1.1 1 (m, 2 H), 0.80-0.69 (m, 2 H), 0.64-0.48 (m, 4 H), 0.42-0.34 (m, 2 H); LCMS
(Method T2) RT 1.50 min; m/z 356 [M+H]+.
Step 2: (R)-10-amino-2-cvclopropyl-7-(cvclopropylmethyl)-1,2,3,4-tetrahydro-f1,4loxazepino-
[2,3-clciuinolin-6(7H)-one
[00308] To a suspension of (R)-4-((1-cyclopropyl-3-hydroxypropyl)amino)-6-nitroquinolin-
2(1/-/)-one (from step 1 ; 30 mg, 0.08 mmol) in ethanol (8.0 ml_) was added ammonium
formate (53 mg, 0.84 mmol) and Pd/C (10 wt%, 9 mg). The flask was flushed with nitrogen
and heated to 80°C for 30 min. The product was directly loaded onto a SCX-2 (2g) column
and washed with methanol. The product was eluted with 2 M methanolic ammonia, and
concentrated in vacuo affording the title compound (12 mg, 42%) as a brown solid. 1H NMR
(500 MHz, methanol-d ) δ 7.43 (d, J = 9.0 Hz, 1 H), 7.14 (d, J = 2.4 Hz, 1 H), 7.04 (dd, J =
9.0, 2.5 Hz, 1 H), 4.38 (ddd, J = 11.8, 7.5, 5.4 Hz, 1 H), 4.21 (dd, J = 6.9, 1.4 Hz, 2 H), 4.13
(dt, J = 11.8, 5.9 Hz, 1 H), 2.86 (td, J = 9.6, 3.6 Hz, 1 H), 2.31 (dddd, J = 13.6, 7.5, 5.9, 3.6
Hz, 1 H), 2.08 (ddt, J = 13.8, 9.6, 5.6 Hz, 1 H), 1.32-1 .17 (m, 2 H), 0.70-0.61 (m, 2 H), 0.52-
0.45 (m, 4 H), 0.45-0.36 (m, 1 H), 0.36-0.31 (m, 1 H); LCMS (Method T2) RT 1.09 min; m/z
326 [M+H]+.
[00309] The following tabulated example was prepared by a method analogous to that used
for the preparation of Intermediate A5a, starting from the intermediate(s) shown in the table.
For Intermediate A5b, reverse-phase chromatography was conducted after the reduction
step.
Intermediate A6a: (R)-10-amino-2-cyclopropyl-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-
c]quinolin-6(7H)-one
[00310] A mixture of (R)-2-cyclopropyl-10-nitro-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-
c]quinolin-6(7/-/)-one (Intermediate A4; 12 mg, 0.04 mmol) and tin(ll) chloride (30 mg, 0.16
mmol) were suspended in ethanol (0.23 ml_) and trifluoroethanol (0.08 ml_) and heated at
120°C under microwave irradiation for 1 h . The crude mixture was carried forward without
any purification. LCMS (Method T2) RT 0.50 min; m/z 272.14 [M+H]+.
Intermediate A7a: (R)-10-amino-2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4]oxaze-
pino[2,3-c][1,8]naphthyridin-6(7H)-one
Step 1: (R)-6-chloro-4-((1-cvclopropyl-3-hvdroxypropyl)amino)- 1-methyl- 1, 8-naphthyridin-
2(1H)-one
[00311] A microwave vial (2. 0-5.0 ml_ volume) was charged with (R)-3-amino-3-
cyclopropyl propan- 1-ol (Intermediate D1a; 139 mg, 1.2 mmol), ethyl 4,6-dichloro-1-methyl-2-
oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate (Intermediate F4; 201 mg, 0.67 mmol),
DIPEA (0.30 ml_, 1.7 mmol) and MeCN (2.7 ml_). The reaction vial was flushed with Ar and
sealed with a cap. The reaction mixture was heated at 90°C under microwave irradation for
2 h . The reaction mixture was transferred to a flask and 2 M sodium hydroxide (2.0 ml_, 4.0
mmol) was added. The reaction mixture was heated at 95 °C for 1 h . The reaction mixture
was cooled to rt and the resulting precipitate was filtered, washed with water (10 ml_) and
dried affording (R)-6-chloro-4-((1-cyclopropyl-3-hydroxypropyl)amino)-1 -methyl-1 ,8-
naphthyridin-2(1/-/)-one (136 mg, 66%) as an off-white solid. 1H NMR (500 MHz, DMSO-cfe) δ
8.75 (d, J = 2.3 Hz, 1 H), 8.62 (d, J = 2.3 Hz, 1 H), 6.77 (d, J = 8.3 Hz, 1 H), 5.54 (s, 1 H),
4.49 (t, J = 4.9 Hz, 1 H), 3.57-3.50 (m, 4 H), 3.50-3.44 (m, 1 H), 3.27-3.20 (m, 1 H), 1.89-
1.82 (m, 1 H), 1.82-1.73 (m, 1 H), 1.08-1 .00 (m, 1 H), 0.52-0.47 (m, 1 H), 0.41-0.36 (m, 1
H), 0.28-0.21 (m, 2 H); LCMS (Method T2) RT 1.40 min; m/z 308.1 16 [M+H]+
Step 2: (R)-3-bromo-6-chloro-4-((1-cvclopropyl-3-hvdroxypropyl)amino)- 1-methyl-1 ,8-
naphthyridin-2( 1H)-one
[00312] Trifluoroacetic acid (0.17 mL, 2.2 mmol) was added was added to a stirred mixture
of /V-bromosuccinimide ( 1 17 mg, 0.66 mmol) and (R)-6-chloro-4-((1-cyclopropyl-3-
hydroxypropyl)amino)-1 -methyl-1 ,8-naphthyridin-2(1/-/)-one (from step 1; 135 mg, 0.44
mmol) in anhydrous CH2CI2 (3.0 mL) at 0°C under Ar. The reaction mixture was stirred at
0°C for 25 min. The reaction mixture was diluted with EtOAc (20 mL) and washed with
saturated aq. NaHCC>3 (2 x 10 mL). The aqueous washings were combined and extracted
with EtOAc (20 mL). The organic extracts were combined, dried (Na2S0 4) and
concentrated in vacuo. Purification by flash chromatography (10 g KP-sil; 0% to 10% MeOH
in CH2CI2) afforded (R)-3-bromo-6-chloro-4-((1-cyclopropyl-3-hydroxypropyl)amino)-1-
methyl-1,8-naphthyridin-2(1/-/)-one (137 mg, 81%) as an off-white solid. 1H NMR (500 MHz,
DMSO-cfe) δ 8.72 (d, J = 2.4 Hz, 1 H), 8.69 (d, J = 2.4 Hz, 1 H), 5.57 (d, J = 10.4 Hz, 1 H),
4.62 (dd, J = 5.1 , 4.3 Hz, 1 H), 3.69-3.63 (m, 4 H), 3.63-3.57 (m, 1 H), 3.57-3.51 (m, 1 H),
1.98-1.91 (m, 1 H), 1.91-1 .82 (m, 1 H), 1.08-1 .00 (m, 1 H), 0.44-0.36 (m, 1 H), 0.31-0.24
(m, 1 H), 0.19-0.1 1 (m, 1 H), -0.01- -0.07 (m, 1 H); LCMS (Method T2) RT 1.45 min; m/z
386.025 [M+H] +
Step 3: (R)-10-chloro-2-cvclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4loxazepino[2,3-cl[1 ,81-
naphthyridin-6(7H)-one
[00313] A microwave vial (2-5 mL volume) was charged with (R)-3-bromo-6-chloro-4-((1-
cyclopropyl-3-hydroxypropyl)amino)-1 -methyl-1, 8-naphthyridin-2(1/-/)-one (from step 2 ; 137
mg, 0.35 mmol). The reaction vial was flushed with Ar, sealed with a cap and then further
flushed with Ar. Anhydrous DMSO (4.71 mL) was added followed by potassium tert-butoxide
( 1 M in THF; 0.64 mL, 0.64 mmol). The reaction mixture was heated at 60°C under
microwave irradiation for 80 min. The reaction mixture was allowed to cool to rt. Water (20
mL) was added followed by EtOAc (20 mL). The layers were separated and the aqueous
layer was further extracted with EtOAc (2 x 20 mL). The organic extracts were combined,
washed with brine (10 mL) and concentrated in vacuo. The crude product was dissolved in
DMSO ( 1 mL) and directly purified by reverse-phase chromatography (Biotage reverse-
phase 12 g C-18 column; 60-84% MeOH in H2O (containing 0.1% formic acid)) affording (R)-
10-chloro-2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-c][1 ,8]naphthyridin-
6(7H)-one (41 mg, 38%) as an off-white solid. 1H NMR (500 MHz, DMSO-cfe) δ 8.69 (d, J =
2.4 Hz, 1 H), 8.55 (d, J = 2.4 Hz, 1 H), 6.22 (d, J = 3.6 Hz, 1 H), 4.27^1.15 (m, 2 H), 3.57 (s,
3 H), 2.93-2.86 (m, 1 H), 2.24-2.16 (m, 1 H), 2.03-1 .95 (m, 1 H), 1.22-1 .14 (m, 1 H), 0.57-
0.48 (m, 2 H), 0.38-0.33 (m, 1 H), 0.29-0.23 (m, 1 H); LCMS (Method T2) RT 1.45 min; m/z
306.1 17 [M+H] +
Step 4: (R)-10-amino-2-cvclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4loxazepino[2,3-cl[1 ,81-
naphthyridin-6(7H)-one
[00314] An oven dried microwave vial (0. 5-2.0 ml_ volume) was charged with (R)-10-chloro-
2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-c][1 ,8]naphthyridin-6(7/-/)-one
(from step 3 ; 32 mg, 0.10 mmol), benzophenone imine (27 mg, 0.15 mmol), sodium tert-
butoxide (15 mg, 0.15 mmol), palladium(ll) acetate (2.3 mg, 0.010 mmol) and Josiphos (5.7
mg, 0.010 mmol). Anhydrous 1,2-dimethoxyethane (0.40 ml_) was added and the vial was
sealed with a cap and Ar was bubbled through the reaction mixture. The reaction mixture
was heated at 70°C in a heating block for 2 h . The reaction mixture was cooled to rt and 3 M
HCI (0.9 ml_) was added for imine hydrolysis. The mixture was stirred at rt for 2 h . The
reaction mixture was directly passed through an SCX-2 (2 g) column, eluting with water (10
ml_), MeOH (20 ml_) and 2 N methanolic ammonia (20 ml_). The basic fraction was
concentrated in vacuo affording the title compound (30 mg, 99%, 0.12 mmol) as a dark






[00315] The starting material: (R)-3-bromo-4-((1-cyclopropyl-3-hydroxypropyl)amino)-1-
methyl-6-nitroquinolin-2(1/-/)-one was prepared using steps 1-2 as shown for Intermediate
Aid.
[00316] To a solution of (f?)-3-bromo-4-((1-cyclopropyl-3-hydroxypropyl)amino)-1 -methyl-6-
nitroquinolin-2(1 H)-one (200 mg, 0.50 mmol) in pyridine (5.0 ml_) cooled to 0 °C was added
tosyl chloride (289 mg, 1.51 mmol). The mixture was stirred with warming to rt for 2 h .
Additional tosyl chloride (289 mg, 1.51 mmol) was added and the mixture stirred overnight at
rt. The reaction mixture was poured into 5% aq. HCI then extracted with CH2CI2. The organic
extracts were combined, washed with 5% aq. HCI, dried (MgSCU) and concentrated in
vacuo. The residue was purified by flash chromatography (25 g KP-sil; 20%-75% EtOAc in
cyclohexane) affording (R)-3-((3-bromo-1-methyl-6-nitro-2-oxo-1,2-dihydroquinolin-4-
yl)amino)-3-cyclopropylpropyl 4-methylbenzenesulfonate (127 mg, 46%) as a yellow solid.
LCMS (Method T2) RT 1.56 min; m/z 550.06 [M+H]+.
Step 2: (R)-S-(3-((3-bromo-1-methyl-6-nitro-2-oxo-J2-dihydroQuinolin-4-yl)amino)-3-
cyclopropylpropyl) ethanethioate
[00317] To a solution of (R)-3-((3-bromo-1-methyl-6-nitro-2-oxo-1,2-dihydroquinolin-4-
yl)amino)-3-cyclopropylpropyl 4-methylbenzenesulfonate (from step 1; 60 mg, 0.1 1 mmol)
in DMF ( 1 . 1 ml_) was added potassium thioacetate (25 mg, 0.22 mmol) followed by sodium
iodide (1.6 mg, 0.01 mmol). The solution was heated to 50°C and stirred for 4 h . The mixture
was cooled to rt and quenched by the addition of water. The mixture was extracted with
EtOAc. The combined organic extracts were washed with water, brine, dried (MgS0 4) and
concentrated in vacuo. The residue (diluted in DMSO ( 1 ml_)) was purified using reverse-
phase flash chromatography (Biotage 12g SNAP Ultra C-18, 30-100% MeOH in H O
(containing 0.1% formic acid)) affording (R)-S-(3-((3-bromo-1-methyl-6-nitro-2-oxo-1,2-
dihydroquinolin-4-yl)amino)-3-cyclopropylpropyl) ethanethioate (38 mg, 77%) as a brown oil.
LCMS (Method T2) RT 1.56 min; m/z 456.04 [M+H]+.
Step 3: (R)-2-cvclopropyl-7-methyl- 10-nitro- 1,2,3, 4-tetrahydro-r 1,4lthiazepino[2, 3-clguinolin-
6(7H)-one
[00318] To a suspension of (R)-S-(3-((3-bromo-1-methyl-6-nitro-2-oxo-1,2-dihydroquinolin-
4-yl)amino)-3-cyclopropylpropyl) ethanethioate (from step 2 ; 38 mg, 0.084 mmol)
in methanol (0.84 mL), cooled to 0°C under an atmosphere of air was added 15% aq. NaOH
(0.50 mL, 0.084 mmol). Stirring was continued with warming to rt overnight. The mixture was
concentrated in vacuo to remove the methanol. DMSO ( 1 .5 mL) and couple of drops of water
were then added. The solution was purified using reverse-phase flash chromatography
(Biotage 12g SNAP Ultra C-18, 30-100% MeOH in H O (containing 0.1% formic acid))
affording (R)-2-cyclopropyl-7-methyl-1 0-nitro-1 ,2,3,4-tetrahydro-[1 ,4]thiazepino[2,3-
c]quinolin-6(7/-/)-one (17 mg, 61%) as a yellow oil. LCMS (Method T2) RT 1.45 min; m/z
332.1 1 [M+H]+.
Step 4: (R)-10-amino-2-cvclopropyl-7-methyl-1,2,3,4-tetrahvdro-[ 1,4lthiazepino[2,3-
clguinolin-6(7H)-one
[00319] To a suspension of (R)-2-cyclopropyl-7-methyl-10-nitro-1 ,2,3,4-tetrahydro-
[1,4]thiazepino[2,3-c]quinolin-6(7/-/)-one (from step 3 ; 17 mg, 0.051 mmol) in ethanol (1.0
ml_) was added ammonium formate (32 mg, 0.51 mmol) and Pd/C (10 wt%, 10). The vial
was sealed and evacuated then refilled with argon three times. The vial was then placed into
a drysyn block preheated to 60°C and stirred for 1 hour. The reaction mixture was directly
passed through an SCX-2 (2 g) column, and the title compound product eluted with
methanolic ammonia. ( )-10-Amino-2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-[1 ,4]thiaze-
pino[2,3-c]quinolin-6(7/-/)-one (6 mg, 39%) was obtained as a yellow solid. LCMS (Method
T2) RT 1.07 min; m/z 302.13 [M+H]+.
[00320] The following tabulated example was prepared by a method analogous to that used
for the preparation of Intermediate A8a, starting from the amino-alcohol shown in the table.
Intermediate A8c: (/?)-/V-(2-cyclopropyl-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-
[1 ,4]thiazepino[2,3-c]quinolin-1 0-yl)formamide
Step 1 is analogous to that used for the preparation of Intermediate A8a.
Step 2: (R)-2-cvclopropyl-7-methyl-10-nitro- 1,2,3, 4-tetrahvdro-f 1,4lthiazepino[2, 3-clguinolin-
6(7H)-one
[00321] To a solution of (R)-3-((3-bromo-1-methyl-6-nitro-2-oxo-1,2-dihydroquinolin-4-
yl)amino)-3-cyclopropylpropyl 4-methylbenzenesulfonate (from step 1; 176 mg, 0.32 mmol)
in DMF (3.2 ml_) was added potassium thioacetate (73 mg, 0.64 mmol) followed by sodium
iodide (5 mg, 0.032 mmol). The solution was heated to 50°C and stirred for 3 h . Once cooled
to rt, 15% aq. sodium hydroxide ( 1 .00 ml_, 0.32 mmol) was added via syringe. The mixture
was allowed to stir at rt overnight. Water (5 ml_) was added to the mixture, forming a
precipitate which was collected under vacuum filtration and further washed with water and
dried in vacuo affording (R)-2-cyclopropyl-7-methyl-10-nitro-1 ,2,3,4-tetrahydro-
[1,4]thiazepino[2,3-c]quinolin-6(7/-/)-one which was used without further purification. LCMS
(Method X2) RT 1.35 min; m/z 354.09 [M+H] +.
[00322] To a suspension of (R)-2-cyclopropyl-7-methyl-10-nitro-1 ,2,3,4-tetrahydro-
[1.4]thiazepino[2,3-c]quinolin-6(7/-/)-one (from step 2 ; 106 mg, 0.32 mmol) in ethanol (3.2
ml_) was added ammonium formate (202 mg, 3.20 mmol) and 10 wt% Pd/C (34 mg). The vial
was sealed and evacuated then refilled with argon three times. The vial was then placed into
a drysyn block preheated to 60°C. After stirring for 1 h additional Pd/C and ammonium
formate (same quantities as above) were added and stirring continued at 60 °C for a further
2 h . The mixture was filtered through a pad of Celite and concentrated in vacuo. The residue
was taken up in ethanol (4 ml_) and tin(ll) chloride (243 mg, 1.28 mmol) was added. The
mixture was heated at 120 °C under microwave irradiation for a total of 9 h 30 min. The
reaction mixture was cooled to rt, and 15% aq. NaOH (2 ml_) was added and the reaction
mixture was stirred at 60 °C overnight. Once cooled, the mixture was concentrated then the
residue taken up in CH2CI2 and washed with water. The organic extracts were dried (MgS0 4)
and concentrated in vacuo. Purification by flash chromatography (Biotage KP-Sil 25 g ; 0-
10% MeOH in CH2CI2). The product-containing fractions were combined, concentrated in
vacuo and further purified by reverse-phase chromatography (Biotage reverse-phase 12 g
C-18 column; 10-100% MeOH in H2O (containing 0.1% formic acid)) affording the title
compound (5 mg, 5% over 2 steps) as a yellow oil. LCMS (Method T2) RT 1.31 min; m/z
330.12 [M+H] +. N.B. Intermediate A8a: (R)-10-amino-2-cyclopropyl-7-methyl-1, 2,3,4-
tetrahydro[1,4]thiaze-pino[2,3-c]quinolin-6(7H)-one (13 mg, 13% over 2 steps) was also
isolated during this reaction.
Intermediate A9a: (/?)-10-amino-2-cyclopropyl-7-methyl-1,2,3,4-tetrahydro-
[1 .4]thiazepino[2,3-c]quinolin-6(7H)-one 5,5-dioxide
Steps 1-3 are analogous to those used for the preparation of Intermediate A8a.
Step 4: (R)-2-cyclopropyl-7-methyl- 10-nitro- 1,2,3, 4-tetrahvdro-f 1,4lthiazepino[2, 3-clguinolin-
6(7H)-one 5,5-dioxide
[00323] 3-Chloroperoxybenzoic acid (126 mg, 0.56 mmol) was added portionwise to a
solution of (R)-2-cyclopropyl-7-methyl-1 0-nitro-1 ,2,3,4-tetrahydro-[1 ,4]thiazepino[2,3-
c]quinolin-6(7/-/)-one (62 mg, 0.19 mmol) in a mixture of CH2CI2 ( 1 .87 ml_) and acetonitrile
( 1 .87 ml_) cooled to 0 °C. After 15 min the mixture was allowed to warm to rt and stirred for
24 h . The mixture was quenched by addition of 10% aq. NaHCC>3 and sat. aq. Na2S2C>3. The
mixture was then extracted 3 times with EtOAc. The combined organic extracts were
combined, washed with 10% aq. Na2CC>3, brine, dried (MgSCL) and concentrated in vacuo
affording (R)-2-cyclopropyl-7-methyl-1 0-nitro-1 ,2,3,4-tetrahydro-[1 ,4]thiazepino[2,3-
c]quinolin-6(7/-/)-one 5,5-dioxide (45 mg, 66%) as a yellow solid which was used without
further purification. LCMS (Method T2) RT 1.20 min; m/z 364.0943 [M+H] +.
Step 5: (R)-10-amino-2-cvclopropyl-7-methyl-1,2,3,4-tetrahvdro-[ 1,4lthiazepino[2,3-
clguinolin-6(7H)-one 5,5-dioxide
[00324] A mixture of (R)-2-cyclopropyl-7-methyl-10-nitro-1 ,2,3,4-tetrahydro-[1,4]thiazepino-
[2,3-c]quinolin-6(7/-/)-one 5,5-dioxide (from step 4 ; 20 mg, 0.055 mmol) and tin(ll) chloride
(42 mg, 0.22 mmol) in ethanol (0.67 ml_) and trifluoroethanol (0.22 ml_) was heated at 70 °C
for 1 h . The reaction mixture was loaded onto an SCX-2 cartridge in 1:1 1 M HCI:MeOH,
flushed with MeOH, then eluted with 2 M NH3 in MeOH, affording the title compound (16 mg,
87%) as a yellow glass which was used without further purification. LCMS (Method X2); RT
1.54 min; m/z 334.1224 [M+H] +.
Intermediate A 10a: (S)-2-cyclopropyl-1 0-((2,5-dichloropyrimidin-4-yl)amino)-3,3-
difluoro-7-methyl-1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7H)-one
[00325] A microwave vial (0. 5-2.0 ml_ volume) was charged with (S)-10-amino-2-
cyclopropyl-3,3-difluoro-7-methyl-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one
(Intermediate Ai m ; 800 mg, 2.49 mmol) and 2,4,5-trichloropyrimidine (531 mg, 2.89 mmol).
The reaction vial was flushed with Ar, sealed with a cap and then further flushed with Ar.
NMP (3 ml_) was added followed by DIPEA ( 1 .7 ml_, 9.76 mmol). The reaction mixture was
heated at 140°C under microwave irradiation for 1 h . The reaction mixture was cooled to rt.
The reaction mixture was added to water (10 ml_) and a beige precipitate formed. Additional
water (10 ml_) was added and the aq. mixture was stirred for 5 min. The precipitate was
filtered, washed with water (25 ml_) and dried affording the title compound (1.16 g , 100%) as
a beige solid which was used without further purification. 1H NMR (600 MHz, DMSO-cfe) δ
9.74 (s, 1 H), 8.39 (s, 1 H), 8.15 (d, J = 2.1 Hz, 1 H), 7.61 (dd, J = 9.0, 2.1 Hz, 1 H), 7.50 (d,
J = 9.0 Hz, 1 H), 6.25 (d, J = 2.7 Hz, 1 H), 4.52-4.44 (m, 1 H), 4.43^1.34 (m, 1 H), 3.58 (s, 3
H), 3.28-3.23 (m, 1 H), 1.35-1.27 (m, 1 H), 0.77-0.67 (m, 1 H), 0.56-0.49 (m, 2 H), 0.36-
0.30 (m, 1 H); LCMS (Method X2); RT 1.60 min; m/z 468.0796 [M+H]+.
[00326] The following tabulated example was prepared by a method analogous to that used
for the preparation of Intermediate A10a, starting from the intermediate(s) shown in the
table. For Intermediate A10b and Intermediate A10c; instead of precipitation, the crude
reaction mixtures were directly purified by reverse-phase chromatography using the
conditions shown in the table to afford the title compounds. For Intermediate A10d; instead
of precipitation, the crude reaction mixture was directly purified by preparative HPLC using
the conditions shown in the table.
Intermediate A 11a : (/?)-/V-(2-cyclopropyl-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-
[1 ,4]oxazepino[2,3-c]quinolin-1 0-yl)formamide
[00327] A mixture of (f?)-10-amino-2-cyclopropyl-7-methyl-1 ,2,3,4-tetrahydro-
[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate Aid; 6 1 mg, 0.21 mmol) and phenyl
formate (25 uL, 0.23 mmol) in anhydrous CH2CI2 (0.60 ml_) was stirred at rt for 1 h . The
reaction mixture was concentrated in vacuo. Purification by flash chromatography (10 g KP-
sil; 0% to 10% MeOH in CH2CI2) afforded the title compound (32 g, 48%) as a yellow solid.
LCMS (Method X2) RT 1.00 min; m/z 314.1499 [M+H] +
Intermediate A 12a: 2-((/?)-1 0-((5-chloro-2-((3S,5/?)-4,4-difluoro-3,5-dimethylpiperidin-1 -
yl)pyrimidin-4-yl)amino)-2-cyclopropyl-6-oxo-1,3,4,6-tetrahydro-[1,4]oxazepino[2,3-
c]quinolin-7(2H)-yl)acetaldehyde
Step 1: (R)-2-cyclopropyl-7-(2, 2-dimethoxyethvD- 10-nitro- 1,2,3, 4-tetrahydro-f 1Aloxazepino-
[2, 3-clciuinolin-6(7H)-one
[00328] A microwave vial (2. 0-5.0 ml_ volume) was charged with (R)-2-cyclopropyl-10-nitro-
1,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (Intermediate A4; 69 mg, 0.23
mmol) and cesium carbonate (82 mg, 0.25 mmol). The reaction vial was flushed with Ar,
sealed with a cap and then further flushed with Ar. DMF (1.5 ml_) was added and the mixture
was stirred at rt for 30 min. 2-bromo-1 ,1-dimethoxyethane (82 uL, 0.69 mmol) was added
and the reaction mixture was heated at 100 °C for 3 h . After this time, additional 2-bromo-
1,1-dimethoxyethan (40 uL, 0.34 mmol) was added and the reaction mixture was heated at
100 °C for a further 2 h . The reaction mixture was cooled to rt, diluted with EtOAc (15 ml_)
and water (10 ml_) was added. The layers were separated and the aqueous mixture was
extracted with EtOAc (2 x 15 ml_). The organic extracts were combined, washed with brine
(10 ml_), dried (Na2S0 4) and concentrated in vacuo. Purification by flash chromatography
(10g KP-sil; 60% to 100% EtOAc in cyclohexane (5 CV) followed by 0% to 3% MeOH in
EtOAc (10 CV)) afforded (R)-2-cyclopropyl-7-(2,2-dimethoxyethyl)-10-nitro-1 ,2,3,4-
tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (42 mg, 47%) as a dark yellow solid. 1H
NMR (500 MHz, methanol-d ) δ 8.96 (d, J = 2.5 Hz, 1 H), 8.34 (dd, J = 9.5, 2.5 Hz, 1 H),
7.84 (d, J = 9.5 Hz, 1 H), 4.69 (t, J = 5.3 Hz, 1 H), 4.54-4.45 (m, 2 H), 4.45^1.38 (m, 1 H),
4.33—4.26 (m, 1 H), 3.41 (s, 3 H), 3.40 (s, 3 H), 3.02 (dt, J = 9.1, 3.9 Hz, 1 H), 2.41-2.33 (m,
1 H), 2.20-2.1 1 (m, 1 H), 1.34-1 .28 (m, 1 H), 0.77-0.63 (m, 2 H), 0.48-0.43 (m, 1 H), 0.36-
0.31 (m, 1 H); LCMS (Method X2) RT 1.34 min; m/z 358.1378 [M-MeOH+H] +
Step 2: (R)-10-amino-2-cvclopropyl-7-(2,2-dimethoxyethyl)-1 ,2,3,4-tetrahydro-
[ 1,4loxazepino[2, 3-clquinolin-6(7H)-one
[00329] A microwave vial (2. 0-5.0 ml_ volume) was charged with (R)-2-cyclopropyl-7-(2,2-
dimethoxyethyl)-1 0-nitro-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (from
step 1; 42 mg, 0.1 1 mmol) and 10 wt% Pd/C (5 mg). The reaction vial was flushed with Ar,
sealed with a cap and then further flushed with Ar. Ethanol ( 1 ml_) was added. The reaction
mixture was stirred at 60 °C under an atmosphere of H2 for 1 h . The reaction mixture was
allowed to cool to rt. The reaction mixture was filtered through celite, the solids washed with
EtOH (25 ml_). The filtrate was concentrated in vacuo affording (R)-10-amino-2-cyclopropyl-
7-(2,2-dimethoxyethyl)-1 ,2,3,4-tetrahydro-[1 ,4]oxazepino[2,3-c]quinolin-6(7/-/)-one (38 mg,
99%) as a yellow solid that was used without further purification. LCMS (Method X2) RT 0.89




[00330] A microwave vial (0. 5-2.0 ml_ volume) was charged with (R)-10-amino-2-
cyclopropyl-7-(2,2-dimethoxyethyl)-1 ,2,3,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-6(7/-/)-
one (from step 2 ; 36 mg, 0.10 mmol) and 5-chloro-2-((3S,5R)-4,4-difluoro-3,5-
dimethylpiperidin-1-yl)-4-(methylsulfonyl)pyrimidine (Intermediate J3; 70 mg, 0.21 mmol).
Trifluoroethanol ( 1 ml_) was added followed by trifluoroacetic acid (8.4 uL, 0.1 1 mmol). The
reaction vial was flushed with Ar, with A r bubbling through the reaction mixture, and sealed
with a cap. The reaction mixture was heated at 60 °C in a heating block for 2 h 30 min. After
this time, the cap was removed and additional 5-chloro-2-((3S,5R)-4,4-difluoro-3,5-
dimethylpiperidin-1-yl)-4-(methylsulfonyl)pyrimidine (Intermediate J3; 4 1 mg, 0.12 mmol)
and trifluoroacetic acid (8.4 uL, 0.1 1 mmol) were added. The vial was re-sealed and heated
at 60 °C for an additional 16 h . The reaction mixture was cooled to rt, and the resulting
precipitate was filtered and washed with Et2<D. The precipitate was identified as hydrolysed
Intermediate J3. The filtrate was transfered using methanol to a microwave vial (0. 5-2.0 ml_
volume). Trifluoroacetic acid (0.3 ml_) and water (0.5 ml_) were added to facilitate acetal de¬
protection. The reaction vial was re-sealed with a cap and heated at 60 °C in a heating block
for 1 h followed by 80 °C for 1 h . The reaction mixture was cooled to rt, and concentrated in
vacuo. The crude aqueous mixture was diluted with DMSO (0.8 ml_) and directly purified by
reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 10-30-100%
MeOH in H2O (containing 0.1% formic acid)), affording the title compound (7 mg, 11%) as an
off-white solid. LCMS (Method X2) RT 1.62 min; m/z 605.2466 [M+MeOH+H] +.
Intermediate B1a: (S)-10-amino-2,7-dimethyl-2,3-dihydro-[1,4]oxazepino[6,5-
c]quinoline-5,6(1 H,7H)-d\one
[00331] A suspension of ethyl 4-chloro-1-methyl-6-nitro-2-oxo-1,2-dihydroquinoline-3-
carboxylate (Intermediate F2; 132 mg, 0.43 mmol), (S)-2-aminopropan-1-ol (64 mg, 0.85
mmol) and DIPEA (0.15 ml_, 0.85 mmol) in NMP ( 1 .5 ml_) was stirred under microwave
irradiation at 160 °C for 1h. The reaction mixture was allowed to cool to rt. The cap was
removed and lithium chloride (108 mg, 2.55 mmol) was then added. The reaction vial was
re-sealed with a cap and the mixture was further stirred under microwave irradiation at
160°C for 1h. The crude reaction mixture was directly purified by preparative HPLC (15 min
gradient of 60:40 to 0:100 H20:MeOH (both modified with 0.1 % formic acid); flow rate 20
mLmin 1) affording (S)-2,7-dimethyl-1 0-nitro-2,3-dihydro-[1 ,4]oxazepino[6,5-c]quinoline-
5,6(1 H,7H)-dione (48 mg, 37%) as a light brown solid. 1H NMR (500 MHz, DMF-d7) δ 9.20
(d, J = 2.4 Hz, 1 H), 8.48 (dd, J = 9.4, 2.4 Hz, 1 H), 8.20 (br s , 1 H), 7.72 (d, J = 9.4 Hz, 1 H),
4.72 (dd, J = 13.0, 1.2 Hz, 1 H), 4.49 (dd, J = 13.0, 5.1 Hz, 1 H), 4.20 (q, J = 6.4 Hz, 1 H),




dione (from step 1 ; 48 mg, 0.16 mmol) and Pd/C (10 wt%, 3 mg) were suspended in EtOH
(4 ml_) under Ar. The mixture evacuated and filled with H2 3 times. The reaction mixture was
stirred under an atmosphere of H2 for 16 h . The reaction mixture was filtered through
Celite™ and the solids washed with MeOH. The filtrate was concentrated in vacuo affording
the title compound (40 mg, 92%) as a yellow oil which was used without further purification.
LCMS (Method T2) RT 0.19 min; m/z 274.1 [M+H]+.
[00333] The following tabulated examples were prepared by a method analogous to that




[00334] Boron trifluoride diethyl etherate (-50% BF3; 0.1 ml_, 0.41 mmol) was added to a
stirred suspension of (S)-10-amino-2,7-dimethyl-2,3-dihydro-[1,4]oxazepino[6,5-c]quinoline-
5,6(1 /-/,7/-/)-dione (Intermediate B1a; 12 mg, 0.042 mmol) in THF (4 ml_) at 0 °C. The
reaction mixture was stirred at 0 °C for 15 min, after which sodium borohydride (5 mg, 0.127
mmol) was added. The reaction mixture was stirred at 0 °C for a further 2 h . The reaction
was quenched with the addition of methanol. The reaction mixture was concentrated in
vacuo. Brine was added to the residue and the aqueous mixture was extracted with EtOAc.
The organic layer was dried (Na2S0 4) and concentrated in vacuo. Purification by flash
chromatography (10 g KP-sil; 5% MeOH in EtOAc) afforded the title compound (4 mg, 32%)
as a yellow solid. 1H NMR (500 MHz, Methanol-d ) δ 7.34 (dd, J = 9.0, 1.4 Hz, 1 H), 7.23
(dd, J = 2.4, 1.4 Hz, 1 H), 7.10 (dd, J = 9.0, 2.4 Hz, 1 H), 4.96 (d, J = 14.4 Hz, 1 H), 4.77 (d,
= 14.4 Hz, 1 H), 3.92 (dt, = 11.2, 2.9 Hz, 1 H), 3.86 (ddt, J = 12.1 , 6.6, 3.0 Hz, 1 H), 3.60
(s, 3 H), 3.60 (ddd, J = 11.2, 8.8, 2.0 Hz, 1 H), 1.29 (d, J = 6.6 Hz, 3 H).
Intermediate B3a: ethyl 4-((1-((ferf-butoxycarbonyl)amino)propan-2-yl)amino)-6-((2-
chloro-3-cyanopyridin-4-yl)amino)-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxylate
Step 1: ethyl 4-((1-((tert-butoxycarbonyl)amino)propan-2-yl)amino)-1-methyl-6-nitro-2-oxo-
1.2-dihvdroguinoline-3-carboxylate
[00335] Ethyl 4-chloro-1-methyl-6-nitro-2-oxo-1 ,2-dihydroquinoline-3-carboxylate
(Intermediate F2; 325 mg, 1.05 mmol), tert-butyl (2-aminopropyl)carbamate (200 mg, 1.15
mmol) and DIPEA (0.2 ml_, 1.15 mmol) were combined in a microwave vial and dissolved
in THF (5.2 ml_). The reaction mixture was then heated to 100 °C for 16 h . Excess amine
was added in 1 ml_ of THF followed by DIPEA (50 uL) and heating was continued for 2 h .
The reaction mixture was cooled to rt, partitioned between EtOAC (25 ml_) and water (25
ml_). The aqueous layer was further extracted with EtOAc (25 ml_) and the organic extracts
were combined, washed with brine (50 ml_), dried (MgSCU) and concentrated in vacuo
affording ethyl 4-((1-((te/f-butoxycarbonyl)amino)propan-2-yl)amino)-1-methyl-6-nitro-2-oxo-
1.2-dihydroquinoline-3-carboxylate (606 mg, 129%) as a yellow solid that was used without
further purification. LCMS (Method T4); RT 2.87 min; m/z 449.2078 [M+H]+. Note: The LCMS
showed a mixture of the desired product and amine starting material. This mixture was
carried forward assuming 100% conversion.
Step 2: ethyl 6-amino-4-((1-((tert-butoxycarbonyl)amino)propan-2-yl)amino)-1-methyl-2-oxo-
1.2-dihvdroguinoline-3-carboxylate
[00336] Ethyl 4-((1-((te/f-butoxycarbonyl)amino)propan-2-yl)amino)-1-methyl-6-nitro-2-oxo-
1.2-dihydroquinoline-3-carboxylate (from step 1 ; 50 mg, 0.1 1 mmol), Pd/C (10 wt%; 1.2
mg) and ammonium formate (70 mg, 1. 1 1 mmol) were combined in a microwave vial which
was sealed and placed under an argon atmosphere by alternating vacuum and argon three
times. Ethanol (0.64 ml_) was then added and the reaction mixture heated to 70 °C for 2 h .
The reaction mixture was filtered over Celite and the solvent removed in vacuo. The crude
product was partitioned between EtOAc (20 ml_) and water (20 ml_). The organic layer was
washed with further water (2 x 20 mL), then dried (MgS0 4) and filtered over a hydrophobic
frit. The solvent was removed in vacuo affording ethyl 6-amino-4-((1-((te/f-
butoxycarbonyl)amino)propan-2-yl)amino)-1-methyl-2-oxo-1,2-dihydroquinoline-3-
carboxylate (44 g, 94%) as a green oil which was used without further purification. LCMS
(Method T2); RT 1.23 min; m/z 419.2728 [M+H] +.
Step 3: ethyl 4-((1-((tert-butoxycarbonyl)amino)propan-2-yl)amino)-6-((2-chloro-3-
cvanopyridin-4-yl)amino)-1-methyl-2-oxo-1 ,2-dihvdroguinoline-3-carboxylate
[00337] Ethyl 6-amino-4-((1-((te/f-butoxycarbonyl)amino)propan-2-yl)amino)-1 -methyl-2-
oxo-1, 2-dihydroquinoline-3-carboxylate (from step 2 ; 50 mg, 0.12 mmol), 2,4-
dichloronicotinonitrile (21 mg, 0.12 mmol) and DIPEA (62 uL, 0.36 mmol) were combined in
a microwave vial and dissolved in NMP ( 1 mL). The reaction mixture was heated at 110 °C
under microwave irradiation for 90 min, followed by heating at 110 °C in a heating block for a
further 8 h . The reaction mixture was cooled to rt, and trifluoroacetic acid (183 uL, 2.39
mmol) was added and the reaction mixture was stirred at 70 °C for 30 min. The reaction
mixture was cooled to rt, and DIPEA (0.5 mL) was added. The reaction mixture was stirred
at 70 °C for 4 h . The reaction mixture was cooled to rt and partitioned between EtOAc (20
mL) and water (20 mL). The aqueous layer was extracted once with EtOAc (20 mL) and the
organic extracts were combined, washed twice with brine, dried (MgS0 4) , and concentrated
in vacuo affording the title compound (62 mg, 94%) as a brown oil which was used without
further purification. LCMS (Method T4); RT 2.91 min; m/z 555.21 1 [M+H] +.
Intermediate C 1 : 9-amino-2,6-dimethyl-2,3,4,6-tetrahydrobenzo[fj][1,6]naphthyridin-
5(1H)-one
Step 1: 4-((4-hydroxybutan-2-vi)amino)- 1-methyl-6-nitroguinolin-2( 1H)-one
[00338] A mixture of 4-chloro-1-methyl-6-nitroquinolin-2(1/-/)-one (Intermediate F1; 250 mg,
1.05 mmol) and 3-aminobutan-1-ol (280 mg, 3.14 mmol) and DIPEA (0.36 mL, 2.10 mmol) in
NMP ( 1 .9 mL) was stirred at 160 °C for 20h. The reaction mixture was allowed to cool to rt.
The reaction mixture was diluted with water and extracted with EtOAc. The organic extracts
were combined, washed with water and brine, dried (Na2S0 4) and concentrated in vacuo.
Purification by flash chromatography (50 g KP-sil; 0% to 10% MeOH in CH2CI2, afforded 4-
((4-hydroxybutan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (200 mg, 66%). 1H NMR
(500 MHz, CDCb) δ 8.48 (d, J = 2.5 Hz, 1H), 8.36 (dd, J = 9.3, 2.5 Hz, 1H), 7.38 (d, J = 9.3
Hz, 1H), 6.05 (d, J = 6.6 Hz, 1H), 5.80 (s, 1H), 4.10 - 3.97 (m, 1H), 3.96 - 3.82 (m, 2H), 3.68
(s, 3H), 2.08 - 1.95 (m, 2H), 1.89 (dtd, J = 14.8, 6.3, 3.5 Hz, 1H), 1.35 (d, J = 6.4 Hz, 3H).
LCMS (Method T2) RT 1.21 min, m/z 292.13 [M+H] +.
Step 2: 3-((1-methyl-6-nitro-2-oxo-1,2-dihvdroauinolin-4-yl)amino)butyl 4-methylbenzene-
sulfonate
[00339] Tosyl chloride (61 mg, 0.32 mmol) was added to a stirred solution of 4-((4-
hydroxybutan-2-yl)amino)-1-methyl-6-nitroquinolin-2(1/-/)-one (from step 1 ; 100 mg, 0.34
mmol) and pyridine (3 ml_, 37.2 mmol) in CH2CI2 (3.43 ml_) at 0 °C. The reaction mixture was
warmed to rt and stirred at that temperature for 20h. The mixture was diluted with water and
extracted with CH2CI2. The organic extracts were combined, washed with 10% citric acid
solution, dried (MgSCL) and concentrated in vacuo. Purification by flash chromatography (25
g KP-sil; 60% to 80% EtOAc in cyclohexane) afforded 3-((1-methyl-6-nitro-2-oxo-1,2-
dihydroquinolin-4-yl)amino)butyl 4-methylbenzenesulfonate (68 mg, 44%) as a yellow solid.
1H NMR (500 MHz, CDCb) δ 8.43 (d, J = 2.4 Hz, 1H), 8.39 (dd, J = 9.3, 2.4 Hz, 1H), 7.77 (d,
J = 8.2 Hz, 2H), 7.41 (d, J = 9.3 Hz, 1H), 7.28 (d, J = 8.2 Hz, 2H), 5.74 (s, 1H), 4.77 (d, J =
7.8 Hz, 1H), 4.22 (t, J = 5.9 Hz, 2H), 3.77 (app. hept, J = 6.7 Hz, 1H), 3.69 (s, 3H), 2.38 (s,
3H), 2.09-2.02 (m, 2H), 1.32 (d, J = 6.5 Hz, 3H). LCMS (Method T2) RT 1.42 min, m/z
446.14 [M+H] +.
Step 3: 2,6-dimethyl-9-nitro-2,3,4, 6-tetrahvdrobenzofhii 1, 61naphthyridin-5(1H)-one
[00340] A mixture of 3-[(1-methyl-6-nitro-2-oxo-4-quinolyl)amino]butyl 4-methylbenzene-
sulfonate (from step 2 ; 34 mg, 0.076 mmol) and DIPEA (40 uL, 0.23 mmol) in NMP (0.76
mL) was heated at 160 °C under microwave irradiation for 1h. The reaction mixture was
allowed to cool to rt. The reaction mixture was diluted with water and extracted with EtOAc.
The organic extracts were combined, washed with water and brine, dried (MgSCL), and
concentrated in vacuo. Purification by flash chromatography (10 g KP-sil; 0% to 10% MeOH
in CH2CI2) afforded 2,6-dimethyl-9-nitro-2,3,4,6-tetrahydrobenzo[/7][1 ,6]naphthyridin-5(1/-/)-
one (14 mg, 67%) as an orange solid. LCMS (Method T2) RT 1.36 min, m/z 274.12 [M+H] +.
Step 4: 9-amino-2, 6-dimethyl-2,3,4, 6-tetrahydrobenzo[hl[1 ,61naphthyridin-5(1H)-one
[00341] To a solution of 2,6-dimethyl-9-nitro-2,3,4,6-tetrahydrobenzo[/7][1 ,6]naphthyridin-
5(1/-/)-one (from step 3 ; 14 mg, 0.051 mmol) in ethanol ( 1 mL) and NMP (0.2 mL) in a 0.5-
2.0 mL microwave vial was added Pd/C (10 wt%, 2.7 mg) followed by ammonium formate
(32 mg, 0.51 mmol). The vial was sealed with a cap and evacuated then refilled with Ar three
times. The reaction mixture was heated at 60°C in a heating block for 30 min. The reaction
mixture was allowed to cool to rt, filtered through Celite™ loaded onto an SCX-2 (2 g)
column, eluting with MeOH (20 ml_) followed by 2 N methanolic ammonia (20 ml_). The
methanolic ammonia fraction was concentrated in vacuo affording the title compound (16
mg, 100%) as a yellow oil (some residual NMP was present). LCMS (Method T2) RT 0.62
min, m/z 244.1443 [M+H]+.
Intermediate D1a: (/?)-3-amino-3-cyclopropylpropan-1-ol
[00342] Lithium aluminium hydride ( 1 M in THF; 18.6 mL, 18.6 mmol) was added dropwise
to a stirred suspension of ethyl (R)-3-amino-3-cyclopropylpropanoate hydrochloride (3.00 g ,
15.5 mmol) in diethyl ether (50 mL) at 0°C under Ar. The reaction mixture was stirred at 0°C
for 90 min. The reaction mixture was quenched with the addition of water (0.7 mL) followed
by 15% aq. sodium hydroxide (0.7 mL) and water (2.1 mL). The quenched reaction mixture
was stirred at rt for 1 h . The resulting aluminium precipitates were filtered through Celite™,
and the solid was washed with Et20 (200 mL). The filtrate was concentrated in vacuo
affording the title compound ( 1 .78 g , 100%) as a yellow oil that was used without further
purification. 1H NMR (500 MHz, MeOD-ck) δ 3.75-3.66 (m, 2 H), 2.10-2.04 (m, 1 H), 1.84-
1.76 (m, 1 H), 1.73-1.65 (m, 1 H), 0.79-0.71 (m, 1 H), 0.53-0.44 (m, 2 H), 0.25-0.18 (m, 2
H).
[00343] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate D1a, starting from the amines shown in the table.
Intermediate E 1 : (2S,4S)-4-aminopentan-2-ol
Step 1: tert-butyl (S)-(4-(methoxy(methyl)amino)-4-oxobutan-2-yl)carbamate
[00344] DIPEA (0.76 mL, 4.36 mmol) followed by T3P (50 wt% in EtOAc, 1.17 g , 1.845
mmol) and Λ/ ,Ο-dimethylhydroxylamine hydrochloride (214 mg, 2.20 mmol) were added
sequentially to a solution of Boc-L-p-homoalanine (296 mg, 1.45 mmol) in DMF under Ar.
The reaction mixture was stirred at rt for 68 h . Water (20 ml_) was added and the aqueous
mixture was stirred for 1 h , then extracted with EtOAc (3 x 5 ml_). The organic extracts were
combined, dried (Na2S0 4) and concentrated in vacuo. Purification by flash chromatography
(25 g KP-sil; 10% to 80% EtOAc in cyclohexane) afforded ted-butyl (S)-(4-
(methoxy(methyl)amino)-4-oxobutan-2-yl)carbamate (341 mg, 95%) as a pale yellow oil. R =
0.24 (50% EtOAc in cyclohexane); 1H NMR (500 MHz, CDCh) δ 5.32 (br s , 1 H), 4.10^1.02
(m, 1 H), 3.69 (s, 3 H), 3.18 (s, 3 H), 2.71 (dd, J = 15.6, 4.8 Hz, 1 H), 2.55 (dd, J = 15.6, 4.4
Hz, 1 H), 1.44 (s, 9 H), 1.25 (d, J = 6.7 Hz, 3 H).
Step 2: tert-butyl (S)-(4-oxopentan-2-yl)carbamate
[00345] Methylmagnesium bromide (3 M in Et20 ; 0.46 ml_, 1.38 mmol) was added dropwise
to a stirred solution of tert-butyl (S)-(4-(methoxy(methyl)amino)-4-oxobutan-2-yl)carbamate
(from step 1 ; 341 mg, 1.38 mmol) in THF (4.5 ml_) at -15°C under Ar. After stirring at this
temperature for 15 min, additional methylmagnesium bromide (3 M in Et20 ; 0.57 ml_, 1.71
mmol) was added dropwise to the reaction mixture at -15°C. The reaction mixture was then
allowed to warm to rt and stirred at that temperature for 2 h . The reaction mixture was cooled
to 0 °C and saturated aq. NH4C I (10 ml_) was added. The aqueous mixture was extracted
with EtOAc (3 x 15 ml_). The organic extracts were combined, dried (Na2S0 4) and
concentrated in vacuo. Purification by flash chromatography (10 g KP-sil; 0% to 70% EtOAc
in cyclohexane) afforded tert-butyl (S)-(4-oxopentan-2-yl)carbamate (149 mg, 54%) as a
white solid. Rf = 0.58 (70% EtOAc in cyclohexane); 1H NMR (500 MHz, CDCh) δ 4.84 (br s ,
1 H), 4.07-3.97 (m, 1 H), 2.70 (dd, J = 16.5, 5.3 Hz, 1 H), 2.57 (dd, J = 16.5, 6.3 Hz, 1 H),
2.16 (s, 3 H), 1.44 (s, 9 H), 1.20 (d, J = 6.7 Hz, 3 H).
Step 3: tert-butyl ((2S,4S)-4-hydroxypentan-2-vi)carbamate and tert-butyl ((2S,4R)-4-
hydroxypentan-2-yl)carbamate
[00346] Sodium borohydride (36 mg, 0.96 mmol) was added portionwise to a stirred solution
of tert-butyl (S)-(4-oxopentan-2-yl)carbamate (from step 2 ; 149 mg, 0.74 mmol) in anhydrous
ethanol (5 ml_) at 0°C under Ar. The reaction mixture was stirred at 0°C for 5 min, then
warmed to rt and stirred for 2 h . Additional sodium borohydride (40 mg, 1.06 mmol) was
added and the reaction mixture was stirred at rt for a further 20 min. Saturated aq. NH4C I (10
ml_) was added. The aqueous mixture was extracted with EtOAc (3 x 15 ml_). The organic
extracts were combined, dried (Na2S0 4) and concentrated in vacuo. The crude reaction
mixture was dry-loaded onto silica and purified by flash chromatography (10 g KP-sil; 30% to
80% EtOAc in cyclohexane) affording tert-butyl ((2S,4S)-4-hydroxypentan-2-yl)carbamate
(82 mg, 55%) as a white crystalline solid followed by tert-butyl ((2S,4R)-4-hydroxypentan-2-
yl)carbamate (68 mg, 45%) as a white crystalline solid. (2S,4S)-4-hydroxypentan-2-
vDcarbamate: R = 0.66 (70% EtOAc in cyclohexane); 1H NMR (500 MHz, CDCh) δ 4.51 (br
s , 1 H), 3.92 (br s , 1 H), 3.86-3.75 (m, 1 H), 3.74-3.40 (br s , 1 H), 1.57-1.50 (m, 1 H), 1.46
(s, 9 H), 1.35-1 .28 (m, 1 H), 1.19 (d, J = 6.0 Hz, 3 H), 1.18 (d, J = 6.4 Hz, 3 H); tert-butyl
((2S,4R)-4-hydroxypentan-2-vi)carbamate: R = 0.51 (70% EtOAc in cyclohexane) 1H NMR
(500 MHz, CDCh) δ 3.96-3.88 (m, 1 H), 3.82-3.72 (m, 1 H), 1.63-1.57 (m, 1 H), 1.55-1.49
(m, 1 H), 1.45 (s, 9 H), 1.22 (d, J = 6.3 Hz, 3 H), 1.18 (d, J = 6.6 Hz, 3 H).
Step 4: (2S,4S)-4-aminopentan-2-oi
[00347] Trifluoroacetic acid ( 1 ml_, 13 mmol) was added dropwise to a solution of tert-butyl
((2S,4S)-4-hydroxypentan-2-yl)carbamate (from step 3 ; 82 mg, 0.40 mmol) in anhydrous
CH2CI2 (4 ml_) at 0 °C under Ar. The reaction mixture was allowed to warm to rt over 2 h . The
reaction mixture was concentrated in vacuo and the resulting residue was diluted with
CH2CI2 (10 ml_) and concentrated in vacuo. The crude product was passed through an SCX-
2 column (2 g), eluting with MeOH (20 ml_) followed by 2 M methanolic ammonia (30 ml_).
The ammonia fractions were collected and concentrated in vacuo affording the title
compound (31 mg, 74%) as a pale yellow oil that was used without further purification.
LCMS (Method T4) RT 0.20 min; m/z 104.1080 [M+H] +.
Intermediate F 1 : 4-chloro-1-methyl-6-nitroquinolin-2(1H)-one
Step 1: 4-chloroguinolin-2( 1H)-one
[00348] To a stirred solution of 2,4-dichloroquinoline (24.9 g , 126 mmol) in 1,4-dioxane (126
ml_) was added cone. HCI (83.8 ml_, 1.01 mol) dropwise. The reaction mixture was refluxed
for 18h. The mixture was cooled to room temperature, poured into excess ice water and
allowed to stir for 1h. The precipitate was filtered and dried under vacuum to afford 4-
chloroquinolin-2(1/-/)-one (19.2 g , 85%) as an off-white solid. LCMS (Method T2) RT 1.25
min; m/z 180.03 [M+H] +.
Step 2: 4-chloro-6-nitroguinolin-2(1 H)-one
[00349] A mixture of 4-chloro-1/-/-quinolin-2-one (from step 1; 17.8 g , 98.9 mmol) in sulfuric
acid (52.7 mL, 989 mmol) was cooled to 0 °C. Nitric acid (70%) (9.9 mL, 109 mmol) was
added dropwise. The solution was stirred at 0 °C for 1h and then poured onto ice water. The
yellow precipitate that formed was filtered and washed with water, methanol, ethyl acetate
and diethyl ether before being stirred under vacuum at 120 °C for approx. 10 min affording
4-chloro-6-nitroquinolin-2(1/-/)-one (21.5 g , 97%) as a pale yellow solid. LCMS (Method T2)
RT 1.27 min; m/z 225.01 [M+H]+.
Step 3: 4-chloro-1-methyl-6-nitroguinolin-2(1H)-one
[00350] Sodium hydride (60% in mineral oil; 2.6 g , 63.9 mmol) was added portionwise to a
stirred solution of 4-chloro-6-nitroquinolin-2(1/-/)-one (from step 2 ; 7.1 g , 3 1 .7 mmol) in DMF
(60 ml_) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min, after which
iodomethane (3 ml_, 48.2 mmol) was added dropwise. The reaction mixture was stirred at rt
for 75 min. Water (80 ml_) was added and the aqueous mixture was stirred for 20 min. The
resulting yellow precipitate was filtered, washed with water (2 x 100 ml_), Et20 (2 x 50 ml_)
and dried affording the title compound (6.1 g , 81%) as a yellow solid. LCMS (Method T2) RT
1.30 min; m/z 239.02 [M+H]+.
Intermediate F2: ethyl 4-chloro-1-methyl-6-nitro-2-oxo-1,2-dihydroquinoline-3-
carboxylate
Step 1: 1-methyl-6-nitro-2H-benzo[dl[1 ,31oxazine-2,4(1H)-dione
[00351] To a solution of 5-nitro-isatoic anhydride (25.1 g , 120.6 mmol) in DMF (241 ml_) at
rt was added sodium hydride (60% in mineral oil; 7.24 g , 180.9 mmol). The solution was
allowed to stir for 15 min with warming to RT. Iodomethane (18.8 ml_, 301 .5 mmol) was
added and the mixture was stirred at rt for 4 h . The reaction mixture was poured onto ice, the
resulting precipitate filtered and washed with water (5 litres). The solid was collected and
dried under vacuum overnight affording 1-methyl-6-nitro-2/-/-benzo[c(][1 ,3]oxazine-2,4(1/-/)-
dione (19.7 g , 73%) as an orange powder. LCMS (Method T2) RT 1.35 min, m/z 2 11.069
[M+MeOH-C0 2]+.
Step 2: ethyl 4-hvdroxy-1-methyl-6-nitro-2-oxo-1,2-dihydrociuinoline-3-carboxylate
[00352] To a solution of 1-methyl-6-nitro-2/-/-benzo[c(][1,3]oxazine-2,4(1/-/)-dione (from step
1; 19.6 g , 88.2 mmol) in DMF (177 mL) was added diethyl malonate (40.4 mL, 264.7 mmol).
The solution was cooled to 0°C, then Sodium hydride (60% in mineral oil) (7.06 g , 176.46
mmol) was added in 4 portions over 30 min. The solution was allowed to warm to rt and
stirred at that temperature for 3 h . Water was added with care to the reaction mixture
followed by 10% aq. HCI until the pH of the mixture was ~pH5. The resulting precipitate was
filtered through a sinter funnel and washed with water (5 litres). The resulting solid was
transferred to a round bottom flask and dried under vacuum affording ethyl 4-hydroxy-1-
methyl-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate (24.2 g , 94%) as a pale yellow solid.
LCMS (Method T2) RT 1.45 min; m/z 293.074 [M+H] +.
Step 3: ethyl 4-chloro-1-methyl-6-nitro-2-oxo-1,2-dihydrociuinoline-3-carboxylate
[00353] Phosphorus oxychloride (250 ml_, 2700 mmol) was added to a flask containing ethyl
4-hydroxy-1-methyl-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate (24.1 g , 82.5 mmol).
The flask was fitted with a suba-seal and an argon balloon then heated to 80°C with stirring
for 2.5 h . The mixture was concentrated in vacuo. The residue was diluted with water and
extracted with EtOAc. The combined organic extracts were washed with brine, dried
(MgS04) and concentrated in vacuo. Purification by flash chromatography (340 g KP-sil; 0%
to 10% MeOH in CH2CI2) afforded the title compound (14.5 g , 57%) as a dark orange solid.
1H NMR (500 MHz, CDC ) δ 8.95 (d, J = 2.5 Hz, 1H), 8.50 (dd, J = 9.3, 2.5 Hz, 1H), 7.53 (d,
J = 9.3 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 1.42 (t, J = 7.1 Hz, 3H); LCMS
(Method T2) RT 1.42 min; m/z 3 11.043 [M+H] +.
Intermediate F3: ethyl 4-chloro-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate
Step 1: ethyl 4-hvdroxy-6-nitro-2-oxo-1,2-dihydrociuinoline-3-carboxylate
[00354] Sodium hydride (60 wt% in mineral oil; 1.93 g , 48.2 mmol) was added in 3 portions
over 30 min to a solution of diethyl malonate ( 1 1.0 mL, 72.5 mmol) and 5-nitro-isatoic
anhydride (5.03 g , 24.2 mmol) in DMF (80.0 mL) at 0°C under Ar. The reaction mixture was
allowed to warm to 25 °C and stirred for 3 d . The reaction mixture was cooled to 0°C and
water (150 mL) was added. The aqueous mixture was neutralised to pH 7 using 10% HCI
and the resulting mixture was stirred at rt for 30 min. The resulting yellow precipitate was
filtered and washed with water (200 mL). The filtrate was further acidified to pH 5 using 10%
HCI and more precipitate formed. The additional yellow precipitate was filtered and dried
under vacuum affording ethyl 4-hydroxy-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate
(6.29 g , 93%) as a pale yellow solid. LCMS (Method T2) RT 1.42 min; m/z 279.061 [M+H] +.
Step 2: ethyl 2.4-dichloro-6-nitroQuinoline-3-carboxylate
[00355] Phosphorus oxychloride (50 mL, 534.8 mmol) was added to a flask containing ethyl
4-hydroxy-6-nitro-2-oxo-1,2-dihydroquinoline-3-carboxylate (from step 1 ; 6.29 g , 22.6 mmol).
The flask was fitted with a reflux condenser, suba-seal and an argon balloon then heated to
80°C with stirring for 4 h . The reaction mixture was cooled to rt and concentrated in vacuo.
The crude reaction mixture was dissolved in EtOAc (100 mL) and washed with water (2 x 50
mL) and saturated aq. NaHCOs (50 mL). The organic layer was dried (Na2S0 4) and
concentrated in vacuo affording ethyl 2,4-dichloro-6-nitroquinoline-3-carboxylate (5.12 g ,
72%) as a yellow solid which was used without further purification. LCMS (Method T2) RT
1.58 min; m/z 314.995 [M+H] +.
Step 3: ethyl 4-chloro-6-nitro-2-oxo-1,2-dihydrociuinoline-3-carboxylate
[00356] A mixture of ethyl 2,4-dichloro-6-nitroquinoline-3-carboxylate (from step 2 ; 5.12 g ,
16.3 mmol) and sodium acetate ( 1 .48 g , 18.0 mmol) in acetic acid (30 mL) was heated at
120°C for 8 h . The reaction mixture was cooled to rt and water (100 mL) was added. The
precipitate was filtered, washed with water (200 mL) and dried, affording the title compound
(4.02 g , 83%) as a pale yellow solid. 1H NMR (500 MHz, DMSO-cfe) δ 13.00 (s, 1 H), 8.67 (d,
J = 2.5 Hz, 1 H), 8.50 (dd, = 9.1 , 2.5 Hz, 1 H), 7.56 (d, J = 9.1 Hz, 1 H), 4.38 (q, J = 7.1 Hz,
2 H), 1.32 (t, J = 7.1 Hz, 3 H); LCMS (Method T2) RT 1.42 min; m/z 297.027 [M+H] +.
Intermediate F4: ethyl 4,6-dichloro-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-
carboxylate
Step 1: methyl 5-chloro-2-(methylamino)nicotinate
[00357] A microwave vial (10-20 ml_ volume) was charged with methyl 5-chloro-2-
fluoronicotinate (404 mg, 2.1 mmol). The reaction vial was flushed with Ar, sealed with a cap
and then further flushed with Ar. Anhydrous THF (6 ml_) was added followed by methylamine
(2 M in THF; 5 ml_, 10 mmol). The reaction mixture was stirred at 40°C for 5 h . The reaction
mixture was concentrated in vacuo. The residue was diluted with water (10 ml_) and
extracted with EtOAc (2 x 15 ml_). The organic extracts were combined, washed with brine
(10 ml_), dried (Na2S04) and concentrated in vacuo. Purification by flash chromatography
(10 g KP-sil; 0% to 30% EtOAc in cyclohexane) afforded methyl 5-chloro-2-
(methylamino)nicotinate (378 mg, 88%) as a white solid. 1H NMR (500 MHz, CDCh) δ 8.25
(d, J = 2.7 Hz, 1 H), 8.07 (d, J = 2.7 Hz, 1 H), 7.87 (br s , 1 H), 3.88 (s, 3 H), 3.05 (d, J = 4.9
Hz, 3 H); LCMS (Method T2) RT 1.40 min; m/z 201 .052 [M+H] +.
Step 2: ethyl 6-chloro-4-hydroxy- 1-methyl-2-oxo- 1,2-dihydro- 1, 8-naphthyridine-3-carboxylate
[00358] A microwave vial (2. 0-5.0 ml_ volume) was charged with methyl 5-chloro-2-
(methylamino)nicotinate (from step 1; 378 mg, 1.9 mmol). The reaction vial was flushed with
Ar, sealed with a cap and then further flushed with Ar. Anhydrous CH2CI2 (7 ml_) was added
followed by ethyl 3-chloro-3-oxopropanoate (0.37 ml_, 2.9 mmol) and triethylamine (0.53 ml_,
3.8 mmol). The reaction mixture was heated at 60°C in a heating block for 2 h . Additional
ethyl 3-chloro-3-oxo-propanoate (0.37 ml_, 2.9 mmol) and triethylamine (0.53 ml_, 3.8 mmol)
were added and the reaction mixture was stirred at 60°C for a further 1 h . The reaction
mixture was concentrated in vacuo. Water (20 ml_) was added, followed by 10% aq. HCI (10
ml_). The aqueous mixture was extrated with EtOAc (3 x 20 ml_). The organic extracts were
combined, washed with brine (10 ml_), dried (Na2S0 4) and concentrated in vacuo.
Purification by flash chromatography (10 g KP-sil; 0% to 10% MeOH in CH2CI2) afforded
ethyl 6-chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxylate (378
mg, 71%) as a pale yellow solid. 1H NMR (500 MHz, DMSO-cfe) δ 8.77 (d, J = 2.5 Hz, 1 H),
8.42 (d, J = 2.5 Hz, 1 H), 4.30 (q, J = 7.1 Hz, 2 H), 3.58 (s, 3 H), 1.29 (t, J = 7.1 Hz, 3 H);
LCMS (Method T2) RT 1.53 min; m/z 283.057 [M+H] +
Step 3: ethyl 4,6-dichloro-1-methyl-2-oxo-1,2-dihvdro-1,8-naphthyridine-3-carboxylate
[00359] Phosphorus oxychloride (4 ml_, 42.8 mmol) was added to a flask containing ethyl 6-
chloro-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1 ,8-naphthyridine-3-carboxylate (from step 2 ;
378 mg, 1.3 mmol). The flash was fitted with a reflux condenser with a suba-seal and an
argon ballon then heated to 80°C with stirring for 1 h . The reaction mixture was cooled to rt
and concentrated in vacuo. The crude reaction mixture was dissolved in EtOAc (20 ml_) and
washed with water (2 x 10 ml_) and saturated aq. NaHCOs (10 ml_). The aqueous washings
were combined and extracted with EtOAc (20 ml_). The organic extracts were combined,
washed with brine (10 ml_), dried (Na2S0 4) and concentrated in vacuo. Purification by flash
chromatography attempted (10 g KP-sil; 20-80% EtOAc in cyclohexane) afforded the title
compound (207 mg, 51%) as a yellow solid. 1H NMR (500 MHz, DMSO-cfe) δ 8.87 (d, J = 2.5
Hz, 1 H), 8.46 (d, J = 2.5 Hz, 1 H), 4.38 (q, J = 7.1 Hz, 2 H), 3.67 (s, 3 H), 1.31 (t, J = 7.1 Hz,
3 H); LCMS (Method T2) RT 1.48 min; m/z 302.020 [M+H] +
Intermediate G 1: (S)-(4,5-dichloropyridin-2-yl)(2-(methoxymethyl)pyrrolidin-1 -yl)-
methanone
[00360] A mixture of HATU (155 mg, 0.41 mmol), 4,5-dichloropicolinic acid (39 mg, 0.20
mmol) and (S)-2-(methoxymethyl)pyrrolidine ( 1 17 mg, 1.02 mmol) was stirred at 25°C for
16h. The crude reaction mixture was directly purified by preparative HPLC (15 min gradient
of 60:40 to 0:100 O eOH (both modified with 0.1 % formic acid); flow rate 20 mLmin 1)
affording the title compound (39 g, 66%) as a colourless oil that existed as a mixture of
rotamers. Rotamer . 1H NMR (500 MHz, Methanol-d ) δ 8.71 (s, 1 H), 7.96 (s, 1 H), 4.44-
4.38 (m, 1 H), 3.82-3.75 (m, 1 H), 3.68-3.64 (m, 2 H), 3.40 (s, 3 H), 2.14-1 .96 (m, 5 H).
Rotamer B: 1H NMR (500 MHz, Methanol-d 4) δ 8.69 (s, 1 H), 7.95 (s, 1 H), 4.85-4.78 (m, 1
H), 3.75-3.69 (m, 1 H), 3.63-3.58 (m, 2 H), 3.17 (s, 3 H), 2.14-1 .96 (m, 4 H), 1.94-1 .80 (m,
1 H). LCMS (Method T2) Rt = 1.39 min; m/z 289.1 [M+H]+.
Intermediate H1: 5-chloro-4-iodo-2-((tetrahydro-2H-pyran-4-yl)oxy)pyridine
[00361] Sodium hydride (60% in mineral oil; 103 mg, 2.56 mmol) was added to a
suspension of tetrahydro-2/-/-pyran-4-ol (262 mg, 2.56 mmol) in THF (10 ml_) at 0 °C. The
reaction mixture was stirred at 0 °C for 10 min, then rt for 15 min, after which 5-chloro-2-
fluoro-4-iodopyridine (550.0 mg, 2.137 mmol) was added. The resulting solution was stirred
at rt for 16 h . The crude reaction mixture was concentrated in vacuo and a portion of this
was purified by preparative HPLC (15 min gradient of 60:40 to 0:100 H20:MeOH (both
modified with 0.1 % formic acid); flow rate 20 mLmin 1) affording the title compound (63 mg)
as a white crystalline solid. 1H NMR (500 MHz, Methanol-d ) δ 8.13 (s, 1 H), 7.39 (s, 1 H),
5.18 (tt, J = 8.5, 4.0 Hz, 1 H), 3.95 (dt, J = 11.8, 4.6 Hz, 2 H), 3.60 (ddd, J = 11.8, 9.0, 3.0
Hz, 2 H), 2.22-1.97 (m, 2 H), 1.74 (dtd, J = 13.0, 8.5, 4.0 Hz, 2 H). LCMS (Method T2) RT
1.60 min; m/z 340.0 [M+H]+.
Intermediate 11 : (2S,6/?)-2,6-dimethyl-4-(4,5,6-trichloropyrimidin-2-yl)morpholine
Step 1: (2S, 6R)-4-(5-chloro-4, 6-dimethoxypyrimidin-2-yl)-2, 6-dimethylmorpholine
[00362] A mixture of 2-chloro-4,6-dimethoxypyrimidine ( 1 .05 g , 6.0 mmol), (2S,6R)-2,6-
dimethylmorpholine (0.78 mL, 6.3 mmol) and triethylamine (0.84 mL, 6.0 mmol) in NMP
(12.0 mL) was sealed in a vial then heated at 140°C under microwave irradiation for 2 h . The
reaction mixture was cooled to rt, and /V-chlorosuccinimide ( 1 .60 g , 12.0 mmol) was added
and the mixture was stirred at 60°C overnight. The mixture was poured into water forming a
brown precipitate which was collected under vacuum filtration. The aqueous filtrate was
extracted with EtOAc and combined with the solid obtained earlier. The mixture was loaded
onto silica and purified by flash chromatograph (50 g KP-sil; 10-30% EtOAc in cyclohexane)
afforded (2S,6R)-4-(5-chloro-4,6-dimethoxypyrimidin-2-yl)-2,6-dimethylmorpholine (916 g,
53%) as a white solid. 1H NMR (500 MHz, CDCh) δ 4.47-4.43 (m, 2 H), 3.95 (s, 6 H), 3.62
(dqd, J = 10.6, 6.2, 2.5 Hz, 2 H), 2.55 (dd, J = 13.3, 10.6 Hz, 2 H), 1.25 (d, J = 6.2 Hz, 6 H);
LCMS (Method T2) RT 1.62 min; m/z 288.32 [M+H]+.
Step 2: 5-chloro-2-((2S, 6R)-2, 6-dimethylmorpholino) pyrimidine-4, 6-diol
[00363] A mixture of (2S,6R)-4-(5-chloro-4,6-dimethoxypyrimidin-2-yl)-2, 6-dimethyl-
morpholine (from step 1; 624 mg, 2.2 mmol) and HCI (32% aq. solution; 10.0 ml_, 2.2 mmol)
was stirred at 60°C overnight. The suspension was diluted with water and filtered. A
precipitate formed in the filtrate, so was passed though the filter pad once more affording 5-
chloro-2-((2S,6R)-2,6-dimethylmorpholino)pyrimidine-4, 6-diol (475 mg, 84%) as a white
solid. LCMS (Method T2) RT 0.76 min; m/z 260.0848 [M+H]+.
Step 3: (2S, 6R)-2, 6-dimethyl-4-(4, 5,6-trichloropyrimidin-2-yl) morpholine
[00364] Phosphorus oxychloride (2.0 mL, 2 1 .4 mmol) was added to 5-chloro-2-((2S,6R)-2,6-
dimethylmorpholino)pyrimidine-4, 6-diol (from step 2 ; 200 mg, 0.77 mmol). The vial was
sealed and heated to 90°C for 2 h . The excess POC was removed in vacuo until a solid
had crashed out. Water was added, forming a white precipitate which was collected under
vacuum filtration, washed with water and dried affording the title compound (126 mg, 55%)
as a white solid. 1H NMR (500 MHz, CDCh) δ 4.47^1.40 (m, 2 H), 3.64-3.56 (m, 2 H), 2.62
(dd, J = 13.3, 10.7 Hz, 2 H), 1.25 (d, J = 6.2 Hz, 6 H); LCMS (Method T2) RT 1.72 min; m/z
296.01 [M+H]+.
Intermediate J 1 : (1/?,5S,7s)-9-(5-chloro-4-(methylsulfinyl)pyrimidin-2-yl)-3-oxa-9-azabi-
cyclo[3.3.1]nonan-7-ol
Step 1: 2,5-dichloro-4-(methylthio)pyrimidine
[00365] 2,4,5-trichloropyrimidine (3.27 mL, 28.54 mmol) was dissolved in THF (29
mL) and water (29 mL) and chilled to 0 °C. To this mixture was added sodium thiomethoxide
(2.00 g , 28.54 mmol) and the reaction mixture was allowed to warm to room temperature
and stirred for 4 h . EtOAc (50 mL) and water (50 mL) were added and the layers separated.
The aqueous layer was extracted with a further 50 mL of EtOAc and the organic layers were
combined, dried, and concentrated to afford a clear oil which rapidly crystallised to give 2,5-
dichloro-4-methylsulfanyl-pyrimidine (5.5 g , 99%) as a white solid. LCMS (Method X2); RT
1.35 min; m/z 194.9542 [M+H] +
Step 2: (1R,5S, 7s)-9-(5-chloro-4-(methylthio)pyrimidin-2-yl)-3-oxa-9-azabicvclo!3.3. Ilnonan-
7-ol
[00366] A n oven-dried microwave vial (2. 0-5.0 ml_ volume) was charged with 2,5-dichloro-
4-(methylthio)pyrimidine (from step 1; 234 mg, 1.20 mmol), endo-7-hydroxy-3-oxa-9-
azabicyclo[3.3.1]nonane hydrochloride (238 mg, 1.32 mmol) and DIPEA (0.84 ml_, 4.82
mmol). Isopropanol (3.4 ml_) was added, the reaction vial was sealed with a cap and the
reaction mixture was heated at 120°C in a heating block for 24 h . The reaction mixture was
cooled to rt and concentrated in vacuo. Purification by flash chromatography (10 g KP-sil;
0% to 70% EtOAc in cyclohexane) afforded (1R,5S,7s)-9-(5-chloro-4-(methylthio)pyrimidin-
2-yl)-3-oxa-9-azabicyclo[3.3.1]nonan-7-ol (221 mg, 61%) as a colourless oil which solidified
to an off-white solid when stored at 4 °C. 1H NMR (500 MHz, CDCh) δ 7.97 (s, 1 H), 5.63 (d,
J = 12.6 Hz, 1 H), 4.80-4.65 (m, 2 H), 4.00-3.92 (m, 3 H), 3.87-3.82 (m, 2 H), 2.48 (s, 3 H),
2.26-2.15 (m, 2 H), 1.89 (d, J = 15.0 Hz, 2 H); LCMS (2 min); RT 1.49 min; m/z 284.0726 [M-
H20+H] +
Step 3: (1R.5S, 7s)-9-(5-chloro-4-(methylsulfinyl)pyrimidin-2-yl)-3-oxa-9-azabicyclo-[3.3. 11-
nonan-7-ol
[00367] (1R,5S,7s)-9-(5-Chloro-4-(methylthio)pyrimidin-2-yl)-3-oxa-9-azabicyclo[3.3.1]-
nonan-7-ol (from step 2 ; 68 mg, 0.22 mmol) was dissolved in CH2CI2 ( 1 . 1 mL) and MeCN
( 1 . 1 mL). 3-Chloroperoxybenzoic acid (53 mg, 0.24 mmol) was added and the reaction
mixture was stirred for 1 h at room temperature. CH2CI2 (20 mL) was added and the reaction
mixture was extracted with saturated aq. NaHCC>3 (20 mL). The aqueous layer was
extracted with CH2CI2 (20 mL) and the organics combined, washed with brine, dried (MgSCL)
and concentrated in vacuo. Purification by flash chromatography (10 g KP-sil; 0% to 10%
MeOH in CH2CI2) afforded the title compound (48 mg, 67%) as a white solid. LCMS (Method
X2); RT 0.98 min; m/z 300.0593 [M-H20+H] +.
[00368] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate J 1 . The amine used in step 2 is shown in the table.
For Intermediate J2 and Intermediate J3: during step 3 , 2.5 equiv of 3-
chloroperoxybenzoic acid (mCPBA) was used to fully oxidise the sulfide to the sulfone.
Intermediate K1a and Intermediate K1b represent a pair of enantiomers where one is the
(R)- and the other is the (S)-(piperidin-3-yl)methanol. It has not been determined which is the
(R)- and which is the (S)-enantiomer. The compounds were separated by preparative chiral
SFC during Step 3 using the method described below.
Intermediate K1a and Intermediate K1b: (S)-(1-(5-chloro-4-(methylthio)pyrimidin-2-yl)-
4,4-difluoropiperidin-3-yl)methanol and (R)-(1-(5-chloro-4-(methylthio)pyrimidin-2-yl)-
4,4-difluoropiperidin-3-yl)methanol
Step 1 is analogous to that used for the preparation of Intermediate J 1 .
Step 2: rac-( 1-(5-chloro-4-(methylsulfonyl)pyrimidin-2-yl)-4,4-difluoropiperidin-3-yl)methanol
[00369] A mixture of rac-(1-benzyl-4,4-difluoropiperidin-3-yl)methanol (400 mg, 1.66 mmol)
and palladium hydroxide (10 mg, 0.08 mmol) in EtOH (3.3 ml_) was stirred at rt under a
balloon of H2 gas for 16 h . (Note: LCMS and NMR analysis showed approx.. 3:1 ratio of
product:starting material). The reaction mixture was concentrated in vacuo affording 287 mg
of material. A microwave vial (2. 0-5.0 ml_ volume) was charged with this crude mixture, 2,5-
dichloro-4-methylsulfanyl-pyrimidine (217 mg, 1.1 1 mmol), and DIPEA (0.58 ml_, 3.34 mmol).
Isopropanol (3.4 ml_) was added, the reaction vial was sealed with a cap and the reaction
mixture was heated at 120°C for 4 h . The reaction mixture was concentrated in vacuo and
the crude product was loaded onto silica, and purified by normal-phase chromatography
(Biotage 25 g KP-sil; 0% to 50% EtOAc in cyclohexane) to affording rac-(1-(5-chloro-4-
(methylsulfonyl)pyrimidin-2-yl)-4,4-difluoropiperidin-3-yl)methanol (316 mg, 78%) as a clear
oil, which slowly crystallised on standing. LCMS (Method T2); RT 1.54 min; m/z 310.0594
[M+H] +.
Step 3: (S)-(1-(5-chloro-4-(methylsulfonyl)pyrimidin-2-yl)-4,4-difluoropiperidin-3-yl) methanol
and (R)-(1-(5-chloro-4-(methylsulfonyl)pyrimidin-2-yl)-4,4-difluoropiperidin-3-yl)methanol
[00370] rac-(1-(5-Chloro-4-(methylsulfonyl)pyrimidin-2-yl)-4,4-difluoropiperidin-3-yl)methanol
(from Step 2 ; 256 mg) was dissolved to 25 mg/mL in 1:1 isopropanokCFhCL and was then
purified by SFC (Lux C4 (21 .2 mm x 250 mm, 5 µηι) , 10:90 isopropanol:CC>2; flow rate 50
mLmin 1) . The earlier eluting enantiomer was identified as Intermediate K1a and the later
eluting enantiomer was identified as Intermediate K1b. Combined fractions of each were
then concentrated in vacuo before being stored in a vacuum oven at 35°C and 5mbar
affording Intermediate K1a (101 mg) and Intermediate K1b (105 mg) as colourless gums.
[00371] Chiral purity analysis was determied by SFC (Lux C4 (4.6 mm x 250 mm, 5 µηι) ,
15:85 isopropanol:CC>2; flow rate 4 mLmin 1) . Intermediate K1a: ee = 98.4 % ; RT 2.17 min.
Intermediate K1b: ee = 98.4 % ; RT 2.52 min.
Intermediate K2a: (S)-(1 -(5-chloro-4-(methylsulfonyl)pyrimidin-2-yl)-4,4-
difluoropiperidin-3-yl)methanol or (R)-(1-(5-chloro-4-(methylsulfonyl)pyrimidin-2-yl)-
4,4-difluoropiperidin-3-yl)methanol
[00372] To a solution (S)-(1-(5-chloro-4-(methylthio)pyrimidin-2-yl)-4,4-difluoropiperidin-3-
yl)methanol or (R)-(1-(5-chloro-4-(methylthio)pyrimidin-2-yl)-4,4-difluoropiperidin-3-yl)-
methanol (Intermediate K1a; 50 mg, 0.16 mmol) in CH2CI2 (0.85 ml_) and MeCN (0.85 mL)
at 0 °C was added 3-chloroperoxybenzoic acid (73 mg, 0.33 mmol) portion-wise. The
reaction mixture was then warmed to room temperature and stirred for 16 h . The reaction
mixture was diluted with CH2CI2 (20 mL) and the reaction mixture was washed with sat. aq.
sodium thiosulfate and sat. aq. NaHCC>3 (20 mL). The organic layer was separated, dried
(MgSCL) and concentrated in vacuo. To a solution (S)-(1-(5-chloro-4-(methylthio)pyrimidin-2-
yl)-4,4-difluoropiperidin-3-yl)methanol or (R)-(1-(5-chloro-4-(methylthio)pyrimidin-2-yl)-4,4-
difluoropiperidin-3-yl)methanol (Intermediate K1a; 50 mg, 0.16 mmol) in CH2CI2 (0.85 ml_)
and MeCN (0.85 ml_) at 0 °C was added 3-chloroperoxybenzoic acid (73 mg, 0.33 mmol)
portion-wise. The reaction mixture was then warmed to room temperature and stirred for 16
h . The reaction mixture was diluted with CH2CI2 (20 ml_) and the reaction mixture was
washed with sat. aq. sodium thiosulfate and sat. aq. NaHCC>3 (20 ml_). The organic layer
was separated, dried (MgSCU) and concentrated in vacuo. The residue was purified by
normal phase chromatography (Biotage 10 g KP-Sil; 0% to 5% MeOH in CH2CI2) affording
the title compound (40 mg, 73%) as an off-white solid. 1H NMR (600 MHz, CDC ) δ 8.48 (s,
1 H), 4.37-4.25 (m, 1 H), 4.22-4.10 (m, 1 H), 3.98 (dd, J = 11.4, 4.5 Hz, 1 H), 3.86-3.79 (m,
1 H), 3.79-3.72 (m, 1 H), 3.60 (dd, J = 11.4, 8.8 Hz, 1 H), 3.33 (s, 3 H), 2.34-2.23 (m, 1 H),
2.14-2.04 (m, 1 H), 2.06-1 .90 (m, 1 H); OH not observed; LCMS (Method T2); RT 1.20 min;
m/z 342.04 [M+H] +.
[00373] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate K2a, starting from the aryl sulfide shown in the
table.
[00374] Intermediate L1a and Intermediate L1b represent a pair of enantiomers where
one is the (R)- and the other is the (S)-methyl-piperidine. It has not been determined which is
the (R)- and which is the (S)-enantiomer. The compounds were separated by preparative
chiral SFC during Step 3 using the method described below.
Intermediate L1a and Intermediate L1b: (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-
1-yl)pyrimidin-4-ol and (/?)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1 -yl)pyrimidin-4-
ol
Step 1: 2,5-dichloropyrimidin-4-ol
[00375] 2 M sodium hydroxide (6 ml_, 12 mmol) was added to a stirred solution of 2,4,5-
trichloropyrimidine ( 1 .29 g , 7.0 mmol) in THF (4 ml_). The reaction mixture was stirred at rt
for 24 h . The reaction mixture was concentrated in vacuo and the aqueous mixture was
neutralised with 3 M HCI. The aqueous mixture was extracted with Et20 (2 x 10 ml_) followed
by EtOAc (2 x 10 ml_). The organic extracts were combined, washed with brine (10 ml_),
dried (Na 2SC>4) and concentrated in vacuo affording 2,5-dichloropyrimidin-4-ol (923 mg,
80%) as a yellow solid which was used without further purification. 1H NMR (500 MHz,
DMSO-cfe) δ 8.26 (s, 1 H); LCMS (Method T2) RT 0.19 min; m/z 164.9602 [M+H] +
Step 2: rac-5-chioro-2-(4,4-difluoro-3-methylpiperidin- 1-yl)pyrimidin-4-ol
[00376] A microwave vial (10-20 ml_ volume) was charged with 2,5-dichloropyrimidin-4-ol
(from step 1 ; 502 mg, 3.0 mmol) and rac-4,4-difluoro-3-methylpiperidine hydrochloride (522
mg, 3.0 mmol). The reaction vial was flushed with Ar, sealed with a cap and then further
flushed with Ar. Ethanol (5 ml_) was added followed by DIPEA ( 1 .4 ml_, 8.0 mmol). The
reaction mixture was heated at 80°C in a heating block for 10 h . The reaction mixture was
concentrated in vacuo. The residue was dissolved in DMSO ( 1 ml_) and directly purified by
reverse-phase chromatography (Biotage reverse-phase 12 g C-18 column; 25-80% MeOH in
H20 (containing 0.1% formic acid)) affording rac-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-
yl)pyrimidin-4-ol (264 mg, 33%) as an off-white solid. 1H NMR (600 MHz, CDCh) δ 12.18 (br
s , 1 H), 7.89 (s, 1 H), 4.49^1.41 (m, 1 H), 4.34^1.27 (m, 1 H), 3.37-3.30 (m, 1 H), 3.08 (dd, J
= 13.8, 10.9 Hz, 1 H), 2.26-2.17 (m, 1 H), 2.17-2.08 (m, 1 H), 2.02-1 .89 (m, 1 H), 1.16 (d, J
= 6.8 Hz, 3 H); LCMS (Method T2) RT 1.21 min; m/z 264.0675 [M+H] +
Step 3: (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-ol and (R)-5-chioro-2-
(4, 4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-ol
[00377] rac-5-Chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-ol (250 mg) was
dissolved to 25 mg/mL in MeOH:CH 2C I2 (4:1) (1% v/v N H 3) and was then purified by SFC
(Amy-C (20 m m x 250 mm, 5 µ η ) , 10:90 MeOH:C0 2 (0.2% v/v N H 3) ; flow rate 50 mLmin
1) . The earlier eluting enantiomer was identified as Intermediate L1a and the later eluting
enantiomer was identified as Intermediate L1b. Combined fractions of Intermediate L1a
were concentrated in vacuo before being stored in a vacuum oven at 35°C and 5mbar
affording Intermediate L1a (85 mg) as a white solid. Combined fractions of Intermediate
L1b were concentrated in vacuo and re-purified and isolated as above to afford
Intermediate L1b (68 mg) as a white solid.
[00378] Chiral purity analysis was determied by SFC (Amy-C (4.6 mm x 250 mm, 5 µηι) ,
10:90 MeOH:CC>2 (0.2% v/v NH3) ; flow rate 4 mLmin 1) . Intermediate L1a: ee = 99.2 % ; RT
3.58 min. Intermediate L1b: ee = 99.0 % ; RT 3.83 min.
Intermediate L2a: (S)-4,5-dichloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidine or
(/?)-4,5-dichloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidine
[00379] To a vial containing (S)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-ol
or (R)-5-chloro-2-(4,4-difluoro-3-methylpiperidin-1-yl)pyrimidin-4-ol (Intermediate L1a; 43
mg, 0.16 mmol) was added POCI3 (0.6 ml_, 6.4 mmol) and the vial was sealed and heated to
90°C for 3 h . The excess POCI3 was removed in vacuo, and the residue was partitioned
between water and EtOAc. The layers were separated and the organic layer was dried
(MgSCU), and concentrated in vacuo to give the title compound (41 mg, 89%) as a
colourless oil which was used without further purification. 1H NMR (500 MHz, CDCI3) δ 8.22
(s, 1 H), 4.56—4.50 (m, 1 H), 4.47^1.41 (m, 1 H), 3.40-3.33 (m, 1 H), 3.1 1-3.04 (m, 1 H),
2.21-2.1 1 (m, 1 H), 2.1 1-1 .98 (m, 1 H), 1.96-1 .82 (m, 1 H), 1.09 (d, J = 6.8 Hz, 3 H); LCMS
(Method T2); RT 1.71 min; m/z 282 [M+H] +.
[00380] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate L2a, starting from the aryl sulfide shown in the
table.
[00381] Intermediate M1a and Intermediate M1b represent a pair of enantiomers where
one is the (3R,5S)- and the other is the (3S,5F?)-piperidinol. It has not been determined
which is the (3R,5S)- and which is the (3S,5F?)-enantiomer. The compounds were separated
by preparative chiral using the method described below.
Intermediate M1a and Intermediate M1b: (3f?,5S)-1-benzyl-5-methylpiperidin-3-ol and
(3S,5/?)-1-benzyl-5-methylpiperidin-3-ol
[00382] The commercially available rac-1-benzyl-5-methylpiperidin-3-ol ( 1 g) was dissolved
to 50 mg/ml_ in MeOH and was then purified by SFC (Lux A 1 (21.2 mm x 250 mm, 5 pm),
15:85 MeOH:CC>2 (0.2% v/v DEA; flow rate 50 mimin 1) . The earlier eluting enantiomer was
identified as Intermediate M1a and the later eluting enantiomer was identified as
Intermediate M1b. Combined fractions of Intermediate M1a were concentrated in vacuo
before being stored in a vacuum oven at 35 °C and 5 mbar affording Intermediate M1a (369
mg) as a white solid. Combined fractions of Intermediate M1b were concentrated in vacuo
and re-purified and isolated as above to afford Intermediate M1b (315 mg) as a white solid.
[00383] Chiral purity analysis was determied by SFC (Amy-C (4.6 mm x 250 mm, 5 pm),
15:85 MeOH:CC>2 (0.2% v/v DEA); flow rate 4 mLmin 1) . Intermediate M1a: ee = 98.4 % ; RT
1.47 min. Intermediate M1b: ee = 99.4 % ; RT 1.84 min.
Intermediate M2a: (3/?,5S)-5-methylpiperidin-3-ol or (3S,5/?)-5-methylpiperidin-3-ol
[00384] A flask containing (3R,5S)-1-benzyl-5-methylpiperidin-3-ol or (3S,5R)-1-benzyl-5-
methylpiperidin-3-ol (Intermediate M1a; 200 mg, 0.97 mmol) in ethanol (10 ml_) was
degassed with argon for 5 min. Pd/C (10 wt%; 104 mg) was added and the suspension was
degassed with argon for a further 10 min. The flask was evacuated and back-filled with
hydrogen twice before being stirred at room temperature under a hydrogen balloon for 2 h .
The reaction was filtered through celite (eluent methanol) and the filtrate was concentrated in
vacuo to give the title compound ( 1 10 mg, 98%) as a white solid which was used without
further purification. 1H NMR (500 MHz, methanol-d ) δ 3.59-3.51 (m, 1 H), 3.1 1-3.04 (m, 1
H), 2.90-2.81 (m, 1 H), 2.20 (dd, J = 11.8, 10.4 Hz, 1 H), 2.07-1.98 (m, 2 H), 1.67-1 .54 (m,
1 H), 1.01-0.86 (m, 4 H).
[00385] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate M2a, starting from the amine shown in the table.
[00386] Intermediate N1a and Intermediate N1b represent a pair of enantiomers where
one is the (S)- and the other is the (R)-(piperidin-3-yl)methanol. It has not been determined
which is the (S)- and which is the (R)-enantiomer. The compounds were separated by
preparative chiral using the method described below.
Intermediate N1a and Intermediate N1b: (f?)-(1 -benzyl-4, 4-difluoropiperidin-3-
yl)methanol and (S)-(1 -benzyl-4, 4-difluoropiperidin-3-yl)methanol
[00387] The commercially available rac-(1 -benzyl-4, 4-difluoropiperidin-3-yl)methanol (254
mg) was dissolved to 50 mg/ml_ in isopropanol and was then purified by SFC (Lux iC5 (21.2
mm x 250 mm, 5 pm), 10:90 isopropanol:CC>2 (0.2% v/v NH3; flow rate 2 1 mimin 1) . The
earlier eluting enantiomer was identified as Intermediate N1a and the later eluting
enantiomer was identified as Intermediate N1b. Combined fractions of each were then
concentrated in vacuo before being stored in a vacuum oven at 35 °C and 5 mbar affording
Intermediate N1a (102 mg) and Intermediate N1b (100 mg) as clear gums.
[00388] Chiral purity analysis was determied by SFC (Lux iC5 (4.6 mm x 250 mm, 5 pm),
10:90 isopropanol:CC>2 (0.2% v/v DEA); flow rate 4 mLmin 1) . Intermediate N1a: ee = 96.6
% ; RT 1.70 min. Intermediate N1b: ee = 97.8 % ; RT 1.91 min.
Intermediate N2a: (F?)-(4,4-difluoropiperidin-3-yl)methanol or (S)-(4,4-difluoropiperidin-
3-yl)methanol
[00389] A flask containing (R)-(1-benzyl-4,4-difluoropiperidin-3-yl)methanol or (S)-(1 -benzyl-
4 ,4-difluoropiperidin-3-yl)methanol (Intermediate N1a; 102 mg, 0.42 mmol) in ethanol (8.0
ml_) was degassed with argon for 2 min. Pd/C (10 wt%; 45 mg) was added and the
suspension was degassed with argon for a further 10 min. The flask was evacuated and
back-filled with hydrogen twice before being stirred at rt under a hydrogen balloon for 3 h .
The reaction was filtered through celite (eluent methanol) and the filtrate was further filtered
through cotton wool. The filtrate was concentrated in vacuo affording the title compound (64
mg, 100%) as a colourless oil which crystallised upon standing. 1H NMR (500 MHz,
methanol-d ) δ 3.92 (dd, J = 11.2, 4.0 Hz, 1 H), 3.51 (dd, J = 11.2, 8.6 Hz, 1 H), 3.27-3.21
(m, 1 H), 3.07-3.00 (m, 1 H), 2.82-2.74 (m, 1 H), 2.61 (t, J = 12.7, 10.3, 1.7 Hz, 1 H), 2.12-
1.96 (m, 2 H), 1.92-1 .78 (m, 1 H).
[00390] The following tabulated examples were prepared by a method analogous to that
used for the preparation of Intermediate N2a, starting from the amine shown in the table.
Intermediate 0 1: (3ft,4r,5S)-4-fluoro-3,5-dimethylpiperidine hydrochloride
Step 1: (3R,4r,5S)-1 -benzyl-3, 5-dimethylpiperidin-4-ol and (3R, 4s, 5S)-1-benzyl-3, 5-
dimethylpiperidin-4-ol
[00391] To a solution of (3ft,5S)-1-benzyl-3,5-dimethylpiperidin-4-one (100 mg, 0.46 mmol)
in methanol ( 1 .0 ml_) at 5°C was added sodium borohydride (21 mg, 0.55 mmol) in two
portions. The reaction was allowed to warm to room temperature and stirred for 16 h . The
reaction was concentrated in vacuo, and the residue was partitioned between water and
EtOAc. The organic layer was separated, dried (MgSCU), and concentrated in vacuo to give
a 1:1 mixture of (3ft,4r,5S)-1-benzyl-3,5-dimethylpiperidin-4-ol and (3ft, 4s,5S)-1 -benzyl-3, 5-
dimethylpiperidin-4-ol (98 mg, 97%) as a colourless oil. 1H NMR (500 MHz, CDCh) δ 7.36-
7.31 (m, 8 H), 7.30-7.25 (m, 2 H), 3.60-3.56 (m, 1 H), 3.52 (s, 2 H), 3.49 (s, 2 H), 2.87-2.79
(m, 2 H), 2.72-2.66 (m, 1 H), 2.56-2.49 (m, 2 H), 1.98 (t, J = 11.4 Hz, 2 H), 1.94-1 .83 (m, 2
H), 1.75-1.65 (m, 4 H), 0.97 (d, J = 6.1 Hz, 6 H), 0.94 (d, J = 6.8 Hz, 6 H); OH not observed.
Step 2: (3R, 4r,5S)- 1-benzyt-4-ftuoro-3, 5-dimethylpiperidine
[00392] To a solution of (3ft, 4r,5S)-1 -benzyl-3, 5-dimethylpiperidin-4-ol and (3ft,4s,5S)-1-
benzyl-3,5-dimethylpiperidin-4-ol (from step 1; 50 mg, 0.23 mmol) in CH2CI2 (2 ml_) at -78°C
was added DAST (60 uL, 0.46 mmol) and the reaction was allowed to warm to room
temperature and stirred for 16 h . To the reaction mixture was added sat. aq. NaHCCh and
the aqueous layer was extracted with CH2CI2. The combined organic layers were dried
(MgSCU), and concentrated in vacuo to give (3ft,4r,5S)-1-benzyl-4-fluoro-3,5-
dimethylpiperidine (47 mg, 88%) as a yellow oil. 1H NMR analysis indicated that a single
diastereoisomer was isolated. 1H NMR (500 MHz, CDCI3) δ 7.39-7.26 (m, 5 H), 3.64 (dt, J =
50.2, 9.9 Hz, 1 H), 3.51 (s, 2 H), 2.86 (dtd, J = 11.2, 4.5, 3.8, 2.0 Hz, 2 H), 2.04-1 .91 (m, 2
H), 1.74 (td, J = 11.7, 1.3 Hz, 2 H), 0.99 (d, J = 6.5 Hz, 6 H).
Step 3: (3R,4r,5S)-4-fiuoro-3, 5-dimethylpiperidine hydrochloride
[00393] A flask containing (3ft,4r,5S)-1-benzyl-4-fluoro-3,5-dimethylpiperidine (from step 2 ;
47 mg, 0.21 mmol) in ethanol (4 ml_) was degassed with argon for 5 min. Pd/C (10 wt%; 23
mg) was added and the suspension was degassed with argon for a further 10 min. The flask
was evacuated and back-filled with hydrogen twice before being stirred at room temperature
under a hydrogen balloon for 5 h . A further sample of Pd/C (10 wt%; 23 mg) was added and
the flask was evacuated and back-filled with hydrogen twice before being stirred at room
temperature under a hydrogen balloon for 16 h . The reaction was filtered through celite
(eluent methanol) and the filtrate was concentrated under 100 mbar pressure. A solution of 3
M HCI in 1,4-dioxane (0.6 ml_) was added to this residue and the solution was stirred for 10
min, before being concentrated under reduced pressure to give the title compound (31 mg,
87%) as a white solid. 1H NMR (500 MHz, methanol-d ) δ 3.98 (dtd, J = 48.8, 10.0, 1.6 Hz, 1
H), 3.42-3.30 (m, 2 H), 2.81 (t, J = 12.8 Hz, 2 H), 2.14-2.02 (m, 2 H), 1. 1 1 (d, J = 6.6 Hz, 6
H); LCMS (Method T4); RT 0.16 min; m/z 132 [M+H]+.
Intermediate P 1 : (1/?,5S,7s)-7-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-ol
Step 1: (1R,5S,7s)-9-benzyl-7-methyl-3-oxa-9-azabicyclo[3.3. 1lnonan-7-ol
[00394] Methylmagnesium bromide (3.0 M solution in Et < ; 0.72 ml_, 2.16 mmol) was added
dropwise to a solution of 9-benzyl-3-oxa-9-azabicyclo[3. 3.1 ]nonan-7-one (100 mg, 0.43
mmol) in THF (4.32 ml_) at rt. The solution was then stirred at 60 °C overnight. After this
time, the reaction mixture was cooled to rt and additional methylmagnesium bromide (3.0 M
solution in Et < ; 0.72 ml_, 2.16 mmol) and THF (5 ml_) was added. The reaction mixture was
stirred at 60 °C for a further 3 d . The mixture was quenched by the careful and slow addition
of water. The mixture was extracted with EtOAc and the organic extracts washed with brine
then dried (MgSCU) and concentrated in vacuo. The residue was purified by normal phase
chromatography (Biotage 10 g KP-Sil; 20% to 100% EtOAc in cyclohexane affording
(1R,5S,7s)-9-benzyl-7-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-ol (77 mg, 72%) as a brown
oil. 1H NMR (500 MHz, CDCh) δ 7.40-7.33 (m, 2 H), 7.36-7.28 (m, 2 H), 7.29-7.22 (m, 1 H),
6.21 (s, 1 H), 3.97-3.93 (m, 2 H), 3.81-3.77 (m, 2 H), 3.76 (s, 2 H), 2.75-2.69 (m, 2 H), 2.18
(dd, J = 14.7, 5.4 Hz, 2 H), 1.60 (d, J = 14.9 Hz, 2 H), 1.32 (d, J = 1.3 Hz, 3H). A single
diastereoisomer was observed. As such, it was assigned as methyl adding from exo face.
NOESY NMR shows cross peaks between methyl and adjacent CH2 protons (both the axial
and equitorial protons) thus implying that the methyl has added from the top face as this
result would not be possible with the methyl trans- to the axial CH2 protons.
Step 2: (1R,5SJs)-7-methyl-3-oxa-9-azabicyclof3.3. 1lnonan-7-ol
[00395] Pd/C (10 wt%) ( 25.00 mg, 0.0235 mmol) was added to a solution of (1R,5S,7s)-9-
benzyl-7-methyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-ol (from step 1 ; 6 1 mg, 0.23 mmol) in
ethanol (2.3 ml_) then placed under an atmosphere of hydrogen and stirred at 30°C
overnight. The mixture was filtered though a pad of Celite on an SCX-2 column and washed
with ethanol. The product was then eluted with 2 M methanolic ammonia. The solvent was
concentrated in vacuo affording the title compound (35 mg, 87%) as a pale brown solid. 1H
NMR (600 MHz, CDCh) δ 7.02 (br s , 1 H), 5.83 (s, 1 H), 4.18 (d, J = 12.4 Hz, 2H), 3.95 (d, J
= 12.4 Hz, 2 H), 3.44-3.39 (m, 2 H), 2.37 (dd, J = 15.2, 5.4 Hz, 2 H), 2.00 (d, J = 15.2 Hz, 2
H), 1.33 (s, 3 H).
Intermediate P2: rac-methyl-3,8-diazabicyclo[3.2.1]octan-2-one
[00396] A mixture of sodium hydride (60% dispersion in mineral oil; 33 mg, 0.82 mmol) and
rac-tert-butyl 2-oxo-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (124 mg, 0.55 mmol) was
stirred at 25 °C in DMF (6 ml_) for 15 min. lodomethane (0.20 ml_, 3.29 mmol) was then
added. The resulting solution was stirred at this temp for 16 h . Brine was added and the
solution was extracted with EtOAc. The combined organic layers were washed with brine
and water, dried (Na2S0 4) and concentrated in vacuo affording the Boc-protected
intermediate (78 mg) as a deep yellow solid. The solid was dissolved in CH2CI2 (8 ml_) and
TFA (0.60 ml_, 0.55 mmol) was added. The resulting solution was stirred at rt for 16 h . The
reacton mixture was concentrated in vacuo and the residue was purified by SCX-2 (2 g)
column affording the title compound (40 mg, 52%) as a colourless oil that was used without
further purification. 1H NMR (500 MHz, methanol-d ) δ 3.74 (ddt, J = 6.3, 3.3, 1.0 Hz, 1 H),
3.69-3.64 (m, 1 H), 3.52 (ddd, = 11.6, 4.3, 1.1 Hz, 1 H), 3.04 (dd, J = 11.6, 1.0 Hz, 1 H),
2.85 (s, 3 H), 2.13-1 .95 (m, 3 H), 1.86-1 .72 (m, 1 H).
Intermediate P3: (1/?,5S)-/V,/V-dimethyl-3-oxa-9-azabicyclo[3.3.1]nonane-7-carbox-
amide
[00397] Dimethylamine (2 M in THF; 0.8 ml_, 1.59 mmol) was added to a stirred solution of
(1R,5S)-9-(te/f-butoxycarbonyl)-3-oxa-9-azabicyclo[3.3.1]nonane-7-carboxylic acid {72 mg,
0.27 mmol) and HATU (121 mg, 0.32 mmol) in DMF (4 ml_). The resulting solution was
stirred at 25 °C for 16 h . Brine was added and the solution was extracted with EtOAc. The
combined organic layers were washed with brine and water, dried (Na2S0 4) and
concentrated in vacuo affording the Boc-protected intermediate (67 mg) as a yellow wax.
The crude product was then dissolved in CH2CI2 (8 ml_) and TFA (0.60 ml_, 0.67 mmol) was
added. The resulting solution was stirred at rt for 16 h . The reaction mixture was
concentrated in vacuo, and the residue was purified by a SCX-2 (2 g) column affording the
title compound (38 mg, 72% mmol) as a white solid which was used without further
purification. 1H NMR (600 MHz, methanol-d ) δ 4.16-4.08 (m, 1 H), 3.98-3.86 (m, 4 H), 3.16
(s, 3 H), 3.00-2.96 (m, 2 H), 2.95 (s, 3 H), 2.10-2.02 (m, 2 H), 1.93-1 .85 (m, 2 H).
Biological assays
HTRF assay
[00398] Each 15 L HTRF reaction in a 384-well black Proxiplate (Perkin Elmer) contained
1 nM Trx-6xHis-BCL6 (in house-produced, human BCL6 BTB domain covering amino-acid
sequence 5-129), 300 nM BCOR-AF633 peptide (RSEIISTAPSSWVVPGP-Cys-AlexaFluor
633-amide, Cambridge Research Biochemical) and 0.5 nM anti-6xHis-Terbium cryptate
(CisBio Bioassays, France), in assay buffer (25 mM Hepes pH8, 100 mM NaCI, 0.05%
Tween20, 0.5 mM TCEP, 0.05% bovine serum albumin). Test compounds in DMSO or
DMSO alone were added to the wells using an ECHO550 acoustic dispenser (Labcyte Inc)
to give the appropriate test concentration in 0.7% v/v DMSO final. After 2 hours incubation at
room temperature the plate was read on an Envision plate reader (Perkin Elmer) with 337
nm laser excitation, a first emission filter APC 665 nm and a second emission filter Europium
615 nm. The % inhibition at each concentration was calculated by normalising FRET ratio to
the appropriate high (DMSO with all reagents) and low (DMSO without BCL6) controls. The
compound IC50S were determined using GraphPad Prism 6.0 or Dotmatics (Bishops
Stortford, UK) software by fitting the normalised data to a sigmoidal four-parameter logistic fit
equation.
[00399] The results of this assay are shown in Table 1 above.
NanoBRET assay
[00400] A cellular nano-Bioluminescence Resonance Energy Transfer (nanoBRET) assay
(Promega NanoBRET Nano-Glo Detection System, catalogue number N1662) was used to
detect inhibition of the BCL6-NCOR2(SMRT) corepressor protein-protein interaction. DNA
encoding full length BCL6 and NCOR2 were inserted into pFC32K.NanoLuc and
pFC14K.HaloTag vectors (Promega) to produce C-terminal tagged fusion proteins BCL6-
nanoLuc and NCOR2-HaloTag, respectively. HEK293T cells (8 *10 5) were plated in each
well of a 6-well plate and co-transfected 24 hours later with Fugene 6 (Promega cat.#
E2691) reagent and 2.2 g total DNA plasmids encoding BCL6-nanoLuc as donor and
NCOR2-HaloTag as acceptor, at a donor: acceptor DNA ratio of 1:25. At 20 hr post
transfection, cells were collected, washed with PBS, and exchanged into media containing
phenol red-free OptiMEM+4% FBS (Life Technology). The cell density was adjusted to
5x1 05 cells/ml and 20 L plated in each well of the 384-well NUNC white assay plate
(ThermoScientific NUNC cat.#1 0080681), containing test compounds in DMSO or DMSO
alone to give 0-100 pM in 0.5% v/v DMSO final concentrations plus 0.5 pg/ml NanoBRET
618 fluorescence ligand. Cells were incubated for 6 hr at 37°C/5% CO2 then NanoBRET
furimazine substrate (Promega) was added to give a final concentration of 10 pM. After a
short centrifugation the plates were read on an Envision (Perkin Elmer) plate reader
equipped with a LUM/D600 Dual mirror, Lum 450/40 nm bandpass and D605 nm longpass
filters, with a 0.1 sec reading to determine the BRET ratio. The % inhibition at each test
concentration was calculated by normalising the BRET ratio to the appropriate high and low
controls. The compound IC50S were determined using Graphpad Prism 6.0 or Dotmatics
software by fitting the normalised data to a sigmoidal four-parameter logistic fit equation.
[00401] The results obtained using this assay are shown in Table 2 above.
Immunofluorescence-based BCL6 degradation assay
[00402] DC50 values (compound concentration at which 50% of endogenous BCL6 protein is
degraded) were determined in SUDHL-4 cells (American Type Culture Collection) in an
immunofluorescence-based assay using an lnCell2200 high content imaging system (GE
Healthcare). Briefly, 40 pL of lymphoma suspension cells cultured in RPMI 1640-10% FBS
(Sigma-Aldrich or PAN Biotech UK Ltd) were platted on fibronectin (Sigma catalogue F 1141)
-coated 384 well Cell Carrier Ultra plate (Perkin Elmer catalogue 6057300) at 1.2 104
cells/well. After 20 hours cell culture at 37°C/C02 incubator, compounds were dispensed in
the cell culture plate using ECHO550 acoustic dispenser (Labcyte, Inc.), as 8 point-
concentration response (ranging from 5 nM to 10 pM) in 0.67% final DMSO concentration.
Cells were incubated with compound for 2 hours at 37°C/C02 incubator followed by fixation
in 4.5% formaldehyde (37% formaldehyde solution, Sigma catalogue F8775) at room
temperature for 15 min. After fixing, cells were washed in 1xTBS (Tris Buffer Saline) using a
Power Washer 384 (Tecan Group Ltd). Blocking and cell permeabilisation were performed
by incubating the fixed cells for 1 hour at room temperature in 1xTBS, 5% BSA, 1% Triton
X100, followed by three washes on PW384 plate washer. Primary and secondary antibodies
were prepared in 1xTBS, 1% BSA, 0.2% Triton X100. BCL6 expression was detected by
incubating the cells for 1h30 with BCL6 rabbit polyclonal antibody (Sigma Catalogue
HPA004899) at 1:250, 0.8pg/ml, followed by 1 hour in chicken anti-Rabbit Alexa 488
conjugated antibody (Life Technology) at 1:500. After incubation in each antibody, cells were
washes four times in 1xTBS-0.05% tween on PW384 plate washer. Cells were finally
incubated for 60 min with nuclear staining RedDot2 dye (Biotium) at 0.5x the stock
concentration in 1xTBS. BCL6 expression in the absence or presence of compound was
detected on lnCell2200 with 20x objective and quantified on InCell Analyser 3.7.2
workstation (GE Healthcare). The % response at each concentration was calculated by
normalising BCL6 expression in the presence of compound to the appropriate high (DMSO)
and low (DMSO with 7 µΜ of a control compound (5-((5-chloro-2-((3R,5S)-4,4-difluoro-3,5-
dimethylpiperidin-1-yl)pyrimidin-4-yl)amino)-3-(3-hydroxy-3-methylbutyl)-1 -methyl-1, 3-
dihydro-2H-benzo[d]imidazol-2-one)) controls. The compound DCso values were determined
using GraphPad Prism 6.0 or Dotmatics (Bishops Stortford, UK) software by fitting the
normalised data to a sigmoidal four-parameter logistic fit equation.
[00403] The results obtained using this assay are shown in Table 3 above.
[00404] While specific embodiments of the invention have been described herein for the
purpose of reference and illustration, various modifications will be apparent to a person
skilled in the art without departing from the scope of the invention as defined by the
appended claims.
CLAIMS




Xi is selected from N or CRa
,
wherein Ra is selected from hydrogen, (1-2C)alkyl,
halogen, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, cyano or NR Rc,
wherein R and Rc are each independently selected from hydrogen or (1-
2C)alkyl;
X 2 IS selected from N , CH, CF, CCI or C-CH 3;
R1 is selected from hydrogen or a group of the formula:
-L-Y-Z
wherein:
L is absent or (1-3C)alkylene;
Y is absent or O, C(O), C(0)0 or C(0)N(R e) , wherein Re is selected
from hydrogen or (1-4C)alkyl; and
Z is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5
or 6 membered heteroaryl or 4 to 7 membered heterocyclyl; wherein Z
is optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or (1-4C)alkyl;
R2 is selected from a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N , CH or CF;
X b is selected from N or CRx 1 , wherein Rx 1 is selected from hydrogen,
fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, acetylenyl,
CH2F, CF2H or CF3;
R6 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl, (1-
2C)alkoxy, cyano, acetylenyl, CH2F, CF2H or C F3 ;
R7 is selected from hydrogen, halo, (1-4C)alkyl, (1-4C)alkoxy, (1-
4C)haloalkyl, (1-4C)haloalkoxy, cyano, nitro, (2-4C)alkenyl, (2-
4C)alkynyl or a group of the formula:
-Y3-Z3
wherein:
Y 3 is absent or O, S, SO, SO2, N(Rj)(CR jRk)qi (where qi is 0 , 1
or 2), C(O), C(0)0, OC(O), C(0)N(R ) , N(R )C(0),
N(Rj)C(0)N(R k) , N(R )C(0)0, 0C(0)N(Ri), S(0) 2N(R ) or
N(Rj)S0 2, wherein Rj and Rk are each independently selected
from hydrogen or (1-4C)alkyl; and
Z 3 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (2-
4C)alkenyl, (2-4C)alkynyl, (3-6C)cycloalkenyl, heteroaryl or 4
to 12-membered heterocyclyl; wherein Z 3 is optionally further
substituted by one or more substituent groups independently
selected from (1-4C)alkyl, (3-6C)cycloalkyl, halo, oxo, (1-
4C)haloalkyl, (1-4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano,
C0 2H , SO2NH2, C(0)NR'R m, NR'Rm, OR' or SR' wherein R' and
Rm are each independently selected from hydrogen, (1-
4C)alkyl or (3-6C)cycloalkyl; or Z3 is optionally further
substituted by a group of the formula:
-Lz-Wz
wherein:
Lz is a (1-5C)alkylene optionally substituted by one or more
substituents selected from (1-2C)alkyl or oxo; and
W z is halo, (1-4C)haloalkyl, (1-4C)haloalkoxy, cyano, hydroxy,
(1-4C)alkoxy, C R 3, COOR , C O NR R * or NR^R 3* ,
wherein R*3 and R * are each independently selected from
hydrogen or (1-4C)alkyl;
R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl, (1-4C)haloalkyl or cyano,
wherein each (1-4C)alkyl and/or (3-6C)cycloalkyl substituent is optionally
further substituted by one or more substituents selected from (1-4C)alkyl, (3-
6C)cycloalkyl, hydroxy, (1-2C)alkoxy, NR RV, (1-2C)aminoalkyl or halo, wherein
R and Rv are independently selected from hydrogen or (1-2C)alkyl;




Y 5 is absent or selected from C(0)0 or C(0)N(R w) , wherein Rw is
selected from hydrogen or (1-2C)alkyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is hydrogen, (1-6C)alkyl, aryl, (3-6C)cycloalkyl, 5 or 6 membered
heteroaryl or 4 to 6-membered heterocyclyl; wherein Z 5 is optionally
substituted by one or more substituents selected from (1-2C)alkyl,
halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano,
nitro or hydroxy; or
R30 and R3 1 are linked such that, together with the carbon atom to which they
are attached, they form a 4-6 membered carbocyclic ring or a heterocyclic ring;
and
Ring A is a 6- or 7-membered heterocyclic ring, which, in addition to the
substituent groups R30 and R3 1 , is optionally further substituted by one or more
substituent groups selected from oxo, (1-2C)alkyl, cyclopropyl, spiro-
cyclopropyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano
or hydroxy.
2 . A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
claim 1, wherein X 2 is CH.
3 . A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
claims 1 or 2 , wherein X 1 is selected from N or CH.
4 . A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 3 , wherein X 1 is CH.
5 . A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 4 , wherein R2 is a group of Formula A shown below:
Formula A
wherein:
denotes the point of attachment;
Xa is selected from N , CH or CF;
X b is selected from N or CRx 1
,
wherein Rx 1 is selected from hydrogen,
fluoro, chloro, bromo, (1-2C)alkyl, (1-2C)alkoxy, cyano, acetylenyl,
CH2F, CF2H or CF3;
R6 is selected from hydrogen, fluoro, chloro, bromo, (1-2C)alkyl,
cyano, acetylenyl, CH2F, CF2H or CF3;
R7 is selected from hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-
2C)haloalkyl, (1-2C)haloalkoxy, cyano or a group of the formula:
-Y3-Z3
wherein:
Y3 is absent or O, C(O), C(0)0, OC(O), C(0)N(Ri) or N(R )C(0),
wherein Rj is selected from hydrogen or (1-4C)alkyl; and
Z3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-membered
heteroaryl or 4 to 12-membered heterocyclyl; wherein Z3 is optionally
further substituted by one or more substituent groups independently
selected from (1-4C)alkyl, halo, oxo, (1-4C)haloalkyl, (1-
4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or OR',
wherein R' and Rm are each independently selected from hydrogen,
(1-4C)alkyl or (3-6C)cycloalkyl.
6 . A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 5 , wherein the compound has the structural formula lc shown
below:
Formula lc
wherein each of R1, R6, R7, Xa, X b, R30, R3 1 and Ring A are as defined in claim 1 .
7 . A compound according to claim 6 , wherein X b is selected from CH, CCI, CF, CBr or
CCHs.
8 . A compound according to claim 6 or 7 , wherein R6 is selected from chloro, fluoro,
bromo, methyl or cyano.
9 . A compound according to any one of claims 6 to 8 , wherein R7 is selected from
hydrogen, halo, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, cyano
or a group of the formula:
-Y3-Z3
wherein:
Y3 is absent or O, C(O), C(0)0 or C(0)N(R j) , wherein Rj is selected
from hydrogen or (1-4C)alkyl; and
Z3 is hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, 5- or 6-membered
heteroaryl or 4 to 11-membered heterocyclyl; wherein Z3 is optionally
further substituted by one or more substituent groups independently
selected from (1-4C)alkyl, halo, oxo, (1-4C)haloalkyl, (1-
4C)haloalkoxy, (1-4C)alkoxyalkyl, cyano, C(0)NR'R m, NR'Rm or OR',
wherein R' and Rm are each independently selected from hydrogen,
(1-4C)alkyl or (3-6C)cycloalkyl.
10. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to




L is absent or (1-3C)alkylene; and
Z is (1-6C)alkyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, 5 or 6
membered heteroaryl or 5 or 6 membered heterocyclyl; wherein Z is
optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or (1-2C)alkyl.
11
.
A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 10, wherein R1 is selected from hydrogen, (1-6C)alkyl or a
group of the formula:
-L-Z
wherein:
L is (1-2C)alkylene; and
Z is (3-6C)cycloalkyl or 4 to 7 membered heterocyclyl; wherein Z is
optionally further substituted by one or more substituent groups
independently selected from oxo, (1-2C)alkyl, halo, (1-2C)haloalkyl,
(1-2C)haloalkoxy, (1-2C)aminoalkyl, cyano, NR Rh or OR9; wherein R9
and Rh are each independently selected from hydrogen or methyl.
12. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 11 , wherein R30 is selected from (1-4C)alkyl, (3-6C)cycloalkyl,
(1-4C)haloalkyl, or cyano, wherein each (1-4C)alkyl and/or (3-6C)cycloalkyl
substituent is optionally further substituted by one or more substituents selected from
(1-4C)alkyl, cyclopropyl, hydroxy, (1-2C)alkoxy or halo.
13. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 12, wherein R3 1 is selected from hydrogen, (1-4C)alkyl, cyano,
(1-4C)haloalkyl or a group of the formula:
Y5-L5-Z5
wherein:
Y 5 is absent or C(0)N(R w) , wherein Rw is selected from hydrogen or
methyl;
l_5 is absent or (1-2C)alkylene; and
Z 5 is hydrogen, (1-6C)alkyl, cyclopropyl or a 5 or 6 membered
heteroaryl; wherein is Z 5 optionally substituted by one or more
substituents selected from (1-2C)alkyl, halo, (1-2C)haloalkyl, (1-
2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano, nitro or hydroxy.
14. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 13, wherein Ring A is a 7-membered heterocyclic ring, which,
in addition to the substituent groups R30 and R3 1 , is optionally further substituted by
one or more substituent groups selected from oxo, (1-2C)alkyl, cyclopropyl, spiro-
cyclopropyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, NH2, cyano or
hydroxy.
15. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 14, wherein Ring A is a 7-membered heterocyclic ring, which,
in addition to the substituent groups R30 and R3 1 , is optionally further substituted by
one or more substituent groups selected from oxo, (1-2C)alkyl, cyclopropyl, fluoro,
(1-2C)fluorooalkyl, (1-2C)alkoxy or cyano.
16. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
claim 1, wherein the compound has the structural formula Id shown below:
Formula Id,
wherein each of X 1, X2, R1, R2, R30 and R3 1 are as defined in any preceding claim;
X3 is CH2, O, S, S0 2 or NH; and
R40, R4 1 , R50 and R5 1 are independently selected from hydrogen, (1-2C)alkyl, (3-
6C)cycloalkyl, halo, (1-2C)haloalkyl, (1-2C)haloalkoxy, (1-2C)alkoxy, (1-
4C)alkoxyalkyl, (1-2C)aminoalkyl, NH2, cyano, nitro, OH, C(0)0R 1 , C(0)N(R 2)R 1
NR 2C(0)R 1 , wherein R 1 and R 2 are each independently selected from hydrogen or
(1-2C)alkyl; or
R40 and R4 1 , and/or R50 and R5 1 , are linked such that, together with the carbon atom
to which they are attached, they form a 3-6 membered carbocyclic ring or
heterocyclic ring.
17. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 16, wherein R1 is methyl.
18. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 1 to 17, wherein R3 0 is cyclopropyl.
19. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 16 to 18, wherein X 3 is O.
20. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 16 to 19, wherein R 0 and R5 1 are hydrogen.
2 1. A compound, or a pharmaceutically acceptable salt or solvate thereof, according to
any one of claims 16 to 20, wherein R4 0 and R4 1 are fluoro.
22. A compound, or a pharmaceutically acceptable salt or solvate thereof, selected from








[ 1 ,4]oxazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitrile;
(S)-2-chloro-4-((2-cyclopropyl-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-






















[ 1 .4]oxazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitrile;
2-chloro-4-((2-cyclopropyl-3,3-difluoro-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-




[ 1 .4]thiazepino[2,3-c]quinolin-1 0-yl)amino)nicotinonitrile;
(S)-6-chloro-5-cyano-4-((2,7-dimethyl-6-oxo-1,2,3,4,6,7-hexahydro-
[ 1 .4]oxazepino[2,3-c]quinolin-1 0-yl)amino)picolinic acid;
(f?)-6-chloro-5-cyano-4-((2-cyclopropyl-7-methyl-6-oxo-1,2,3,4,6,7-hexahydro-
[ 1 .4]oxazepino[2,3-c]quinolin-1 0-yl)amino)picolinic acid;
(S)-6-(azetidine-1-carbonyl)-2-chloro-4-((2,7-dimethyl-6-oxo-1,2,3,4,6,7-hexahydro-






























































[ 1 ,4]oxazepino[6,5-c]quinolin-1 0-yl)amino)nicotinonitrile;
2-chloro-4-((2-cyclopropyl-7-methyl-5,6-dioxo-1 ,2,3,5,6,7-hexahydro-
























































































































































































cyclopropyl-3, 3-difluoro-7-methyl-1 ,2 ,3 ,4-tetrahydro-[1,4]oxazepino[2,3-c]quinolin-
6(7/-/)-one.
23. A pharmaceutical composition comprising a compound according to any one of
claims 1 to 22, or a pharmaceutically acceptable salt or hydrate thereof and a
pharmaceutically acceptable carrier or excipient.
24. A compound according to any one of claims 1 to 22, or a pharmaceutically
acceptable salt or hydrate thereof, or a pharmaceutical composition according to
claim 23, for use in therapy.
25. A compound according to any one of claims 1 to 22, or a pharmaceutically
acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition
according to claim 23, for use in the treatment of cancer.
26. A compound or a pharmaceutical composition according to claim 25, wherein said
cancer is diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitt
lymphoma (BL), angioimmunoblastic T-cell lymphoma (AITL), acute lymphoblastic
leukaemia (ALL), chronic myeloid leukaemia (CML), multiple myeloma, breast
cancer, non-small cell lung cancer (NSCLC) or squamous cell carcinomas (SCC) of
the head and neck, oesophagus, lung or ovary.
27. A method for the treatment of cancer in a subject in need of such treatment, said
method comprising administering a therapeutically effective amount of a compound
according to any of claims 1 to 22, or a pharmaceutically acceptable salt or hydrate
thereof, or a pharmaceutical composition according to claim 23.
28. A method according to claim 27, wherein said cancer is diffuse large B-cell
lymphoma (DLBCL), follicular lymphoma (FL), Burkitt lymphoma (BL),
angioimmunoblastic T-cell lymphoma (AITL), acute lymphoblastic leukaemia (ALL),
chronic myeloid leukaemia (CML), multiple myeloma, breast cancer, non-small cell
lung cancer (NSCLC) or squamous cell carcinomas (SCC) of the head and neck,
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